The impact of social and economic factors on outcomes within people living with Crohn's and Colitis in the UK: A scoping review

Primary contact / Principle investigator

Professor Morris Gordon

Director, Biomedical evidence Synthesis and Translation to Practice (BEST) Unit,

University of Central Lancashire

mgordon@uclan.ac.uk

Executive summary / scientific abstract

Crohn's and colitis can impact on any and all areas of a person's life. It is not clear how social and economic factors impact on different groups within those affected by Crohn's and Colitis or how these groups are differently affected by the conditions.

This scoping review set out to systematically map the evidence base exploring these issues, summarise main findings, propose areas for systematic review and suggest appropriate future research areas.

In June 2023, an initial search strategy was devised and several rounds of pilot searching completed to refine and revise it. A final search strategy was agreed and the search ran on 26th June 2023 in Medline/EMBASE. Separate screening by two researchers of 5,462 citations was completed for potential inclusion, with all disagreements solved by discussion to research consensus. A total of 100 studies were selected for full text review and this was also completed in duplicate. The final sample of 77 studies was extracted, again in duplicate, for key demographics, research findings and conclusions.

The studies reported a total of 1,212,558 participants. The studies primarily originated from the UK (15), USA (27) and Canada (10). The participants included were mostly mixed groups of Crohn's and Colitis patients. A variety of methods were included, but no experimental studies were included.

There was a broad range of topics included, but the majority of studies focused on racial factors, with a quarter of the studies focused on racial distribution of patients at either diagnosis or in cross-sectional studies. A further quarter of studies focused on racial disparity in disease outcomes or management.

The core findings of the studies were related to race, including racial patterns in incidence of IBD, as well as disease outcomes and management. International studies were unclear and conflicting in findings in this area. UK based studies found south Asians have both higher incidence of more severe morbidity with Crohn's and Colitis and yet lower rates of some key therapies, such as biologics. Further studies found younger people were particularly affected by cultural barriers to their care and a number of suggested cultural factors that may explain such barriers to south Asians with Crohn's and Colitis.

International studies described the economic impact of Crohn's and Colitis on those it affects as a direct result of the cost of therapies and the ability to continue employment and that lower socio-economic status patients were less likely to have participated in a peer mentoring or education program and less likely to reach out to patient support groups. No exploration of the causes of these

differences was included. A small number of studies investigated gender, findings were rates of sickness in women with Crohn's and higher mental health illness in pregnant people with IBD.

Gaps in research were related to further and more in-depth investigation of religious, economic and gender factors. Future systematic review could focus on UK based studies of race-based outcomes in Crohn's and Colitis. Future primary research could focus on content gaps in the areas above, but once demographic trends are found, qualitative methods that can investigate 'how' and 'why' such differences occur may be particularly indicated.

Introduction

A recent project tender from CCUK highlights previous research in IBD demonstrating impairment to daily activities and impact on an individual's ability to progress with key milestones. What is not clear is how social and economic factors impact on different demographic groups within the Crohn's and Colitis community. This could be considered through a range of potential group characteristics including:

- Age
- Educational stage
- Racial origin
- Social economic
- Gender
- Mental wellbeing or health
- Religion

It was not clear from the tender what the focus of the commissioning society was for consideration of study types, questions of relevance or outcomes of interest. This is not unusual when a complicated conceptual paradigm is considered within research, particularly when there is a new or emerging focus on this area.

This report details the findings of a scoping review to address this area of interest.

Scoping review is a type of evidence synthesis that uses a systematic and iterative approach to identify and synthesize an existing or emerging body of literature on a given topic (Thomas 2017). While there are several reasons for conducting a scoping review, the main reasons are to map the extent, range, and nature of the literature, identifying peaks of converging findings to inform future systematic reviews, as well as to determine possible gaps in the literature on a topic (Peters 2020).

Scoping reviews are particularly helpful when the literature is complex and heterogeneous, as in this area. Scoping reviews can provide useful insight for decision-makers into the nature of a concept and how that concept has been studied in the literature over time. They can be used to develop a research agenda, advance the field, and identify areas for future systematic reviews or other types of evidence synthesis, informing options for consideration in future research (Peters 2020).

Despite many examples of poor practice (4), as with guidance for the more traditional systematic reviews, the guidance for scoping reviews explicitly addressed the need for scoping reviews to be

rigorously conducted, transparent, and trustworthy (Peters 2014). Most importantly, this tradition should be employed for the correct reasons (3).

For this review, the specific aims were defined after review by the commissioners to understand how social and economic factors impact on different demographic groups and in particular how ethnicities and people from different economic demographics living with IBD may differ within the relative impact of these factors.

The research goals were to:

- To map the literature using a scholarly and systematic approach,

- Identifying current peaks of converging evidence

- Identifying evidence gaps

- Determine areas for future review of evidence

Methods

This scoping review was conducted in a rapid timeframe (8 weeks from protocol completion to this report). The speed with which it was conducted, however, did not compromise rigor or systematicity, as we have exemplified in previous published works (7). The work was guided by the model for scoping reviews described by Arksey and O'Malley (8) and the more recent update by Peters et al (2020). The report aligns with the reporting standards of the PRISMA-SR (9).

The five stages of a scoping review followed (Arksey and O'Malley 2005) were:

Stage 1: identifying the research aims/questions (as stated above)

Stage 2: identifying relevant studies

Stage 3: study selection

Stage 4: charting the data

Stage 5: collating, summarizing and reporting the results

Stage 2: identifying relevant studies

This is a vital stage within a scoping review. Because scoping reviews are amenable to the inclusion of diverse methodologies on broad and wider ranging questions, as well as considering wide ranging types of research, there is a strong risk that the search and the inclusion criteria informing this search are flawed. This can lead to falsely focussed searches with minimal evidence, not reflecting the literature. Alternatively, too wide a search can lead to unfocussed low utility findings.

The three core elements to consider are the participants, the context and the concept or focus.

The participants were described as people with Crohn's or Colitis who are adults (over 16, matching NHS service delivery in the UK).

The context was the list of factors stated within the introduction and stated below in the search strategy.

The concept was the most challenging element. It was unclear from the needs of the commissioner and initial discussion as to what the concept or phenomena of interest was or specific outcomes or interventions.

Considering the lack of clarity on the concept, the search strategy was designed to focus on Participants and context.

Studies of any research method focussing on how these context factors affected the course of Crohn's or Colitis or in turn how Crohn's or Colitis impacted these factors were all considered for inclusion. Whilst global research was within scope, a focus on UK based works underpinned the search.

Our initial inclusion criteria were defined as follows:

- Papers that described social and economic factors impacting on people with Crohn's and colitis
- Studies using any methodology, including observational, cross-sectional, action based, before and after, non-randomised and randomised trials
- Studies in any language and from any date

Our exclusion criteria will be as follows:

- Opinion pieces, commentaries, editorials, perspectives, calls for change, needs assessments and other studies where no actual new knowledge had been developed
- Studies in multiple conditions where data from Crohn's and Colitis cannot be separated
- Studies in Children exclusively

The strategy was designed with an expert information specialist and a first pilot search was ran on 3rd June 2023. This led to 100,000 results. Further refinement and limitation to title and abstract dropped this to 10,000 results. Review of these results found little of interest with less than 1 potential relevant result per 100 citations. Further refinement was completed and a search submitted to the commissioners on 12th June 2023. On joint review of potential results, some concepts were clarified, including the addition of terms to capture educational and mental wellbeing focussed studies. A final strategy was agreed on 20th June 2023. This had no language or date limitations and all citation types were considered. There had been a total of ten iterations of the strategy with sample searches, discussion with CCUK as the commissioning body and further refinement of terms to ensure the validity and reliability of the approach and in alignment with

scoping review, which allows for post hoc revision of criteria, as authors become more familiar with the evidence base (Levac et al. 2010).

The search terms are shown in **Table 1**.

Participants	**Context**
crohn disease	social factors
Ulcerative colitis	Economic
inflammatory bowel diseases	unemployed
crohn	financial factors
Crohn's	employment
inflammatory bowel disease	employed
IBD	absenteeism
Colitis	Education
	Travel
	transport
	Race
	minority background
	Religion
	Stigma
	Ethnic
	Ethnicity
	mental illness
	mental health

Table 1. Search terms used for online databases.

The two groups of search terms were combined using Boolean OR operations and then the final lists were combined used AND operations, with limits to title and abstract.

Inter-rater reliability will be calculated using Cohen's Kappa. Full texts will be retrieved and independently reviewed by two authors. Discrepancies at all stages will be resolved through discussion, including a third author as needed, until consensus is reached.

Stage 3: study selection

Deduplication was conducted using Endnote. Retrieved citations were uploaded in covidence, an online data management system for performing systematic reviews. All titles and abstracts were independently screened by two authors against the criteria defined above.

Disagreements were highlighted in the covidence system and discussed to reach consensus for inclusion.

All potential citations were then accessed and downloaded in full. Further independent screening by two team members was completed to determine relevance for inclusion. Once again, any disagreements were discussed in full to reach consensus.

Stage 4: charting the data

We developed a data-charting form modified from the form used in our prior review (5) to align with the aims of this scoping review. The form was loaded into MS Teams to facilitate sharing of data. A team meeting was held to ensure shared understanding of terms and focus of extraction, prior to wider article distribution. Primary studies were once again extracted separately by two authors and any disagreements resolved on completion.

Quality assessments were planned to be undertaken if studies were of an interventional methodology that lend themselves to this (Risk of bias for randomised trials)

Data extracted included:

- Article identifiers (author(s), month of publication)
- Context items of focus
- Geographic origin
- Participants (both type and number), disease type, mix
- Data on patient's demographics including any data on social economic status, ethnicity, nationality and other diversity data. The lack of data in this area will be actively extracted.
- Study methods and quality assessment if appropriate
- Description of core findings
- Primary results with associated data
- Outcome of any intervention or experimental study

Stage 5: collating, summarizing and reporting the results

Utilizing data from the MS teams extraction sheets, the authors collated the data into a number of tables and figures for easy visualization, to provide a map of the current evidence base. After charting the large volume of data, we will also produce a narrative account of our findings that considers the extent and range of data included in the review, as well as the outcomes assessed. This will follow good practice for narrative review, but will not include specific meta-analysis. Instead, if data or studies exist with appropriate homogeneity to allow for such synthesis, this will be identified as a future research goal. We planned to use our charting process and visual aids to summarise broad areas of convergences and divergence to guide the commissioning organisation goals.

Thematic analysis of core factors found and the impact of these factors on patient outcomes was also planned if significant conceptual or theoretical data was available. This was planned to follow a three phase process of coding by two authors independently and then by consensus. Thes phases were open, axial and selective, with the themes from each phase informing the next. In the selective phase, a framework of whether and how core themes interact would be proposed. This was only planned to occur if the studies are aligned sufficiently with convergence of other characteristics as to be valid to do so. If the range of studies are divergent and heterogenous, no thematic analysis was to be performed and reasons described.

We planned to identify areas where a paucity of research exists and in particular where this is an area of clear agreement in multiple papers. We will suggest areas for future primary and secondary studies (i.e. systematic reviews).

Results

We electronically searched two databases (MEDLINE, EMBASE) on the 26th June 2023 with no date or language limitations. We included abstracts, such as from the recent DDW and UEGW meetings, to ensure studies not published in full were considered.

A total of 5462 citations were recovered, with 5141 after de-duplication. These were screened independently by two researchers. The agreement was calculated at 0.91, which is categorised as high reliability.

After meeting to discuss disagreements, this left 100 studies to review in full. All could be accessed and full text screening was completed again in duplicate. A total of 21 studies were excluded. This was due to 14 being review articles, 5 opinion pieces and 1 the wrong context focus.

This left a final cohort of 79 full studies included. The PRISMA flow diagram is shown in Figure 1.

Figure 1. PRISMA flow diagram



Demographics of included studies

There were a total of 1,212,558 participants reported as included in the studies, with 13 studies not specifying population sizes. The studies primarily originated from the UK (15), USA (27) and Canada (10), with other countries including Israel, Brazil, Norway, Holland, Sweden, Switzerland and Hungary.

The participants included were mostly mixed groups of Crohn's and Colitis patients in 60 of the studies, with 10 studies focusing on Crohn's and 7 focusing on Colitis.

A variety of methods were included, but no experimental studies were included. The most common method was Cohort studies (23), followed by Big data (22), Qualitative research (21), Cross-sectional (9) and Audits (2).

There was a broad range of topics included, but the majority of studies focused on racial factors, with a quarter of the studies focused on racial distribution of patients at either diagnosis or in cross-sectional studies. A further quarter of studies focused on racial disparity in disease outcomes or management.

The remaining studies had a broader focus, with some examples included Factors that affect outcomes in IBD (14), Broader impacts of IBD on life (5), Impacts on employment (4) and factors affecting the choices of treatments (3).

Table 2 is a detailed summary of the characteristics of included studies.

Supplementary appendix 1 is a full database of the included studies and their references, together with demographics. Supplementary appendix 2 is the full data set of studies included, together with the previous studies supplied by the commissioner.

Study ID	Topic	Condition	Methods	Location	Sample Size	Key findings	Conclusions
Kaplan 2015	Global epidemiology	IBD	Audit of published studies	Canada	UNCLEAR		Over 1 million residents in the USA and 2.5 million in Europe are estimated to have IBD, with substantial costs for health care. IBD increasing in newly industrialized countries and forecasts the global effects of IBD in 2025.
Sedano 2022	Representation in trials	IBD	Audit of published trials	canada	19476	22% of Induction and 26% of maintenance trials don't report race.	Potential under-representation of minorities in trials in IBD
Aniwan 2019	Racial distribution IBD	IBD	Big data	USA	UNCLEAR	Adjusted annual incidence rate of IBD for whites was 21.6 cases per 100,000 person-years and for nonwhites it was 13 per 100,000 and increased by 39% and 134%, respectively, from 1970 through 2010.	There were significant racial and ethnic differences in the incidence and temporal trends of IBD over the last four decades in this US population-based cohort.
Asotibe 2022	Racial disparities in outcomes	IBD	Big data	USA	177574	There was no significant difference in inpatient mortality for black vs white patients and no difference in the odds of developing septic shock	White patients hospitalized with a principal diagnosis of IBD had no difference in inpatient mortality or septic shock but had worse outcomes such as increased odds of bowel perforation compared to black patients.
Barnes 2018	Racial disparities in outcomes	IBD	Big data	USA	5537	Black patients were more likely to report a Crohn's disease (CD)-related complication at baseline (adjusted odds ratio [aOR], 1.44; 95% confidence interval [CI], 1.06-1.95). Black patients with ulcerative colitis were more likely to have proctitis (24% vs 13%, P = 0.033) at baseline.	Black patients with CD demonstrated increased complications at baseline and during follow-up in this cohort.
Barnes 2021b	Patterns of drugs use based on drugs	IBD	Big data	USA	14735	there was no significant difference in the odds of anti-tumor necrosis factor use by race for CD (adjusted odds ratio [aOR] = 1.13; 95% confidence interval [CI], 0.99-1.28] or ulcerative colitis (aOR = 1.12; 95% CI, 0.96-1.32).	Disparities in IBD treatment discussed in prior literature seem to be driven by socioeconomic or other issues affecting access to care, not race.
Barnes 2022	Racial distribution IBD	IBD	Big data	USA	212393	Black adult patients were significantly less likely than White patients to have a diagnosis of CD (odds ratio [OR], 0.53; 95% CI, 0.52-0.54) or UC (OR, 0.41; 95% CI, 0.40-0.43). Pediatric Black patients were also less likely to have a diagnosis of CD (OR, 0.41; 95% CI,	CD and UC are modestly less prevalent among patients of non-White races and Hispanic ethnicity.

						0.39-0.43) or UC (OR, 0.38; 95% CI, 0.35-0.41).	
Bernstein 2001	broad determinants	IBD	Big data	Canada	UNCLEAR	In study A we found that, compared with the general population, patients with IBD were more likely to be unemployed. Crohn's disease appeared to affect employment more than ulcerative colitis	Individuals with IBD at some time in the course of their illness are more likely not to be working than are those in the general population
DosSantosMarques 2022	Racial factors impacting distribution of drug use	IBD	Big data	USA	14735	barriers to a positive surgical experience included inadequate personal knowledge of IBD, ineffective written and verbal communication, lack of a support system and complications after surgery	Black and White patients with IBD have varied surgical experiences but all stressed the importance of accurate, trustworthy and understandable health information. These findings highlight the value of providing health literacy-sensitive care in surgery.
Eglinton 2012	Racial distribution Peri-anal disease	CD	Big data	new Zealand	715	Perianal disease was associated with younger age at diagnosis (P < 0.0001), complicated intestinal disease (P < 0.0001), and ileal disease location (P = 0.002). There was no association with gender, ethnicity, smoking, or breast feeding.	This study suggests that younger age at diagnosis, complicated disease behavior, and ileal disease location are risk factors for perianal CD.
Farrukh 2015b	Racial factors impacting distribution of drug use	CD	Big data	UK	UNCLEAR	In three Trusts, the number of South Asian patients who received such treatment was significantly less than British/White patients. These were: Pennine Acute Hospitals NHS Trust covering Oldham and North Manchester, Barking, Havering & Redbridge University Hospitals NHS Trust and University Hospitals of Leicester NHS Trust.	It is unacceptable for there to be a difference based on racial grounds.
GunnellsDJJr 2016	Racial disparities in outcomes (surgery)	IBD	Big data	USA	2523	On multivariable analysis, black race remained a significant predictor for 30-day readmissions in patients with IBD (odds ratio 1.6, 95Â % confidence interval 1.1-2.5).	Black patients with IBD have an increased risk for readmission after colorectal surgery.
Kochar 2018	Racial distribution IBD	IBD	Big data	USA	5412	Adjusting for confounders, Asians had half the odds of being treated with biologics compared with whites (OR: 0.45, 95% CI: 0.30-0.67). Adjusting for disease behavior and remission status, there were no differences in IBD-related surgery or hospitalization, new biologic or steroid prescription or relapse rates between Asians and whitesat follow-up.	Asians are more likely to have perianal disease and ocular extra-intestinal manifestations. After controlling for confounders, Asians were less likely to be treated with biologic agents.

Lichtenstein 2020	Impact of age on economic burden of IBD	IBD	Big data	USA	164375	Lifetime total cost was $405,496, consisting of outpatient ($163,670), inpatient ($123,190), pharmacy ($105,142), and ER ($13,493) costs.	we estimated lifetime costs for patients with CD or UC to exceed previously published estimates.
Longobardi 2003	Employement impact of IBD	IBD	Big data	Canada	UNCLEAR	Based on this, the indirect cost of nonparticipation attributable to IBD in 1998/1999 was more than $3.6 billion U.S. dollars (USD) or $5228 USD per person with IBD and symptoms. According to the second weighted logistic regression, for those who are in the labor force, having IBD had no association with the duration of work.	This method of estimation can be used to predict the overall paid-employment burden of IBD.
Malhotra 2015	Racial distribution IBD	IBD	Big data	USA	30812	UC was more commonly associated with Indian and Jewish ethnicity and less commonly associated with East Asian and Hispanic ethnicity. Similar patterns also applied to CD and to all types of IBD analyzed jointly.	Patients of Indian origin living in the United States have a greater risk for all types of IBD than other American populations.
Misra 2016	Racial differences in colectomy rates	UC	Big data	UK	212430	Indians had a significantly higher colectomy rate than WE (9.8% versus 6.9%, $p < 0.001$). Indian patients were 21% more likely to require colectomy for UC compared with WE group (OR: 1.21, 95% CI: 1.04-1.42, and $p = 0.001$).	The colectomy rate in this cohort was higher in Indians compared to WE
Misra 2019	Racial distribution IBD	IBD - Inception study	Big data	UK	339	The age adjusted incidence of IBD and UC were significantly higher in the Indian group (25.2/100000 and 20.5/100000) compared to White European (14.9/100000, $P = 0.009$ and 8.2/100000, $P < 0.001$) and Pakistani groups (14.9/100000, $P = 0.001$ and 11.2/100000, $P = 0.007$). The Indian group were significantly more likely to have extensive disease than White Europeans (52.7% vs 41.7%, $P = 0.031$). There was no significant difference in time to diagnosis, disease activity and treatment.	This is the only prospective study to report the incidence of IBD in an ethnically diverse United Kingdom population. The Indian ethnic group showed the highest age-adjusted incidence of UC (20.5/100000).
Probert 1992	Racial distribution IBD	CD	Big data	UK	UNCLEAR	The mean standardized incidence in Bangladeshis was 1.2/10(5)/year in the 1970s and 2.3/10(5)/year in the 1980s compared with 3.8/10(5)/year and 4.1/10(5)/year in Europeans, and 4.6/10(5)/year and 5.4/10(5)/year in West Indians, respectively.	The apparent similarity of the incidences of Crohn's disease in Bangladeshis and Europeans contrasts with findings in other South Asians.

						None of the changes with time was statistically significant.	
Sewell 2010	Racial disparities in outcomes	IBD	Big data	USA	UNCLEAR	The proportion of hospitalizations including a discharge diagnosis of IBD increased significantly from 1994 to 2006 among the total population and among Asian, black, and white patients separately.	The proportion of hospitalizations including a discharge diagnosis of IBD increased significantly among minority and nonminority patients from 1994 through 2006. The causes underlying these changes are not certain and should be further investigated.
Shapira 1994	Racial distribution IBD	CD	Big data	israel	UNCLEAR	he mean annual incidence rate in the Kinneret sub-district among Jews was 1.96/100,000 during 1960-1990 and 2.98/100,000 in the last decade. The prevalence rate in 1990 among Jews was 45.9/100,000 and was twofold among European-American-born compared to other ethnic groups.	(1) morbidity rate of Crohn's disease increased over time, and (2) in the last decade incidence rates among Jews of Asian-African origin are similar to, or even higher than those of European-American origin.
Vigod 2019	Pregnancy association with mental health in IBD	IBD	Big data	Canada	UNCLEAR	About 22.7% of women with IBD had new-onset mental illness versus 20.4% without, risk was elevated in the post partum (aHR 1.20, 95%â€‰CI 1.09 to 1.31).	Women with IBD were at an increased risk of new-onset psychiatric diagnosis in the postpartum period, but not during pregnancy.
Vij 2019	Racial disparities in outcomes (Colon cancer)	IBD	Big data	USA	57542	In patients with IBD, advanced age conferred an increased risk for developing CC while female gender conferred a protective effect. In this subset of patients, black race conferred a protective effect	Racial disparity exists in the overall incidence of CC and among patients with IBD who develop CC. Interestingly, black race conferred a protective effect for patients with IBD, contrary to what is seen in the general population.
Wang 2013	Racial distribution IBD	IBD	Big data	USA	202468	The prevalence of IBD was higher in Whites [Crohn's disease: 154; ulcerative colitis (UC): 89] than Blacks (Crohn's disease: 68; UC: 25), Hispanics (Crohn's disease: 15; UC: 35), and Asians (Crohn's: 45; UC: 40) (all $p < 0.05$, except for UC in Asians).	There were significant racial/ethnic differences in the prevalence of IBD in the USA.
Zhornitskiy 2021	Racial distribution IBD	IBD	cohort	USA	UNCLEAR	Prevalence of IBD per 100,000 people was 418 (95% CI 341-512) for Hispanics and 557 (95% CI 431-739) for NHWs. Notably, the proportion of Hispanic IBD patients with a history of smoking was 21.5% vs 50.8% in NHWs ($p = 0.011$).	In one of the largest US studies of Hispanics with IBD, and the only one to have both clinical and histopathologic confirmation as inclusion criteria, we found the incidence and prevalence of IBD among Hispanics to be higher than previously recognized and comparable to NHWs.

Gadhok 2020	Outcomes depending on race	IBD	Cohort study	UK	224	Bangladeshi patients started an anti-TNF 4.3Â years earlier after diagnosis than Caucasian patients (3.9Â years vs. 8.2Â years: pâ€‰<â€‰0.01). Bangladeshi patients experienced shorter failure-free survival than Caucasian patients (1.8 vs. 4.8Â years pâ€‰<â€‰0.01).	This is the first study to suggest that Bangladeshi patients resident in the UK with CD respond less well to treatment with TNF antagonists than Caucasian patients.
Bernstein 2020	Impact of lower socio-economic status	IBD	Cohort study	Canada	9298	Comparing persons with Lower Socieconomic State (LSS) vs those without any markers of LSS, there were increased rates of annual outpatient physician visits (relative risk [RR] = 1.10, 95% confidence interval [CI] = 1.06-1.13), hospitalizations (RR = 1.38, 95% CI = 1.31-1.44), intensive care unit admission (RR = 1.94, 95% CI = 1.65-2.27), use of corticosteroids >2,000 mg/yr (RR = 1.12, 95% CI = 1.03-1.21), and death (hazard ratio 1.53, 95% CI = 1.36-1.73).	LSS was associated with worse outcomes in persons with IBD. Social determinants of health at time of diagnosis should be highly considered and addressed.
Wetwittayakhlang 2023	Factors associated with diagnosis	IBD	cohort study - three timer periods	hungary	2240	Rates of active smoking significantly decreased over time in Crohn's disease (CD): 60.2%, 49.9%, and 38.6% in cohorts A/B/C (p < 0.001). In UC, the rates were low and stable: 15.4%, 15.4%, and 14.5% in cohorts A/B/C (p = 0.981).	The association between trends of known environmental factors and IBD is complex. Smoking has become less prevalent in CD, but no other major changes occurred in socioeconomic factors over the last four decades that could explain the sharp increase in IBD incidence.
Acosta-RamÃrez 2001	MEntal healht characteristics in ibd	IBD	cross-sectional	Puerto Rico	67	Patients older than 34 years old had three times higher probability of developing a depressive disorder (p = 0.043, OR = 3.22). Patients with a psychiatric history had seven times higher probability of developing depressive disorder (p = 0.004, OR = 7).	The risk factors identified with an increased probability of developing a depressive disorder were age older than 34 years and psychiatric history.
Can 2022	Factors affecting medication adherence	IBD	cross-sectional	Turkey	253	Intentional (29.3% in ulcerative colitis and 16.3% in Crohn's disease [P = .031] and unintentional non-adherence to treatment (28.1% in ulcerative colitis, 16.3% in Crohn's disease [P = .037] were significantly higher in ulcerative colitis than in Crohn's disease. Female gender (odds ratio = 2.59, P = .005), low education level (odds ratio = 4.8, P = .015), distal involvement in ulcerative colitis	The negative perception of treatment in inflammatory bowel disease affects adherence to the treatment.

						(P = .014), and thoughts about the disease would last too soon in Crohn's disease (odds ratio = 4.17, P = .049) were risk factors for non-adherence to treatment.	
Click 2016	Predictors of high heathcare utilisation	IBD	cross-sectional	USA	400	In multivariate analysis, unemployment (Crohn's disease [CD]: odds ratio [OR], 3.04; 95% confidence interval [CI], 1.32-7.02; ulcerative colitis [UC]: OR, 2.68; 95% CI, 1.20-5.99), psychiatric illness (UC: OR, 2.08; 95% CI, 1.03-4.19), opiates (CD: OR, 5.61; 95% CI, 2.67-11.82; UC: OR, 5.14; 95% CI, 2.52-10.48), prior surgery (CD: OR, 3.29; 95% CI, 1.59-6.82; UC: OR, 2.72; 95% CI, 1.39-5.32), penetrating CD (OR, 3.29; 95% CI, 1.02-10.62), and corticosteroid requirement (CD: OR, 3.78; 95% CI, 1.86-7.65; UC: OR, 2.98; 95% CI, 1.51-5.90) remained independently associated with high charges.	High expenditure IBD patients were affected by more severe disease. The high prevalence of depression, anxiety, and chronic pain in these patients suggests the need for focused treatment of these comorbidities ultimately to reduce financial burden.
Damas 2022	Social barriers impact on outcomes	IBD	cross-sectional	USA	316	Social barriers associated with poor IBD outcomes included low educational attainment, poor health literacy, and financial insecurity. High social barrier scores was associated with greater depressive symptoms [odds ratio (OR) 1.94, 95% confidence interval (CI) 1.21-2.9, pâ€‰=â€‰0.001] and lower reported use of medications.	Our study identifies social barriers that may impact IBD care and are disproportionately higher in non-Hispanic Blacks and Hispanics in the United States.
DosSantosMarques 2020	Factors impacting health literacy in IBD	ibd	cross-sectional	USA	175	On multivariable analysis, low health literacy was associated with older age and African American race (P < 0.05). Of 83 IBD patients undergoing abdominal surgery, mean postoperative LOS was 5.5 days and readmission rate was 28.9%.	Low health literacy is present in IBD populations and more common among older African Americans.
Farrukh 2016	Racial disparities in outcomes	IBD	cross-sectional	UK	70	South Asian patients were significantly less likely to see a consultant and more likely to be discharged. South Asian patients were admitted to hospital more often but had significantly fewer tests than European patients.	Patients with ulcerative colitis who are of South Asian origin receive poorer quality clinical care than their European counterparts.
Greenberg 2015	Factors affecting utility weights	CD	cross-sectional	Israel	425	significant predictors of utility weights in a multivariable regression analysis were the HBI [Î² = -0.494; p < 0.001], economic status [Î² =	Utility weights for patients in the remission and mild disease states were generally lower as compared with values

	(health economics)					0.198; p < 0.001], time since diagnosis [Î² = 0.106; p < 0.001], male [compared with female] gender [Î² = 0.099; p = 0.009], hospital admission in the past year for any cause	used in published cost-effectiveness analyses.
Naftali 2022	Factors effecting patient preference	IBD	cross-sectional	israel	361	Multivariable regression analysis revealed that higher patient preferences were associated with Jewish ethnicity (OR 4.77; 95%CI 2.36-9.61, P < 0.001) and disease activity.	The highest priority for treatment outcomes was symptom relief., Patients preferences were impacted by ethnicity, gender, and socio-economic disparity.
Nazarinasab 2019	Mental healht characteristics in CD	CD	cross-sectional	Iran	96	Multivariate analysis of mental health showed that steroid consumption (P value < 0.001) and nonsmoking (P value = 0.038) were associated with higher mental health in the individuals.	Crohn's patients suffered from decreased mental parameters
Nguyen 2010	Racial disparities in utilisation	IBD	cross-sectional	Canada	286	blacks were less likely than whites to be under the regular care (defined as at least annual visit) of a gastroenterologist (adjusted odds ratio (aOR) 0.43; 95% confidence interval (CI): 0.25-0.75) or IBD specialist (aOR 0.37; 95% CI: 0.22-0.61).	There are racial differences in utilization of IBD-related specialist services, ED visits, and infliximab that are independent of income and education.
Odufalu 2023	broad determinants	UC	cross-sectional	GLOBAL	1000	Low-income vs high-income patients were less likely to have participated in a peer mentoring (OR, 0.30) or UC education program (OR, 0.51). Patients not employed were less likely to report being in "good/excellent" health (OR, 0.58) than patients employed full time. Patients with low vs high educational levels were less likely to have reached out to patient associations/organizations (OR, 0.59). Patients aged younger than 50 years vsâ€…those aged 50 years and older were less likely to have visited an office within an inflammatory bowel disease center/clinic in the past 12 months (OR, 0.53).	Substantial differences in disease management and health care experience were identified
Walldorf 2021	Factors impacting childlessness	IBD	cross-sectional	Germany	533	Poor knowledge was not associated with increased childlessness (CCPKnow of <â€Š8 was found in 29.8â€Š% of patients with children and 28.9â€Š% of childless patients, pâ€Š>â€Š0.5). Instead, the patients'	Factual knowledge does not reduce disease-related concerns or childlessness.

						education, medical advice, FPP-related concerns, impaired body image, and sexual dysfunction had a significant impact on childlessness.	
Schenker 2021	Guideline for Transgender IBD	IBD	Guideline / position statement	USA	UNCLEAR	Despite an increase in provider awareness of TGNC health over the past decade, no original research or societal guidelines exist on TGNC patients with inflammatory bowel disease (IBD).	high-quality care to the Trans-gender IBD population can be divided into 3 categories: medications, anatomy, and mental health.
Montgomery 1999	Racial distribution IBD	IBD	Longituidunal birth cohort study	UK	UNCLEAR	Young Asians born in Britain were significantly more likely than indigenous Europeans to have a diagnosis of IBD by age 26 years, with relative odds of 6.10 (95% CI 2.14-17.33).	Young Asians who were born in Britain are at a significantly higher risk of developing IBD than the indigenous European population.
Ediger 2007	Factors determining medical adherence	IBD	Propsective cohort	Canada	326	or men, predictors of low adherence included diagnosis (UC: OR 4.42, 95% CI 1.66-11.75) and employment status (employed: OR 11.27, 95% CI 2.05-62.08). For women, predictors of low adherence included younger age (under 30 versus over 50 OR 3.64, 95% CI 1.41-9.43; under 30 vs. 40-49 yr: OR 2.62, 95% CI 1.07-6.42). High scores on the Obstacles to Medication Use Scale strongly related to low adherence for both men (OR 4.05, 95% CI 1.40-11.70) and women (OR 3.89, 95% CI 1.90-7.99).	Approximately one-third of IBD patients were low adherers. Predictors of adherence differed markedly between genders
Acciari 2019	Social aspects influence wellbeing vs clinical aspects	IBD	Qualitative research	Brazil	104	There were also significant differences in the use of Coping: usually, women used more developed escape and avoidance strategies; single, married or in stable-union patients used more self-control; not religious used positive revaluation strategy; the ones who were employed showed more self-control and positive reassessment; the ones who had lower family income indicated that they used less the self-control; the ones who had higher family income used more positive re-evaluation; patients who were diagnosed with Crohn's disease between the second decade of life showed to use mores more the	Social aspects influenced psychological well-being, resilience and Coping in patients with Crohn's disease more strongly than clinical aspects.

						positive reassessment strategy than those who were 20 years old or younger.	
Agrawal 2019	Factors influencing disability in IBD	IBD	Qualitative research	USA	323	On multivariable analysis, Hispanic ethnicity (aOR 2.7, 95% CI 1.3-5.6), non-Hispanic non-black minority race (aOR 3.5, 95% CI 1.3-8.9), public payer (aOR 2.1, 95% CI 1.1-4.0) and low annual household income (aOR 3.0, 95% CI 1.7-5.4) were associated with moderate-to-severe disability controlling for disease characteristics.	IBD patients who are minorities, have public insurance, or low household income, are 2-3 times more likely to report moderate-to-severe disability independent of disease characteristics in the United States.
Alexakis 2015	Factors associated with challenges in IBD in young people	IBD	Qualitative research	UK	20	A thematic analysis of their experiences identified many commonalities with other young people with IBD, such as the problematic route to formal diagnosis and the impact of IBD on education. The young people also experienced tensions between effective self-management strategies and cultural norms and practices relating to food. Moreover, the ability of parents to provide support was hampered for some young people by the absence of culturally competent services that were responsive to the families' communication needs.	The findings highlight the need for more culturally appropriate information concerning IBD, and improved responsiveness to young people with IBD within primary care and the education system
Bernklev 2006	Employement impact of IBD	IBD	Qualitative research	Norway	495	Sick leave for all causes was reported in 47% with ulcerative colitis and 53% with CD, whereas IBD-related sick leave was reported in 18% and 23%, respectively. A majority (75%) had been sick <4 weeks, and a relatively small number of patients (25%) contributed to a large number of the total sick leave days. Both unemployment and DP reduced HRQOL scores, but the most pronounced effect on HRQOL was found in patients reporting IBD-related sick leave, measured with SF-36 and N-IBDQ.	Unemployment or sick leave is more common in IBD patients than in the Norwegian background population.
Blumenstein 2013	Racial differences in knowledge	IBD	Qualitative research	Germany	303	German patients obtained knowledge from a wider range of sources than Irish patients ($p<0.001$), most notably from the internet ($p<0.001$), newspapers and magazines ($p=0.002$).	Our data suggest few differences between German and Irish IBD patients, despite cultural and linguistic differences, with regard to disease related knowledge of IBD.

Chrobak-BieÅ„ 2018	Factors afffecting acceptance of UC	UC	Qualitative research	Poland	50	Analysis of the results showed a reduced degree of acceptance of the disease among patients in the phase of exacerbation of the disease. The mean point score of the AIS scale for the study group was 29.65, which indicates the average level of acceptance of the disease among respondents	People with higher education, professionally active and treated conservatively, accepted their illness to a better extent.
Engel 2021	Psychological parameters across key factors	IBD	Qualitative research	Germany	62	Levels of depression and anxiety were higher in CD/UC patients than in HC with large effect sizes. Comparing personality functioning in CD/UC with HC, psychodynamic structural characteristics differed between CD/UC and HC with medium effect sizes, with structural differences occurring primarily in the domain of self-perception and regulation.	Our data show that compared to HC, patients with CD/UC are characterized by a higher level of psychological burden and structural alterations in the domain of self.
Freitas 2015	Religious coping as predictor for other factors	IBD	Qualitative research	Brazil	147	Positive religious coping was negatively associated with anxiety (b = 0.256; p = 0.007) as well as with overall, physical, and mental health HRQoL. Religious struggle was significantly associated with depression (b = 0.307; p < 0.001) and self-reported adherence (b = 0.258; p = 0.009). Finally, anxiety symptoms fully mediated the effect of positive religious coping on overall HRQoL.	Religious coping is significantly associated with psychological distress, HRQoL, and adherence in IBD.
Harvey 2022	Perspectives of patients with lower educational attainment	IBD	Qualitative research	Canada	23	Thematic analysis found focus on communication with health care professionals, access to care, symptoms and treatment, and outside support. Access to an IBD specialist was the most important aspect of care. Good care, kind and receptive staff, and a lengthy delay to diagnosis were frequently reported experiences. IBD specialists, nurses, and family and friends were most helpful in managing disease. Physical and emotional symptoms, reduced social engagement, and medications were difficult aspects of living with IBD.	An ideal IBD clinic would provide access to traditional and non-traditional services and assist with obtaining support to help patients engage in social activities, increase affordability of care, and maintain employment.
Larussa 2020	Factors affecting willingness to	IBD	Qualitative research	Italian	145	Multivariate analysis showed a significant positive association between interest in clinical trials and previous experience (p = 0.014), high education (p < 0.001), poor QoL	In a native local resident series of IBD patients, the majority of the patients were willing to participate in a clinical therapeutic trial. A long-standing

	take part in trials					(p = 0.016), money retributions (p = 0.03) and informative materials (p = 0.02). On the other hand, a long-standing disease (p = 0.017), the possibility of receiving a placebo (p = 0.04) and the frequent colonoscopies required by the study protocol (p = 0.04) were significantly associated with the lack of interest in clinical trials	disease, placebo and invasive procedures represented a barrier to enrollment while previous experience, high education, monetary compensation and adequate information could be facilitative.
Long 2014	Factors associated with depression in edlerly	IBD	Qualitative research	USA	359	ower education levels (p=0.001), higher corticosteroid use (<0.01) and lower exercise levels (<0.001) were associated with depression. For both CD and ulcerative colitis (UC), those with depression had increased disease activity (short Crohn's disease activity index 52.5 versus 29, p=0.005, and simple clinical colitis activity index 5 versus 2, p=0.003).	Depression is common in this geriatric IBD cohort. Depression is independently associated with reduced medication adherence.
Mahlich 2017	Employement impact of IBD	IBD	Qualitative research	Japan	1068	We found that the labor force participation rate is lower and unemployment higher for patients with IBD compared to the general population. Factors associated with unemployment in the IBD sample are older age, female gender, and the prevalence of depression.	IBD constitutes a high burden for patients in Japan regarding employment outcome.
Moradkhani 2013	Racial disparities in outcomes	IBD	Qualitative research	USA	134	Multivariate analyses revealed that the variables most strongly associated with HRQOL were perceived stress (p<0.001), number of previous IBD relapses (p<0.001), gender (p<0.001), and perceived social support (p<0.05).	Individuals with IBD who report higher perceived stress, lower perceived social support, greater number of relapses, or are female may be at increased risk for decreased HRQOL.
Mukherjee 2021	South asian patients experiences	IBD	Qualitative research	UK	33	Although many experiences align with those of the general IBD population, participants believed that South Asian cultures and/or religions can lead to additional challenges. These are linked to: family and friends' understanding of IBD; self and family attributions regarding IBD; stigma surrounding ill health; the taboo of bowel symptoms; managing 'spicy food'; beliefs about food and ill health; roles within the family; living with extended family; the use of	Gastroenterology services have an important role to play in helping patients to overcome the challenges they encounter in their everyday life, both by providing individual patients with culturally appropriate care and advice.

						complementary and alternative therapies; and visits to family overseas. Religious faith helped many to cope with having IBD	
Multone 2015	Factors of non-responders to national surveys	IBD	Qualitative research	Switzerland	1943	Factors inversely associated with non-response to study questionnaires were: age >30 years, colonic only disease location, higher education and higher IBD-related quality of life for CD, and age >50 years or having a positive social support for UC	Characteristics of non-responders differed between UC and CD. The risk of non-response to repetitive solicitations (longitudinal versus transversal study) seemed to decrease with age.
Pittet 2017	Gender impact on coping	IBD	Qualitative research	Switzerland	1102	We identified six domains of concern: socialization and stigmatization, disease-related constraints and uncertainty, symptoms and their impact on body and mind, loss of body control (including sexuality), disease transmission, and long-term impact of the disease. Cancer concerns were among the highest scored by all patients (median 61.8).	Patients have numerous concerns related to their illness that need to be reassessed regularly. Concerns differ between men and women
Sarid 2017	Gender difference in coping with IBD	IBD	Qualitative research	Israel	402	A model split by gender and disease activity showed that in active CD economic status impacted SIBDQ in men ($\hat{I}^2 = 0.43$) more than women ($\hat{I}^2 = 0.26$); emotional coping impacted SWLS in women ($\hat{I}^2 = 0.36$) more than men ($\hat{I}^2 = 0.14$).	Gender differences in coping and the impacts of economic status and emotion-focused coping vary with activity of CD.
Sorensen 1987	broad determinants	CD	Qualitative research	Norway	106	54% of patients with Crohn's disease felt exacerbations of their disease strained their professional and personal life. During the previous year 23% reported decreased working capacity and 21% reported decreased leisure activities, compared with their own expectations.	During the previous year 23% reported decreased working capacity and 21% reported decreased leisure activities, compared with their own expectations.
Stjernman 2011	Broad determinants	IBD	Qualitative research	Sweden	497	Women with CD had higher rates of sickness and disability than men with CD and were more often living single, though procreation was not affected.	CD had higher impact on HRQL, compared with UC. Women with CD had worse outcome in subjective health status, but not in objective assessment of disease activity.
Farrukh 2015	Racial factors impacting distribution of drug use	CD	Retrospective cohort	UK	139	Based on a population composition, rather than prevalence data, in which 24% of the Leicester community should have been of South Asian origin, 33 patients would have received biologics compared with 92 patients	Suggested reasons for these differences have included concerns about the animal origins of infliximab as well as difficulties associated with accessing the service, such as the provision of

						of English origin (66%). This is significantly different to the 13 patients who did receive treatment (z=-3.2, PÂ <Â 0.001).	information in an appropriate language through appropriate media.
Hoie 2007	Broad determinants	UC	Retrospective cohort	10 countries	771	The time to first relapse showed a greater hazard ratio (HR) (1.2, CI 1.0-1.5) for women and for patients with a high level of education (1.4, CI 1.1-1.8). The number of relapses decreased with age, and current smokers had a lower relapse rate (0.8, CI 0.6-0.9) than nonsmokers. The relapse rate in women was 1.2 (CI 1.1-1.3) times higher than in men.	In 67% of patients, there was at least one relapse. Smoking status, level of education, and possibly female gender were found to influence the risk of relapse.
Jayanthi 1992	Racial distribution IBD	CD	Retrospective cohort	UK	UNCLEAR	The standardized incidence in Europeans has risen significantly to 4.7/10(5)/year from 3.4/10(5)/year in the 1970s (chi 2 = 8.1, p less than 0.005). In Leicester this increase can be accounted for entirely by new cases of colonic disease.	Overall, Hindus have a much lower incidence of Crohn's disease than Europeans.
Jordan 2022	Depression rates amongst AA	IBD	Retrospective cohort	USA	UNCLEAR	Overall prevalence of major depressive disorder was 25.3%; 45.8% had minimal, 8.3% mild, 33.3% moderate, and 12.5% severe depression. A total of 34.7% of patients were never screened for depression, and 13.8% had other psychiatric conditions. There was a difference in depression rates based on psychiatric conditions (pÂ =Â 0.00), but no difference based on sex (pÂ =Â 0.37), IBD subtype (pÂ =Â 0.34), or medical conditions (pÂ =Â 0.84).	Rates of depression among minority patients, predominantly African American, with inflammatory bowel disease were higher than previously reported for all patients with inflammatory bowel disease.
Li 2014	Racial disparities in outcomes	UC	Retrospective cohort	USA	7350	Compared with whites, the male-to-female ratio differed for African-Americans (0.68 vs. 0.91, pÂ <Â 0.01) and Asians (1.3 vs. 0.91, pÂ <Â 0.01). Asians had fewer co-morbid conditions (pÂ <Â 0.01) than whites, whereas more African-Americans had hypertension and asthma (pÂ <Â 0.01). Use of immunomodulators did not differ significantly among race and/or ethnic groups.	In this population of UC patients with good access to care, overall health-care utilization patterns and clinical outcomes were similar across races and ethnicity. Asians may have milder disease than other races whereas Hispanics had a trend toward more aggressive disease, although the differences we observed were modest.
Mangat 2011	Racial distribution IBD	IBD	Retrospective cohort	Canada	186	The South Asian population had a higher rate of UC, with an increased rate of complications and male predominance. Interestingly, the	These racial differences - which were statistically significant - suggest a role for ethnodiversity and environmental

						rate of CD and UC was lowest in the Pacific Asian population.	changes in the prevalence of IBD in Vancouver.
MontgomerySRJr 2018	Racial disparities in outcomes (surgery)	IBD	Retrospective cohort	USA	14679	After adjustment, black patients remained at increased risk of DSM compared white patients (OR: 1.37; 95% CI 1.14-1.64). CONCLUSIONS: Black patients are at increased risk of post-operative DSM following surgery for IBD	Black patients are at increased risk of post-operative DSM following surgery for IBD. The elevated rates of DSM are not explained by traditional risk factors like obesity, ASA class, emergent surgery, or stoma creation.
Moore 2012	Racial distribution IBD	UC	Retrospective cohort	USA	311	African American patients had a shorter median duration (8.0, interquartile range [IQR] = 4.0, 14.0) of UC than Caucasians (10.0, IQR = 6.0, 18.0) (P = 0.006). African American disease patients had more distal disease than controls. African Americans were significantly less likely to use corticosteroids (74.2% vs. 88.8%, P = 0.002), or use immunomodulators (25.8% vs. 69.7%, P < 0.001) than Caucasians.	There appear to be differences in the natural history of UC in our African American patients when compared with Caucasian controls, while ethnicity was not shown to be a risk factor for colectomy.
Norwood 2009	Racial disparities in outcomes (surgery)	IBD	Retrospective cohort	UK	107	Postoperative complications occurred in 40 (37%) patients, being major in 11 (10%) patients with relaparotomy required in 9 (8%) with no difference between South Asian and non-South Asian Caucasian patients. Long-term pouch function, with a median of five times over 24 h (range 2-15), was similar between the two groups. The incidence of pouchitis was 57 (53%) and this was significantly greater in the South Asian population [17/21 (77%); 39/86 (46%); P = 0.006].	Surgical results were similar in South Asian and non-South Asian Caucasian patients, but the incidence of pouchitis was greater in the former group.
Pressman 2008	Factors associated with medication use	CD	Retrospective cohort	USA	2964	Initiators were appreciably younger than controls (P < 0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio [OR] = 1.52 with 95% confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab.	In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not.

Smith 2023	Barriers to success of post surgical enhanced recovery	IBD Post surgical	Retrospective cohort	USA	466	In multivariable analysis stratified by enhanced recovery period, Black race was associated with increased odds of complications in the pre-ERP (OR 3.6, 95%CI 1.4-9.3) and ERP groups (OR 3.1 95%CI 1.3-7.6). Race was not a predictor of LOS or readmission in either group. High social vulnerability was associated with increased odds of readmission pre-ERP (OR 15.1, 95%CI 2.1-136.3), but this disparity was mitigated under ERPs (OR 1.4, 95%CI 0.4-5.6).	While enhanced recovery period mitigated some disparities by social vulnerability, racial disparities persist in IBD populations even under ERPs.
Walker 2011	Racial distribution IBD	IBD	Retrospective cohort	UK	367	63.0% of South Asian UC patients had extensive colitis compared with 42.5% of the Northern European cohort (P < 0.0001). Proctitis was uncommon in South Asian UC patients (9.9 vs. 26.1% in Northern European patients, P<0.0001). In the South Asian CD cohort, disease location was predominantly colonic (46.8%). CD behavior differed significantly between the groups, with less penetrating disease compared with Northern Europeans (P=0.01) and a reduced need for surgery (P=0.003).	The phenotype of IBD in South Asians living in North West London is significantly different from that of a white Northern European IBD cohort.
Farrukh 2022	Racial disparities in outcomes	UC surgery	Retrospective cross sectional	UK	476	There was no statistically significant difference in the distribution across the types of surgery undergone by the two communities overall (Ï‡(2) = 1.3, ns) and the proportions who underwent an ileo-anal anastomosis with pouch (z = -1.2, ns). However, within individual trusts, at the University Hospital Southampton NHS Foundation Trust, a significantly greater proportion of South Asian patients had an ileo-anal anastomosis with pouch compared to White British patients.	These findings reinforce the argument that inflammatory bowel disease surgery should be performed in a limited number of high-volume centres rather than across a wide range of hospitals so as to ensure procedures are carried out by surgeons with sufficient and on-going experience.
Stamatiou 2022	Factors affecting surgical outcomes	IBD	Retrospective observational	UK	1620	Ethnic minority background and higher IMD score were further associated with surgical complications for CD but not UC patients.	Ethnic minority status and socioeconomic deprivation were associated with worse surgical outcomes within our cohort of IBD patients.

Frieder 2022	Racial disparities in outcomes	IBD Post surgical	Retrsopective cohort	USA	38143	After multivariable analysis, African american patients had significantly higher overall risk of complications (OR = 1.27; 95% CI, 1.15-1.40) and extended hospital stay (OR = 1.59; 95% CI, 1.45-1.75) than Caucasians. On bivariate analysis, there was no significant difference in mortality between AA and Caucasian patients.	African american patients requiring segmental colectomy for inflammatory colorectal conditions experience significantly higher rates of postoperative complications, longer hospital stays, and lower rates of private insurance.

Table 2. Characteristics of included studies.

Quality appraisal was not performed as there were no experimental works included.

Of the 22 qualitative research works, review of the nature of findings when reading the articles found that the qualitive methods were mostly non-theoretically informed and nonrigorous methods, such as narrative or thematic analysis. Linked to this, the nature of findings were mainly descriptive and did not lend themselves to a more detailed thematic analysis.

To ensure this was the case, an Artificial intelligence tool was employed named infranodus. Analysis is shown below in node map.



Figure 2. Nodal map of themes from the included studies

This analysis uses AI to identify lower and then higher level ideas to approximate three phased coding. It demonstrates the lack of relevant analysis findings and so no further thematic analysis was attempted.

Key research findings

The core findings of the studies were most commonly focussed on race as a determinant of both disease and care. The general trend of increase in prevalence of IBD in industrialised countries, as well as the exponential growth in countries which are industrialising, was noted. Specific research highlighted differences by ethnic and religious groups is well documented. Findings from big data studies was unclear. Even though these involved large samples, the findings were often contradictory. For example, some studies showed clearly worse outcomes for black patients and paradoxically one of the largest big data studies (Asotibe 2022) with almost 200,000 participants found worse outcomes for white patients.

Of particular note are UK based studies suggesting that south Asians have both higher incidence of more severe morbidity with Crohn's and Colitis and yet lower rates of some key therapies, such as biologics. One small UK qualitative study (Mukherjee 2021) found participants believed that South Asian cultures and/or religions can lead to additional challenges linked to a number of social cultural factors affecting communities. This was also seen in another small study focusing on young patients (Alexakis 2015) suggesting that key to supporting care is overcoming cultural communication barriers.

A number of international studies describe findings related to economic status of patients and their families. Notably, the economic impact of Crohn's and Colitis on those it affects as a direct result of the cost of therapies and the ability to continue employment. More recently, a global study (Odufalu 2023) found that lower socio-economic status patients were less likely to have participated in a peer mentoring or education program and less likely to reach out to patient support groups. However, unemployed people were more likely to report being in excellent health. No exploration of the causes of these differences was included.

A small number of studies investigated gender. A Swedish study (Stiernmann 2011) found Women with CD had higher rates of sickness and disability than men. A Canadian study (Vigod 2019) found higher rates of new-onset mental illness in mothers with IBD, although the risk reduced in the post-partum phase. One study reported guidelines for trans-gender patients with IBD

Gaps in research

Despite the patterns in racial morbidity and inequality in treatment distributions, there is limited evidence to explore how and why these differences occur. Specifically, work investigating whether delays in diagnosis or cultural risk factors may be leading to worse disease presentations and perhaps more importantly why there are distinct differences in delivery of therapies to these groups are key. There is also limited work investigating other communities noted globally with similar patterns in the IBD community, for example African Americans in the USA and Ashkenazi jews globally.

Such research must recognise the complex and confounding nature of the evidence in these studies and deploy methods to account for or explore them. This will begin to explain some of the conflicting studies, but also move past 'what' differences exist due to these factors, but 'how' and 'why' they occur.

There are also key content areas that appear to be under-represented in the UK, including studies investigating gender, religion, education and mental health. The studies that existed in these areas suggested relevant important finding but once again these focussed on demographic descriptions of difference.

Future systematic review areas

Whilst it is likely that many studies were not included in this review, given the nature of those included, their own references to the literature and the methodological rigour of the process followed, it appears that in most areas future systematic reviews are not currently warranted and instead primary research is proposed.

The exception to this may be the area of race. There is clearly much work on this topic and a systematic review limited to the UK would allow direct consideration of both UK based differences in incidence and morbidity, but also in outcome measures.

Limitations

A key limitation of this scoping review is that by focussing on the initial question commissioned and thereby searching for studies with the primary goal of exploring the social and economic factors of interest, this has limited studies with subgroup or incidental findings of interest regarding this factors. This is often a finding of such broad studies, but paradoxically, such reviews are vital to inform the very process of refinement of the core questions for future study.

Several stages of iteration within the search strategy were completed with the commissioning organisation. This attempted to balance the impact of a large and complicated search (this study considered over 5,000 citations) with the commissioned requirement to complete this report within a very rapid timeframe. If significantly more time and funds were available, a far more wide search could have been completed and this is a clear limitation. However, it must be noted that there is no evidence base within methodological studies that such wider searches will increase the final yield of studies (Peters 2020). Rather, the scoping reviews is a key step within the scholarly journey within this context and will inform the next steps in spite of any pragmatically enforced limitations.

Future research proposals

Future studies need to consider not just the missing content areas but deploying research methods that can investigate how and why these may occur. There are multiple dimensions and research traditions that could be suited for this.

Much improved data collection study publications are needed within the UK. These need to be deployed on a prospective and longitudinal basis and consider multiple factors. This will allow the interplay of clinical course, treatment deployment and multiple social economic factors to all be considered in multivariate analysis. Whilst such data clearly exists in practice, published and thereby research ready sources are limited.

Once completed, such studies and their data will allow patterns to be identified and potential hypotheses to be made. Then, different forms of research using qualitative methods are best deployed to explore questions from a constructivist paradigm. One that may be particularly suited is ethnography. Ethnography is a type of social science research that involves examining the behavior of the people within the context of their everyday lives and seeks to understand the group members' own interpretation of such behavior. Ethnographic research relies heavily on participant observation—on the researcher participating in the setting or with the people being studied, at least in some marginal role, and seeking to document, in detail, patterns of social interaction and the perspectives of participants, and to understand these in their local contexts.

Conclusions

Research on the impact of social and economic factors on outcomes in IBD is capricious and of a limited nature, focussing primarily on descriptive findings of patterns of clinical differences in IBD incidence that are related to broad outcome categories and often conflicting. Investigation of areas such as gender, religion, employment, and education are very limited. Future work must not only seek to clarify more broadly the factors impacting IBD outcomes for UK people, but also the likely complex causal reasons for these findings.

References

Arksey H, O'Malley L. (2005). Scoping studies: towards a methodological framework. Int J Soc Res. 8(1):19-32. doi: 10.1080/1364557032000119616

Daniel M, Gordon M, Patricio M, Hider A, Pawlik C, Bhagdev R, et al (2021) An update on developments in medical education in response to the COVID-19 pandemic: A BEME scoping review: BEME Guide No. 64, Medical Teacher, 43:3, 253-271, DOI: 10.1080/0142159X.2020.1864310

Hibble S, Connell-smith A. Widening participation strategy in higher education in England. Commons library. Available at: https://commonslibrary.parliament.uk/research-briefings/cbp-8204/

Horsley, T, Weeks, L, Hempel, S et al. (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 169(7):467-473. doi:10.7326/M18-0850

KHALIL, H., PETERS, M.D.J., TRICCO, A.C., POLLOCK, D., ALEXANDER, L., MCINERNEY, P., GODFREY, C.M. and MUNN, Z. (2021). Conducting high quality scoping reviews: challenges and solutions. Journal of clinical epidemiology [online], 130, pages 156-160. Available from: https://doi.org/10.1016/j.jclinepi.2020.10.009

Levac, D., Colquhoun, H. & O'Brien, K.K. (2010) Scoping studies: advancing the methodology. Implementation Sci 5, 69

Peters MDJ, Marnie C, Tricco AC, et al. (2020) Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth 18(10):2119–2126. doi: 10.11124/jbies-20-00167

Peters MDJ, Godfrey C, McInerney P, Soares CB, Khalil H, Parker D. Aromataris E, Munn Z. (2017) Chapter 11: Scoping reviews. JBI, JBI Reviewer's Manual. Adelaide.

Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. (2015) Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. Sep;13(3):141-6. doi: 10.1097/XEB.0000000000000050. PMID: 26134548.

Thomas A, Lubarsky S, Durning SJ, Young ME. (2017) Knowledge syntheses in medical education: demystifying scoping reviews. Acad Med . 92(2):161–166. doi: 10.1097/ACM.0000000000001452

Tricco, A.C., Lillie, E., Zarin, W. et al (2016). A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol 16, 15 https://doi.org/10.1186/s12874-016-0116-4

Appendix 1 – Further data extraction table

Study ID	Topic	Condition	Methods	Location	Sample Ssze	Key findings	Conclusions
Kaplan 2015	Global epidemiology	IBD	Audit of published studies	Canada	UNCLEAR		Over 1 million residents in the USA and 2.5 million in Europe are estimated to have IBD, with substantial costs for health care. IBD increasing in newly industrialized countries and forecasts the global effects of IBD in 2025.
Sedano 2022	Representation in trials	IBD	Audit of published trials	canada	19476	22% of Induction and 26% of maintenance trials don't report race.	Potential under-representation of minorities in trials in IBD
Aniwan 2019	Racial distribution IBD	IBD	Big data	USA	UNCLEAR	Adjusted annual incidence rate of IBD for whites was 21.6 cases per 100,000 person-years and for nonwhites it was 13 per 100,000 and increased by 39% and 134%, respectively, from 1970 through 2010.	There were significant racial and ethnic differences in the incidence and temporal trends of IBD over the last four decades in this US population-based cohort.
Asotibe 2022	Racial disparities in outcomes	IBD	Big data	USA	177574	There was no significant difference in inpatient mortality for black vs white patients and no difference in the	White patients hospitalized with a principal diagnosis of IBD had no difference in inpatient mortality or septic shock but had

						odds of developing septic shock	worse outcomes such as increased odds of bowel perforation compared to black patients.
Barnes 2018	Racial disparities in outcomes	IBD	Big data	USA	5537	Black patients were more likely to report a Crohn's disease (CD)-related complication at baseline (adjusted odds ratio [aOR], 1.44; 95% confidence interval [CI], 1.06-1.95). Black patients with ulcerative colitis were more likely to have proctitis (24% vs 13%, P = 0.033) at baseline.	Black patients with CD demonstrated increased complications at baseline and during follow-up in this cohort.
Barnes 2021b	Patterns of drugs use based on drugs	IBD	Big data	USA	14735	there was no significant difference in the odds of anti-tumor necrosis factor use by race for CD (adjusted odds ratio [aOR] = 1.13; 95% confidence interval [CI], 0.99-1.28] or ulcerative colitis (aOR = 1.12; 95% CI, 0.96-1.32).	Disparities in IBD treatment discussed in prior literature seem to be driven by socioeconomic or other issues affecting access to care, not race.
Barnes 2022	Racial distribution IBD	IBD	Big data	USA	212393	Black adult patients were significantly less likely than White patients to have a diagnosis of CD (odds ratio [OR], 0.53; 95% CI, 0.52-0.54) or UC (OR, 0.41; 95% CI, 0.40-0.43). Pediatric Black patients were also less	CD and UC are modestly less prevalent among patients of non-White races and Hispanic ethnicity.

						likely to have a diagnosis of CD (OR, 0.41; 95% CI, 0.39-0.43) or UC (OR, 0.38; 95% CI, 0.35-0.41).	
Bernstein 2001	broad determinants	IBD	Big data	Canada	UNCLEAR	In study A we found that, compared with the general population, patients with IBD were more likely to be unemployed. Crohn's disease appeared to affect employment more than ulcerative colitis	Individuals with IBD at some time in the course of their illness are more likely not to be working than are those in the general population
DosSantos Marques 2022	Racial factors impacting distribution of drug use	IBD	Big data	USA	14735	barriers to a positive surgical experience included inadequate personal knowledge of IBD, ineffective written and verbal communication, lack of a support system and complications after surgery	Black and White patients with IBD have varied surgical experiences but all stressed the importance of accurate, trustworthy and understandable health information. These findings highlight the value of providing health literacy-sensitive care in surgery.
Eglinton 2012	Racial distribution Peri-anal disease	CD	Big data	new Zealand	715	Perianal disease was associated with younger age at diagnosis (P < 0.0001), complicated intestinal disease (P < 0.0001), and ileal disease location (P = 0.002). There was	This study suggests that younger age at diagnosis, complicated disease behavior, and ileal disease location are risk

						no association with gender, ethnicity, smoking, or breast feeding.	factors for perianal CD.
Farrukh 2015b	Racial factors impacting distribution of drug use	CD	Big data	UK	UNCLEAR	In three Trusts, the number of South Asian patients who received such treatment was significantly less than British/White patients. These were: Pennine Acute Hospitals NHS Trust covering Oldham and North Manchester, Barking, Havering & Redbridge University Hospitals NHS Trust and University Hospitals of Leicester NHS Trust.	It is unacceptable for there to be a difference based on racial grounds.
GunnellsDJJr 2016	Racial disparities in outcomes (surgery)	IBD	Big data	USA	2523	On multivariable analysis, black race remained a significant predictor for 30-day readmissions in patients with IBD (odds ratio 1.6, 95Â % confidence interval 1.1-2.5).	Black patients with IBD have an increased risk for readmission after colorectal surgery.
Kochar 2018	Racial distribution IBD	IBD	Big data	USA	5412	Adjusting for confounders, Asians had half the odds of being treated with biologics compared with whites (OR: 0.45, 95% CI: 0.30-0.67). Adjusting for disease behavior and remission	Asians are more likely to have perianal disease and ocular extra-intestinal manifestations. After controlling for confounders, Asians were less likely to be

						status, there were no differences in IBD-related surgery or hospitalization, new biologic or steroid prescription or relapse rates between Asians and whitesat follow-up.	treated with biologic agents.
Lichtenstein 2020	Impact of age on economic burden of IBD	IBD	Big data	USA	164375	Lifetime total cost was $405,496, consisting of outpatient ($163,670), inpatient ($123,190), pharmacy ($105,142), and ER ($13,493) costs.	we estimated lifetime costs for patients with CD or UC to exceed previously published estimates.
Longobardi 2003	Employement impact of IBD	IBD	Big data	Canada	UNCLEAR	Based on this, the indirect cost of nonparticipation attributable to IBD in 1998/1999 was more than $3.6 billion U.S. dollars (USD) or $5228 USD per person with IBD and symptoms. According to the second weighted logistic regression, for those who are in the labor force, having IBD had no association with the duration of work.	This method of estimation can be used to predict the overall paid-employment burden of IBD.
Malhotra 2015	Racial distribution IBD	IBD	Big data	USA	30812	UC was more commonly associated with Indian and Jewish ethnicity and less commonly associated with	Patients of Indian origin living in the United States have a greater risk for all types of IBD than other

						East Asian and Hispanic ethnicity. Similar patterns also applied to CD and to all types of IBD analyzed jointly.	American populations.
Misra 2016	Racial differences in colectomy rates	UC	Big data	UK	212430	Indians had a significantly higher colectomy rate than WE (9.8% versus 6.9%, p < 0.001). Indian patients were 21% more likely to require colectomy for UC compared with WE group (OR: 1.21, 95% CI: 1.04-1.42, and p = 0.001).	The colectomy rate in this cohort was higher in Indians compared to WE
Misra 2019	Racial distribution IBD	IBD - Inception study	Big data	UK	339	The age adjusted incidence of IBD and UC were significantly higher in the Indian group (25.2/100000 and 20.5/100000) compared to White European (14.9/100000, P = 0.009 and 8.2/100000, P < 0.001) and Pakistani groups (14.9/100000, P = 0.001 and 11.2/100000, P = 0.007). The Indian group were significantly more likely to have extensive disease than White Europeans (52.7% vs 41.7%, P = 0.031). There was no significant difference in time to diagnosis,	This is the only prospective study to report the incidence of IBD in an ethnically diverse United Kingdom population. The Indian ethnic group showed the highest age-adjusted incidence of UC (20.5/100000).

						disease activity and treatment.	
Probert 1992	Racial distribution IBD	CD	Big data	UK	UNCLEAR	The mean standardized incidence in Bangladeshis was 1.2/10(5)/year in the 1970s and 2.3/10(5)/year in the 1980s compared with 3.8/10(5)/year and 4.1/10(5)/year in Europeans, and 4.6/10(5)/year and 5.4/10(5)/year in West Indians, respectively. None of the changes with time was statistically significant.	The apparent similarity of the incidences of Crohn's disease in Bangladeshis and Europeans contrasts with findings in other South Asians.
Sewell 2010	Racial disparities in outcomes	IBD	Big data	USA	UNCLEAR	The proportion of hospitalizations including a discharge diagnosis of IBD increased significantly from 1994 to 2006 among the total population and among Asian, black, and white patients separately.	The proportion of hospitalizations including a discharge diagnosis of IBD increased significantly among minority and nonminority patients from 1994 through 2006. The causes underlying these changes are not certain and should be further investigated.
Shapira 1994	Racial distribution IBD	CD	Big data	israel	UNCLEAR	he mean annual incidence rate in the Kinneret sub-district among Jews was 1.96/100,000 during 1960-1990 and 2.98/100,000	(1) morbidity rate of Crohn's disease increased over time, and (2) in the last decade incidence rates among Jews of Asian-African

						in the last decade. The prevalence rate in 1990 among Jews was 45.9/100,000 and was twofold among European-American-born compared to other ethnic groups.	origin are similar to, or even higher than those of European-American origin.
Vigod 2019	Pregnancy association with mental health in IBD	IBD	Big data	Canada	UNC LEAR	About 22.7% of women with IBD had new-onset mental illness versus 20.4% without, risk was elevated in the post partum (aHR 1.20, 95%â€‰CI 1.09 to 1.31).	Women with IBD were at an increased risk of new-onset psychiatric diagnosis in the postpartum period, but not during pregnancy.
Vij 2019	Racial disparities in outcomes (Colon cancer)	IBD	Big data	USA	57542	In patients with IBD, advanced age conferred an increased risk for developing CC while female gender conferred a protective effect. In this subset of patients, black race conferred a protective effect	Racial disparity exists in the overall incidence of CC and among patients with IBD who develop CC. Interestingly, black race conferred a protective effect for patients with IBD, contrary to what is seen in the general population.
Wang 2013	Racial distribution IBD	IBD	Big data	USA	202468	The prevalence of IBD was higher in Whites [Crohn's disease: 154; ulcerative colitis (UC): 89] than Blacks (Crohn's disease: 68; UC: 25), Hispanics (Crohn's disease: 15; UC: 35), and Asians (Crohn's:	There were significant racial/ethnic differences in the prevalence of IBD in the USA.

						45; UC: 40) (all p < 0.05, except for UC in Asians).	
Zhornitsky 2021	Racial distribution IBD	IBD	cohort	USA	UNC LEAR	Prevalence of IBD per 100,000 people was 418 (95% CI 341-512) for Hispanics and 557 (95% CI 431-739) for NHWs. Notably, the proportion of Hispanic IBD patients with a history of smoking was 21.5% vs 50.8% in NHWs (p = 0.011).	In one of the largest US studies of Hispanics with IBD, and the only one to have both clinical and histopathologic confirmation as inclusion criteria, we found the incidence and prevalence of IBD among Hispanics to be higher than previously recognized and comparable to NHWs.
Gadhok 2020	Outcomes depending on race	IBD	Cohort study	UK	224	Bangladeshi patients started an anti-TNF 4.3Â years earlier after diagnosis than Caucasian patients (3.9Â years vs. 8.2Â years: pâ€‰<â€‰0.01). Bangladeshi patients experienced shorter failure-free survival than Caucasian patients (1.8 vs. 4.8Â years pâ€‰<â€‰0.01).	This is the first study to suggest that Bangladeshi patients resident in the UK with CD respond less well to treatment with TNF antagonists than Caucasian patients.
Bernstein 2020	Impact of lower socio-economic status	IBD	Cohort study	Canada	9298	Comparing persons with Lower Socieconomic State (LSS) vs those without any markers of LSS, there were increased rates of annual outpatient	LSS was associated with worse outcomes in persons with IBD. Social determinants of health at time of diagnosis should be highly

						physician visits (relative risk [RR] = 1.10, 95% confidence interval [CI] = 1.06-1.13), hospitalizations (RR = 1.38, 95% CI = 1.31-1.44), intensive care unit admission (RR = 1.94, 95% CI = 1.65-2.27), use of corticosteroids >2,000 mg/yr (RR = 1.12, 95% CI = 1.03-1.21), and death (hazard ratio 1.53, 95% CI = 1.36-1.73).	considered and addressed.
Wetwittayakhlang 2023	Factors associated with diagnosis	IBD	cohort study - three timer periods	hungary	2240	Rates of active smoking significantly decreased over time in Crohn's disease (CD): 60.2%, 49.9%, and 38.6% in cohorts A/B/C ($p < 0.001$). In UC, the rates were low and stable: 15.4%, 15.4%, and 14.5% in cohorts A/B/C ($p = 0.981$).	The association between trends of known environmental factors and IBD is complex. Smoking has become less prevalent in CD, but no other major changes occurred in socioeconomic factors over the last four decades that could explain the sharp increase in IBD incidence.
Acosta-RamÃrez 2001	MEntal healht characteristics in ibd	IBD	cross-sectional	Puerto Rico	67	Patients older than 34 years old had three times higher probability of developing a depressive disorder ($p = 0.043$, OR = 3.22). Patients with a psychiatric history had seven times higher probability	The risk factors identified with an increased probability of developing a depressive disorder were age older than 34 years and psychiatric history.

						of developing depressive disorder (p = 0.004, OR = 7).	
Can 2022	Factors affecting medication adherence	IBD	cross-sectional	Turkey	253	Intentional (29.3% in ulcerative colitis and 16.3% in Crohn's disease [P = .031] and unintentional non-adherence to treatment (28.1% in ulcerative colitis, 16.3% in Crohn's disease [P = .037] were significantly higher in ulcerative colitis than in Crohn's disease. Female gender (odds ratio = 2.59, P = .005), low education level (odds ratio = 4.8, P = .015), distal involvement in ulcerative colitis (P = .014), and thoughts about the disease would last too soon in Crohn's disease (odds ratio = 4.17, P = .049) were risk factors for non-adherence to treatment.	The negative perception of treatment in inflammatory bowel disease affects adherence to the treatment.
Click 2016	Predictors of high heathcare utilisation	IBD	cross-sectional	USA	400	In multivariate analysis, unemployment (Crohn's disease [CD]: odds ratio [OR], 3.04; 95% confidence interval [CI], 1.32-7.02; ulcerative colitis [UC]: OR, 2.68; 95% CI, 1.20-5.99), psychiatric illness (UC: OR, 2.08; 95% CI, 1.03-	High expenditure IBD patients were affected by more severe disease. The high prevalence of depression, anxiety, and chronic pain in these patients suggests the need for focused treatment of

						4.19), opiates (CD: OR, 5.61; 95% CI, 2.67-11.82; UC: OR, 5.14; 95% CI, 2.52-10.48), prior surgery (CD: OR, 3.29; 95% CI, 1.59-6.82; UC: OR, 2.72; 95% CI, 1.39-5.32), penetrating CD (OR, 3.29; 95% CI, 1.02-10.62), and corticosteroid requirement (CD: OR, 3.78; 95% CI, 1.86-7.65; UC: OR, 2.98; 95% CI, 1.51-5.90) remained independently associated with high charges.	these comorbidities ultimately to reduce financial burden.
Damas 2022	Social barriers impact on outcomes	IBD	cross-sectional	USA	316	Social barriers associated with poor IBD outcomes included low educational attainment, poor health literacy, and financial insecurity. High social barrier scores was associated with greater depressive symptoms [odds ratio (OR) 1.94, 95% confidence interval (CI) 1.21-2.9, pâ€‰=â€‰0.001] and lower reported use of medications.	Our study identifies social barriers that may impact IBD care and are disproportionately higher in non-Hispanic Blacks and Hispanics in the United States.
DosSantos Marques 2020	Factors impacting health literacy in IBD	ibd	cross-sectional	USA	175	On multivariable analysis, low health literacy was associated with older age and African American race ($P < 0.05$). Of 83 IBD patients	Low health literacy is present in IBD populations and more common among older African Americans.

						undergoing abdominal surgery, mean postoperative LOS was 5.5 days and readmission rate was 28.9%.	
Farrukh 2016	Racial disparities in outcomes	IBD	cross-sectional	UK	70	South Asian patients were significantly less likely to see a consultant and more likely to be discharged. South Asian patients were admitted to hospital more often but had significantly fewer tests than European patients.	Patients with ulcerative colitis who are of South Asian origin receive poorer quality clinical care than their European counterparts.
Greenberg 2015	Factors affecting utility weights (health economics)	CD	cross-sectional	Israel	425	significant predictors of utility weights in a multivariable regression analysis were the HBI [$\hat{I}^2$ = -0.494; p < 0.001], economic status [$\hat{I}^2$ = 0.198; p < 0.001], time since diagnosis [$\hat{I}^2$ = 0.106; p < 0.001], male [compared with female] gender [$\hat{I}^2$ = 0.099; p = 0.009], hospital admission in the past year for any cause	Utility weights for patients in the remission and mild disease states were generally lower as compared with values used in published cost-effectiveness analyses.
Naftali 2022	Factors effecting patient preference	IBD	cross-sectional	israel	361	Multivariable regression analysis revealed that higher patient preferences were associated with Jewish ethnicity (OR 4.77; 95%CI 2.36-9.61, P < 0.001) and disease activity.	The highest priority for treatment outcomes was symptom relief., Patients preferences were impacted by ethnicity, gender, and socio-

							economic disparity.
Nazarinasab 2019	Mental healht characteristics in CD	CD	cross-sectional	Iran	96	Multivariate analysis of mental health showed that steroid consumption (P value < 0.001) and nonsmoking (P value = 0.038) were associated with higher mental health in the individuals.	Crohn's patients suffered from decreased mental parameters
Nguyen 2010	Racial disparities in utilisation	IBD	cross-sectional	Canada	286	blacks were less likely than whites to be under the regular care (defined as at least annual visit) of a gastroenterologist (adjusted odds ratio (aOR) 0.43; 95% confidence interval (CI): 0.25-0.75) or IBD specialist (aOR 0.37; 95% CI: 0.22-0.61).	There are racial differences in utilization of IBD-related specialist services, ED visits, and infliximab that are independent of income and education.
Odufalu 2023	broad determinants	UC	cross-sectional	GLOBAL	1000	Low-income vs high-income patients were less likely to have participated in a peer mentoring (OR, 0.30) or UC education program (OR, 0.51). Patients not employed were less likely to report being in "good/excellent" health (OR, 0.58) than patients employed full time. Patients with low vs high educational levels were less likely to have reached out	Substantial differences in disease management and health care experience were identified

						to patient associations/organizations (OR, 0.59). Patients aged younger than 50 years vsâ€…those aged 50 years and older were less likely to have visited an office within an inflammatory bowel disease center/clinic in the past 12 months (OR, 0.53).	
Walldorf 2021	Factors impacting childlessness	IBD	cross-sectional	Germany	533	Poor knowledge was not associated with increased childlessness (CCPKnow of <â€Š8 was found in 29.8â€Š% of patients with children and 28.9â€Š% of childless patients, pâ€Š>â€Š0.5). Instead, the patients' education, medical advice, FPP-related concerns, impaired body image, and sexual dysfunction had a significant impact on childlessness.	Factual knowledge does not reduce disease-related concerns or childlessness.
Schenker 2021	Guideline for Transgender IBD	IBD	Guideline / position statement	USA	UNCLEAR	Despite an increase in provider awareness of TGNC health over the past decade, no original research or societal guidelines exist on TGNC patients with inflammatory	high-quality care to the Trans-gender IBD population can be divided into 3 categories: medications, anatomy, and mental health.

						bowel disease (IBD).	
Montgomery 1999	Racial distribution IBD	IBD	Longitudinal birth cohort study	UK	UNCLEAR	Young Asians born in Britain were significantly more likely than indigenous Europeans to have a diagnosis of IBD by age 26 years, with relative odds of 6.10 (95% CI 2.14-17.33).	Young Asians who were born in Britain are at a significantly higher risk of developing IBD than the indigenous European population.
Ediger 2007	Factors determining medical adherence	IBD	Propsective cohort	Canada	326	or men, predictors of low adherence included diagnosis (UC: OR 4.42, 95% CI 1.66-11.75) and employment status (employed: OR 11.27, 95% CI 2.05-62.08). For women, predictors of low adherence included younger age (under 30 versus over 50 OR 3.64, 95% CI 1.41-9.43; under 30 vs. 40-49 yr: OR 2.62, 95% CI 1.07-6.42). High scores on the Obstacles to Medication Use Scale strongly related to low adherence for both men (OR 4.05, 95% CI 1.40-11.70) and women (OR 3.89, 95% CI 1.90-7.99).	Approximately one-third of IBD patients were low adherers. Predictors of adherence differed markedly between genders
Acciari 2019	Social aspects influence wellbeing vs	IBD	Qualitative research	Brazil	104	There were also significant differences in the use of Coping: usually, women used more developed escape	Social aspects influenced psychological well-being, resilience and Coping in patients with Crohn's

	clinical aspects					and avoidance strategies; single, married or in stable-union patients used more self-control; not religious used positive revaluation strategy; the ones who were employed showed more self-control and positive reassessment; the ones who had lower family income indicated that they used less the self-control; the ones who had higher family income used more positive re-evaluation; patients who were diagnosed with Crohn's disease between the second decade of life showed to use mores more the positive reassessment strategy than those who were 20 years old or younger.	disease more strongly than clinical aspects.
Agrawal 2019	Factors influencing disability in IBD	IBD	Qualitative research	USA	323	On multivariable analysis, Hispanic ethnicity (aOR 2.7, 95% CI 1.3-5.6), non-Hispanic non-black minority race (aOR 3.5, 95% CI 1.3-8.9), public payer (aOR 2.1, 95% CI 1.1-4.0) and low annual household income (aOR 3.0, 95% CI	IBD patients who are minorities, have public insurance, or low household income, are 2-3 times more likely to report moderate-to-severe disability independent of disease

						1.7-5.4) were associated with moderate-to-severe disability controlling for disease characteristics.	characteristics in the United States.
Alexakis 2015	Factors associated with challenges in IBD in young people	IBD	Qualitative research	UK	20	A thematic analysis of their experiences identified many commonalities with other young people with IBD, such as the problematic route to formal diagnosis and the impact of IBD on education. The young people also experienced tensions between effective self-management strategies and cultural norms and practices relating to food. Moreover, the ability of parents to provide support was hampered for some young people by the absence of culturally competent services that were responsive to the families' communication needs.	The findings highlight the need for more culturally appropriate information concerning IBD, and improved responsiveness to young people with IBD within primary care and the education system
Bernklev 2006	Employement impact of IBD	IBD	Qualitative research	Norway	495	Sick leave for all causes was reported in 47% with ulcerative colitis and 53% with CD, whereas IBD-related sick leave was reported in 18%	Unemployment or sick leave is more common in IBD patients than in the Norwegian background population.

						and 23%, respectively. A majority (75%) had been sick <4 weeks, and a relatively small number of patients (25%) contributed to a large number of the total sick leave days. Both unemployment and DP reduced HRQOL scores, but the most pronounced effect on HRQOL was found in patients reporting IBD-related sick leave, measured with SF-36 and N-IBDQ.	
Blumenstein 2013	Racial differences in knowledge	IBD	Qualitative research	Germany	303	German patients obtained knowledge from a wider range of sources than Irish patients ($p<0.001$), most notably from the internet ($p<0.001$), newspapers and magazines ($p=0.002$).	Our data suggest few differences between German and Irish IBD patients, despite cultural and linguistic differences, with regard to disease related knowledge of IBD.
Chrobak-BieÅ„ 2018	Factors afffecting acceptance of UC	UC	Qualitative research	Poland	50	Analysis of the results showed a reduced degree of acceptance of the disease among patients in the phase of exacerbation of the disease. The mean point score of the AIS scale for the study group was 29.65, which indicates the average level of acceptance of the	People with higher education, professionally active and treated conservatively, accepted their illness to a better extent.

						disease among respondents	
Engel 2021	Psychological parameters across key factors	IBD	Qualitative research	Germany	62	Levels of depression and anxiety were higher in CD/UC patients than in HC with large effect sizes. Comparing personality functioning in CD/UC with HC, psychodynamic structural characteristics differed between CD/UC and HC with medium effect sizes, with structural differences occurring primarily in the domain of self-perception and regulation.	Our data show that compared to HC, patients with CD/UC are characterized by a higher level of psychological burden and structural alterations in the domain of self.
Freitas 2015	Religious coping as predictor for other factors	IBD	Qualitative research	Brazil	147	Positive religious coping was negatively associated with anxiety (b = 0.256; p = 0.007) as well as with overall, physical, and mental health HRQoL. Religious struggle was significantly associated with depression (b = 0.307; p < 0.001) and self-reported adherence (b = 0.258; p = 0.009). Finally, anxiety symptoms fully mediated the effect of positive religious coping on overall HRQoL.	Religious coping is significantly associated with psychological distress, HRQoL, and adherence in IBD.
Harvey 2022	Perspectives of	IBD	Qualitative	Canada	23	Thematic analysis found focus on	An ideal IBD clinic would provide

	patients with lower educational attainment		research			communication with health care professionals, access to care, symptoms and treatment, and outside support. Access to an IBD specialist was the most important aspect of care. Good care, kind and receptive staff, and a lengthy delay to diagnosis were frequently reported experiences. IBD specialists, nurses, and family and friends were most helpful in managing disease. Physical and emotional symptoms, reduced social engagement, and medications were difficult aspects of living with IBD.	access to traditional and non-traditional services and assist with obtaining support to help patients engage in social activities, increase affordability of care, and maintain employment.
Larussa 2020	Factors affecting willingness to take part in trials	IBD	Qualitative research	Italian	145	Multivariate analysis showed a significant positive association between interest in clinical trials and previous experience ($p = 0.014$), high education ($p < 0.001$), poor QoL ($p = 0.016$), money retributions ($p = 0.03$) and informative materials ($p = 0.02$). On the other hand, a long-standing disease ($p = 0.017$), the	In a native local resident series of IBD patients, the majority of the patients were willing to participate in a clinical therapeutic trial. A long-standing disease, placebo and invasive procedures represented a barrier to enrollment while previous experience, high education,

						possibility of receiving a placebo (p = 0.04) and the frequent colonoscopies required by the study protocol (p = 0.04) were significantly associated with the lack of interest in clinical trials	monetary compensation and adequate information could be facilitative.
Long 2014	Factors associated with depression in edlerly	IBD	Qualitative research	USA	359	ower education levels (p=0.001), higher corticosteroid use (<0.01) and lower exercise levels (<0.001) were associated with depression. For both CD and ulcerative colitis (UC), those with depression had increased disease activity (short Crohn's disease activity index 52.5 versus 29, p=0.005, and simple clinical colitis activity index 5 versus 2, p=0.003).	Depression is common in this geriatric IBD cohort. Depression is independently associated with reduced medication adherence.
Mahlich 2017	Employement impact of IBD	IBD	Qualitative research	Japan	1068	We found that the labor force participation rate is lower and unemployment higher for patients with IBD compared to the general population. Factors associated with unemployment in the IBD sample are older age, female gender, and the	IBD constitutes a high burden for patients in Japan regarding employment outcome.

						prevalence of depression.	
Moradkhani 2013	Racial disparities in outcomes	IBD	Qualitative research	USA	134	Multivariate analyses revealed that the variables most strongly associated with HRQOL were perceived stress ($p<0.001$), number of previous IBD relapses ($p<0.001$), gender ($p<0.001$), and perceived social support ($p<0.05$).	Individuals with IBD who report higher perceived stress, lower perceived social support, greater number of relapses, or are female may be at increased risk for decreased HRQOL.
Mukherjee 2021	South asian patients experiences	IBD	Qualitative research	UK	33	Although many experiences align with those of the general IBD population, participants believed that South Asian cultures and/or religions can lead to additional challenges. These are linked to: family and friends' understanding of IBD; self and family attributions regarding IBD; stigma surrounding ill health; the taboo of bowel symptoms; managing 'spicy food'; beliefs about food and ill health; roles within the family; living with extended family; the use of complementary and alternative therapies; and visits to family	Gastroenterology services have an important role to play in helping patients to overcome the challenges they encounter in their everyday life, both by providing individual patients with culturally appropriate care and advice.

						overseas. Religious faith helped many to cope with having IBD	
Multone 2015	Factors of non-responders to national surveys	IBD	Qualitative research	Switzerland	1943	Factors inversely associated with non-response to study questionnaires were: age >30 years, colonic only disease location, higher education and higher IBD-related quality of life for CD, and age >50 years or having a positive social support for UC	Characteristics of non-responders differed between UC and CD. The risk of non-response to repetitive solicitations (longitudinal versus transversal study) seemed to decrease with age.
Pittet 2017	Gender impact on coping	IBD	Qualitative research	Switzerland	1102	We identified six domains of concern: socialization and stigmatization, disease-related constraints and uncertainty, symptoms and their impact on body and mind, loss of body control (including sexuality), disease transmission, and long-term impact of the disease. Cancer concerns were among the highest scored by all patients (median 61.8).	Patients have numerous concerns related to their illness that need to be reassessed regularly. Concerns differ between men and women
Sarid 2017	Gender difference in coping with IBD	IBD	Qualitative research	Israel	402	A model split by gender and disease activity showed that in active CD economic status impacted SIBDQ in men (Î² = 0.43) more than women	Gender differences in coping and the impacts of economic status and emotion-focused coping

						(Î² = 0.26); emotional coping impacted SWLS in women (Î² = 0.36) more than men (Î² = 0.14).	vary with activity of CD.
Sorensen 1987	broad determinants	CD	Qualitative research	Norway	106	54% of patients with Crohn's disease felt exacerbations of their disease strained their professional and personal life. During the previous year 23% reported decreased working capacity and 21% reported decreased leisure activities, compared with their own expectations.	During the previous year 23% reported decreased working capacity and 21% reported decreased leisure activities, compared with their own expectations.
Stjernman 2011	Broad determinants	IBD	Qualitative research	Sweden	497	Women with CD had higher rates of sickness and disability than men with CD and were more often living single, though procreation was not affected.	CD had higher impact on HRQL, compared with UC. Women with CD had worse outcome in subjective health status, but not in objective assessment of disease activity.
Farrukh 2015	Racial factors impacting distribution of drug use	CD	Retrospective cohort	UK	139	Based on a population composition, rather than prevalence data, in which 24% of the Leicester community should have been of South Asian origin, 33 patients would have received biologics compared with 92	Suggested reasons for these differences have included concerns about the animal origins of infliximab as well as difficulties associated with accessing the service, such as the provision of information in an

						patients of English origin (66%). This is significantly different to the 13 patients who did receive treatment (z=-3.2, PÂ <Â 0.001).	appropriate language through appropriate media.
Hoie 2007	Broad determinants	UC	Retrospective cohort	10 countries	771	The time to first relapse showed a greater hazard ratio (HR) (1.2, CI 1.0-1.5) for women and for patients with a high level of education (1.4, CI 1.1-1.8). The number of relapses decreased with age, and current smokers had a lower relapse rate (0.8, CI 0.6-0.9) than nonsmokers. The relapse rate in women was 1.2 (CI 1.1-1.3) times higher than in men.	In 67% of patients, there was at least one relapse. Smoking status, level of education, and possibly female gender were found to influence the risk of relapse.
Jayanthi 1992	Racial distribution IBD	CD	Retrospective cohort	UK	UNCLEAR	The standardized incidence in Europeans has risen significantly to 4.7/10(5)/year from 3.4/10(5)/year in the 1970s (chi 2 = 8.1, p less than 0.005). In Leicester this increase can be accounted for entirely by new cases of colonic disease.	Overall, Hindus have a much lower incidence of Crohn's disease than Europeans.
Jordan 2022	Depression rates	IBD	Retrospective cohort	USA	UNCLEAR	Overall prevalence of major depressive	Rates of depression among minority patients,

	amongst AA					disorder was 25.3%; 45.8% had minimal, 8.3% mild, 33.3% moderate, and 12.5% severe depression. A total of 34.7% of patients were never screened for depression, and 13.8% had other psychiatric conditions. There was a difference in depression rates based on psychiatric conditions (pÂ =Â 0.00), but no difference based on sex (pÂ =Â 0.37), IBD subtype (pÂ =Â 0.34), or medical conditions (pÂ =Â 0.84).	predominantly African American, with inflammatory bowel disease were higher than previously reported for all patients with inflammatory bowel disease.
Li 2014	Racial disparities in outcomes	UC	Retrospective cohort	USA	7350	Compared with whites, the male-to-female ratio differed for African-Americans (0.68 vs. 0.91, pÂ <Â 0.01) and Asians (1.3 vs. 0.91, pÂ <Â 0.01). Asians had fewer co-morbid conditions (pÂ <Â 0.01) than whites, whereas more African-Americans had hypertension and asthma (pÂ <Â 0.01). Use of immunomodulators did not differ	In this population of UC patients with good access to care, overall health-care utilization patterns and clinical outcomes were similar across races and ethnicity. Asians may have milder disease than other races whereas Hispanics had a trend toward more aggressive disease, although the differences

						significantly among race and/or ethnic groups.	we observed were modest.
Mangat 2011	Racial distribution IBD	IBD	Retrospective cohort	Canada	186	The South Asian population had a higher rate of UC, with an increased rate of complications and male predominance. Interestingly, the rate of CD and UC was lowest in the Pacific Asian population.	These racial differences - which were statistically significant - suggest a role for ethnodiversity and environmental changes in the prevalence of IBD in Vancouver.
MontgomerySRJr 2018	Racial disparities in outcomes (surgery)	IBD	Retrospective cohort	USA	14679	After adjustment, black patients remained at increased risk of DSM compared white patients (OR: 1.37; 95% CI 1.14-1.64). CONCLUSIONS: Black patients are at increased risk of post-operative DSM following surgery for IBD	Black patients are at increased risk of post-operative DSM following surgery for IBD. The elevated rates of DSM are not explained by traditional risk factors like obesity, ASA class, emergent surgery, or stoma creation.
Moore 2012	Racial distribution IBD	UC	Retrospective cohort	USA	311	African American patients had a shorter median duration (8.0, interquartile range [IQR] = 4.0, 14.0) of UC than Caucasians (10.0, IQR = 6.0, 18.0) (P = 0.006). African American disease patients had more distal disease than controls. African Americans were significantly less likely to use corticosteroids (74.2% vs. 88.8%,	There appear to be differences in the natural history of UC in our African American patients when compared with Caucasian controls, while ethnicity was not shown to be a risk factor for colectomy.

						P = 0.002), or use immunomodulators (25.8% vs. 69.7%, P < 0.001) than Caucasians.	
Norwood 2009	Racial disparities in outcomes (surgery)	IBD	Retrospective cohort	UK	107	Postoperative complications occurred in 40 (37%) patients, being major in 11 (10%) patients with relaparotomy required in 9 (8%) with no difference between South Asian and non-South Asian Caucasian patients. Long-term pouch function, with a median of five times over 24 h (range 2-15), was similar between the two groups. The incidence of pouchitis was 57 (53%) and this was significantly greater in the South Asian population [17/21 (77%); 39/86 (46%); P = 0.006].	Surgical results were similar in South Asian and non-South Asian Caucasian patients, but the incidence of pouchitis was greater in the former group.
Pressman 2008	Factors associated with medication use	CD	Retrospective cohort	USA	2964	Initiators were appreciably younger than controls (P < 0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with	In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not.

						none: 1 comorbidity, odds ratio [OR] = 1.52 with 95% confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab.	
Smith 2023	Barriers to success of post surgical enhanced recovery	IBD Post surgical	Retrospective cohort	USA	466	In multivariable analysis stratified by enhanced recovery period, Black race was associated with increased odds of complications in the pre-ERP (OR 3.6, 95%CI 1.4-9.3) and ERP groups (OR 3.1 95%CI 1.3-7.6). Race was not a predictor of LOS or readmission in either group. High social vulnerability was associated with increased odds of readmission pre-ERP (OR 15.1, 95%CI 2.1-136.3), but this disparity was mitigated under ERPs (OR 1.4, 95%CI 0.4-5.6).	While enhanced recovery period mitigated some disparities by social vulnerability, racial disparities persist in IBD populations even under ERPs.
Walker 2011	Racial distribution IBD	IBD	Retrospective cohort	UK	367	63.0% of South Asian UC patients had extensive colitis compared with 42.5% of the Northern European cohort (P < 0.0001).	The phenotype of IBD in South Asians living in North West London is significantly different from that of a white

						Proctitis was uncommon in South Asian UC patients (9.9 vs. 26.1% in Northern European patients, P<0.0001). In the South Asian CD cohort, disease location was predominantly colonic (46.8%). CD behavior differed significantly between the groups, with less penetrating disease compared with Northern Europeans (P=0.01) and a reduced need for surgery (P=0.003).	Northern European IBD cohort.
Farrukh 2022	Racial disparities in outcomes	UC surgery	Retrospective cross sectional	UK	476	There was no statistically significant difference in the distribution across the types of surgery undergone by the two communities overall (Ï‡(2) = 1.3, ns) and the proportions who underwent an ileo-anal anastomosis with pouch (z = -1.2, ns). However, within individual trusts, at the University Hospital Southampton NHS Foundation Trust, a significantly greater proportion of South Asian patients had an ileo-anal anastomosis with	These findings reinforce the argument that inflammatory bowel disease surgery should be performed in a limited number of high-volume centres rather than across a wide range of hospitals so as to ensure procedures are carried out by surgeons with sufficient and on-going experience.

						pouch compared to White British patients.	
Stamatiou 2022	Factors affecting surgical outcomes	IBD	Retrospective observational	UK	1620	Ethnic minority background and higher IMD score were further associated with surgical complications for CD but not UC patients.	Ethnic minority status and socioeconomic deprivation were associated with worse surgical outcomes within our cohort of IBD patients.
Frieder 2022	Racial disparities in outcomes	IBD Postsurgical	Retrspective cohort	USA	38143	After multivariable analysis, African american patients had significantly higher overall risk of complications (OR = 1.27; 95% CI, 1.15-1.40) and extended hospital stay (OR = 1.59; 95% CI, 1.45-1.75) than Caucasians. On bivariate analysis, there was no significant difference in mortality between AA and Caucasian patients.	African american patients requiring segmental colectomy for inflammatory colorectal conditions experience significantly higher rates of postoperative complications, longer hospital stays, and lower rates of private insurance.

Appendix 2 – Full search results

1: D'Amico F, Fasulo E, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S. Management and treatment optimization of patients with mild to moderate ulcerative colitis. Expert Rev Clin Immunol. 2024 Mar;20(3):277-290. doi: 10.1080/1744666X.2023.2292768. Epub 2023 Dec 12. PMID: 38059454.

2: Olivera PA, Silverberg MS. Biomarkers That Predict Crohn's Disease Outcomes. J Can Assoc Gastroenterol. 2023 Sep 2;7(1):59-67. doi: 10.1093/jcag/gwad024. PMID: 38314176; PMCID: PMC10836989.

3: Yin R, Neyens DM. Examining how information presentation methods and a chatbot impact the use and effectiveness of electronic health record patient portals: An exploratory study. Patient Educ Couns. 2024 Feb;119:108055. doi: 10.1016/j.pec.2023.108055. Epub 2023 Nov 5. PMID: 37976665.

4: Constant BD, Albenberg L, Mitchel EB, De Zoeten EF, Clapp JT, Scott FI; PRIOR AUTHORIZATION IMPACT NETWORK STUDY GROUP. Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey. Clin Gastroenterol Hepatol. 2024 Feb;22(2):423-426. doi: 10.1016/j.cgh.2023.06.021. Epub 2023 Jun 30. PMID: 37394025.

5: Goodsall TM, Day AS, Andrews JM, Ruszkiewicz A, Ma C, Bryant RV. Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study. Inflamm Bowel Dis. 2024 Feb 1;30(2):190-195. doi: 10.1093/ibd/izad043. PMID: 36928672; PMCID: PMC10834160.

6: Loveikyte R, Duijvestein M, Mujagic Z, Goetgebuer RL, Dijkstra G, van der Meulen-de Jong AE. Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol. BMJ

Open. 2024 Jan 30;14(1):e077511. doi: 10.1136/bmjopen-2023-077511. PMID: 38296290; PMCID: PMC10828887.

7: Ni Z, Zhu L, Li S, Zhang Y, Zhao R. Characteristics and associated factors of health information-seeking behaviour among patients with inflammatory bowel disease in the digital era: a scoping review. BMC Public Health. 2024 Jan 27;24(1):307. doi: 10.1186/s12889-024-17758-w. PMID: 38279086; PMCID: PMC10821566.

8: Zheng C, Chen X, Ke Y, Xu X, Wu C, Jiang L. Constructing models for Crohn's disease diagnosis and prediction of infliximab non-response based on angiogenesis-related genes. Front Immunol. 2024 Jan 26;15:1239496. doi: 10.3389/fimmu.2024.1239496. PMID: 38343536; PMCID: PMC10853379.

9: Lyu S, Zhong G, Song Y, Sun Y, Li J, Fan X, Qing Q, Li M. A novel nomogram for predicting endoscopic remission in refractory Crohn's disease with ustekinumab administration. Rev Esp Enferm Dig. 2024 Jan 18. doi: 10.17235/reed.2024.10212/2023. Epub ahead of print. PMID: 38236159.

10: Iqbal N, Fletcher J, Bassett P, Hart A, Lung P, Tozer P. Exploring methods of improving patient understanding and communication in a complex anal fistula clinic: results from a randomized controlled feasibility study. Colorectal Dis. 2024 Jan 18. doi: 10.1111/codi.16861. Epub ahead of print. PMID: 38235831.

11: Zeng X, Jiang H, Dai Y, Zhang J, Zhao S, Wu Q. A radiomics nomogram based on MSCT and clinical factors can stratify fibrosis in inflammatory bowel disease. Sci Rep. 2024 Jan 12;14(1):1176. doi: 10.1038/s41598-023-51036-w. PMID: 38216597; PMCID: PMC10786819.

12: Stacy S, Belcher E, Nazarey PP, Cazzetta SE, Salinas GD. Patient and Caregiver Perspectives on Their Experiences With Crohn's Perianal Fistulas.

Crohns Colitis 360. 2024 Jan 6;6(1):otad081. doi: 10.1093/crocol/otad081. PMID: 38259605; PMCID: PMC10803099.

13: Naritsin A, Mehta N, Pellish R. Discordance Between Inflammatory Bowel Disease Specialists and Insurance Authorization Denials-A Survey of Specific Inflammatory Bowel Disease Treatment Scenarios. Crohns Colitis 360. 2023 Dec 30;6(1):otad082. doi: 10.1093/crocol/otad082. PMID: 38264509; PMCID: PMC10805526.

14: Rubens M, Smith R. Management of Dysplasia in Inflammatory Bowel Disease. Clin Colon Rectal Surg. 2023 Apr 9;37(1):18-21. doi: 10.1055/s-0043-1762559. PMID: 38188069; PMCID: PMC10769576.

15: Chang S, Murphy M, Malter L. A Review of Available Medical Therapies to Treat Moderate-to-Severe Inflammatory Bowel Disease. Am J Gastroenterol. 2024 Jan 1;119(1):55-80. doi: 10.14309/ajg.0000000000002485. Epub 2023 Aug 24. PMID: 37615291.

16: Marafini I, Laudisi F, Salvatori S, Lavigna D, Venuto C, Giannarelli D, Monteleone G. Diagnostic value of anti-integrin αvβ6 antibodies in ulcerative colitis. Dig Liver Dis. 2024 Jan;56(1):55-60. doi: 10.1016/j.dld.2023.06.024. Epub 2023 Jul 6. PMID: 37407314.

17: Liu XY, Tian ZB, Zhang LJ, Liu AL, Zhang XF, Wu J, Ding XL. Clinical value of the Toronto inflammatory bowel disease global endoscopic reporting score in ulcerative colitis. World J Gastroenterol. 2023 Dec 28;29(48):6208-6221. doi: 10.3748/wjg.v29.i48.6208. PMID: 38186862; PMCID: PMC10768397.

18: Freeman M, Lally L, Teigen L, Graziano E, Shivashankar R, Shmidt E. Hormone Replacement Therapy Is Associated with Disease Activity Improvement among Post-Menopausal Women with Inflammatory Bowel Disease. J Clin Med. 2023 Dec

23;13(1):88. doi: 10.3390/jcm13010088. PMID: 38202098; PMCID: PMC10779540.

19: Brady RE, Salwen-Deremer JK, Tunnell NC, Winter MW. Understanding Medication Nonadherence in Crohn's Disease Patients: A Qualitative Evaluation. Inflamm Bowel Dis. 2023 Dec 22:izad296. doi: 10.1093/ibd/izad296. Epub ahead of print. PMID: 38134389.

20: Barchi A, Dal Buono A, D'Amico F, Furfaro F, Zilli A, Fiorino G, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M. Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis. J Clin Med. 2023 Dec 8;12(24):7569. doi: 10.3390/jcm12247569. PMID: 38137644; PMCID: PMC10744120.

21: Rimondi A, Gottlieb K, Despott EJ, Iacucci M, Murino A, Tontini GE. Can artificial intelligence replace endoscopists when assessing mucosal healing in ulcerative colitis? A systematic review and diagnostic test accuracy meta-analysis. Dig Liver Dis. 2023 Dec 5:S1590-8658(23)01023-X. doi: 10.1016/j.dld.2023.11.005. Epub ahead of print. PMID: 38057218.

22: Uhlig HH, Booth C, Cho J, Dubinsky M, Griffiths AM, Grimbacher B, Hambleton S, Huang Y, Jones K, Kammermeier J, Kanegane H, Koletzko S, Kotlarz D, Klein C, Lenardo MJ, Lo B, McGovern DPB, Özen A, de Ridder L, Ruemmele F, Shouval DS, Snapper SB, Travis SP, Turner D, Wilson DC, Muise AM. Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards. Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):810-828. doi: 10.1038/s41575-023-00838-4. Epub 2023 Oct 3. PMID: 37789059.

23: Vermeer E, Hebing RCF, van de Meeberg MM, Lin M, de Meij TGJ, Struys EA, Jansen G, Nurmohamed MT, Ćalasan MB, de Jonge R. Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature. Curr Rheumatol Rep. 2023 Dec;25(12):276-284. doi:

10.1007/s11926-023-01116-7. Epub 2023 Sep 28. PMID: 37768405; PMCID: PMC10754736.

24: Levartovsky A, Ben-Horin S, Kopylov U, Klang E, Barash Y. Towards AI-Augmented Clinical Decision-Making: An Examination of ChatGPT's Utility in Acute Ulcerative Colitis Presentations. Am J Gastroenterol. 2023 Dec 1;118(12):2283-2289. doi: 10.14309/ajg.0000000000002483. Epub 2023 Aug 23. PMID: 37611254.

25: Ali H, Shahzad M, Sarfraz S, Sewell KB, Alqalyoobi S, Mohan BP. Application and impact of Lasso regression in gastroenterology: A systematic review. Indian J Gastroenterol. 2023 Dec;42(6):780-790. doi: 10.1007/s12664-023-01426-9. Epub 2023 Aug 18. PMID: 37594652.

26: Fernandez C, Gajic Z, Esen E, Remzi F, Hudesman D, Adhikari S, McAdams-DeMarco M, Segev DL, Chodosh J, Dodson J, Shaukat A, Faye AS. Preoperative Risk Factors for Adverse Events in Adults Undergoing Bowel Resection for Inflammatory Bowel Disease: 15-Year Assessment of the American College of Surgeons National Surgical Quality Improvement Program. Am J Gastroenterol. 2023 Dec 1;118(12):2230-2241. doi: 10.14309/ajg.0000000000002395. Epub 2023 Jul 7. PMID: 37410929; PMCID: PMC10841104.

27: Hradsky O, Copova I, Durilova M, Kazeka D, Lerchova T, Mitrova K, Schwarz J, Vetrovcova R, El-Lababidi N, Karaskova E, Veghova-Velganova M, Sulakova A, Gonsorčíková L, Veverkova M, Zeniskova I, Zimen M, Bortlik M, Bronsky J. Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis. Pediatr Res. 2023 Nov 27. doi: 10.1038/s41390-023-02913-7. Epub ahead of print. PMID: 38012309.

28: Nagarajan KV, Bhat N. Intestinal ultrasound in inflammatory bowel disease: New kid on the block. Indian J Gastroenterol. 2023 Nov 23. doi:

10.1007/s12664-023-01468-z. Epub ahead of print. PMID: 37996771.

29: Pan S, Jiang X, Zhang K. WSGMB: weight signed graph neural network for microbial biomarker identification. Brief Bioinform. 2023 Nov 22;25(1):bbad448. doi: 10.1093/bib/bbad448. PMID: 38084923; PMCID: PMC10714318.

30: Song F, Ma M, Zeng S, Shao F, Huang W, Feng Z, Rong P. CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn's disease. Radiol Med. 2023 Nov 20. doi: 10.1007/s11547-023-01748-w. Epub ahead of print. PMID: 37982937.

31: Quach G, Zielinski MD. Surgical Management of Small Bowel Obstruction - What You Need to Know. J Trauma Acute Care Surg. 2023 Nov 13. doi: 10.1097/TA.0000000000004195. Epub ahead of print. PMID: 37962129.

32: Toja-Camba FJ, García-Quintanilla L, Rodríguez-Martinez L, Tomine J, Cajade-Pascual F, Feitosa C, Zarra-Ferro I, Barreiro-De-Acosta M, González-López J, Mondelo-García C, Fernández-Ferreiro A. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA. Pharmaceutics. 2023 Nov 11;15(11):2615. doi: 10.3390/pharmaceutics15112615. PMID: 38004593; PMCID: PMC10675023.

33: Stallmach A, Atreya R, Grunert PC, Stallhofer J, de Laffolie J, Schmidt C. Treatment Strategies in Inflammatory Bowel Diseases. Dtsch Arztebl Int. 2023 Nov 10;120(45):768-778. doi: 10.3238/arztebl.m2023.0142. PMID: 37408514; PMCID: PMC10745558.

34: Kabir M, Thomas-Gibson S, Tozer PJ, Warusavitarne J, Faiz O, Hart A, Allison L, Acheson AG, Atici SD, Avery P, Brar M, Carvello M, Choy MC, Dart RJ, Davies J, Dhar A, Din S, Hayee B, Kandiah K, Katsanos KH, Lamb CA, Limdi JK, Lovegrove

RE, Myrelid P, Noor N, Papaconstantinou I, Petrova D, Pavlidis P, Pinkney T, Proud D, Radford S, Rao R, Sebastian S, Segal JP, Selinger C, Spinelli A, Thomas K, Wolthuis A, Wilson A. DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making. J Crohns Colitis. 2023 Nov 8;17(10):1652-1671. doi: 10.1093/ecco-jcc/jjad083. PMID: 37171140.

35: Xiang D, Li N, Liu L, Yu H, Li X, Zhao T, Liu D, Gong X. Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels. Heliyon. 2023 Nov 4;9(11):e21858. doi: 10.1016/j.heliyon.2023.e21858. PMID: 38034789; PMCID: PMC10682623.

36: Celentano V, Manzo CA. Assessment of the ileoanal pouch for the colorectal surgeon. Langenbecks Arch Surg. 2023 Nov 1;408(1):423. doi: 10.1007/s00423-023-03151-5. PMID: 37910244; PMCID: PMC10620320.

37: Dagci AOB, Cushing KC. Genetic Defects in Early-Onset Inflammatory Bowel Disease. Rheum Dis Clin North Am. 2023 Nov;49(4):861-874. doi: 10.1016/j.rdc.2023.06.006. Epub 2023 Aug 12. PMID: 37821200.

38: Moein A, Langenhorst J, Plan EL, Jin JY, Kågedal M, Kassir N. A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. Clin Transl Sci. 2023 Nov;16(11):2310-2322. doi: 10.1111/cts.13632. Epub 2023 Sep 22. PMID: 37718498; PMCID: PMC10651636.

39: Raza D, Mubashir M, Sachdeva K, Kawji L, Deville A, Raza SM, Morris J, Pandit S. B-Lymphoblastic Leukaemia Presenting as Intrahepatic Cholestasis. Eur J Case Rep Intern Med. 2023 Oct 30;10(12):004121. doi: 10.12890/2023_004121. PMID: 38077708; PMCID: PMC10705825.

40: Gao J, Nie R, Chen Y, Yang W, Ren Q. Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis. Medicine (Baltimore). 2023 Oct 27;102(43):e35689. doi: 10.1097/MD.0000000000035689. PMID: 37904440; PMCID: PMC10615430.

41: James JP, Nielsen BS, Christensen IJ, Langholz E, Malham M, Poulsen TS, Holmstrøm K, Riis LB, Høgdall E. Mucosal expression of PI3, ANXA1, and VDR discriminates Crohn's disease from ulcerative colitis. Sci Rep. 2023 Oct 27;13(1):18421. doi: 10.1038/s41598-023-45569-3. PMID: 37891214; PMCID: PMC10611705.

42: Assadsangabi A, Evans CA, Corfe BM, Lobo AJ. Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach. Inflamm Bowel Dis. 2023 Oct 27:izad241. doi: 10.1093/ibd/izad241. Epub ahead of print. PMID: 37889841.

43: Abraham BP, Ziring DA, Dervieux T, Han PA, Shim A, Battat R. Real-world impact of infliximab precision-guided dosing on management of patients with IBD. Am J Manag Care. 2023 Oct;29(12 Suppl):S227-S235. doi: 10.37765/ajmc.2023.89447. PMID: 37844322.

44: St-Pierre J, Delisle M, Kheirkhahrahimabadi H, Goodsall TM, Bryant RV, Christensen B, Vaughan R, Al-Ani A, Ingram RJM, Heatherington J, Carter D, Lu C, Ma C, Novak KL. Bedside Intestinal Ultrasound Performed in an Inflammatory Bowel Disease Urgent Assessment Clinic Improves Clinical Decision-Making and Resource Utilization. Crohns Colitis 360. 2023 Sep 21;5(4):otad050. doi: 10.1093/crocol/otad050. PMID: 37809033; PMCID: PMC10558199.

45: Blum L, Jarach CM, Ellen ME. Perceptions of shared decision making in gastroenterology and inflammatory bowel disease: A qualitative analysis. Patient Educ Couns. 2023 Oct;115:107877. doi: 10.1016/j.pec.2023.107877. Epub 2023 Jun

28. PMID: 37437510.

46: Agrawal M, Ebert AC, Poulsen G, Ungaro RC, Faye AS, Jess T, Colombel JF, Allin KH. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study. Gastroenterology. 2023 Oct;165(4):976-985.e3. doi: 10.1053/j.gastro.2023.05.051. Epub 2023 Jun 13. PMID: 37321356; PMCID: PMC10527197.

47: Sica GS, Sensi B, Siragusa L, Blasi F, Crispino B, Pirozzi B, Angelico R, Biancone L, Khan J. Surgical management of colon cancer in ulcerative colitis patients with orthotopic liver transplant for primary sclerosing cholangitis. A systematic review. Eur J Surg Oncol. 2023 Oct;49(10):106922. doi: 10.1016/j.ejso.2023.04.021. Epub 2023 May 13. PMID: 37210276.

48: Papamichael K, Stocco G, Ruiz Del Agua A. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases. Ther Drug Monit. 2023 Oct 1;45(5):579-590. doi: 10.1097/FTD.0000000000001095. Epub 2023 Apr 3. PMID: 37012629; PMCID: PMC10497208.

49: Rentea RM, Renaud E, Ricca R, Derderian C, Englum B, Kawaguchi A, Gonzalez K, Speck KE, Villalona G, Kulaylat A, Wakeman D, Yousef Y, Rialon K, Somme S, Lucas D, Levene T, Chang H, Baerg J, Acker S, Fisher J, Kelley-Quon LI, Baird R, Beres AL; APSA Outcomes and Evidence-Based Practice Committee. Surgical Management of Ulcerative Colitis in Children and Adolescents: A Systematic Review from the APSA Outcomes and Evidence-Based Practice Committee. J Pediatr Surg. 2023 Oct;58(10):1861-1872. doi: 10.1016/j.jpedsurg.2023.02.042. Epub 2023 Feb 21. PMID: 36941170.

50: West J, Tan K, Devi J, Macrae F, Christensen B, Segal JP. Benefits and

Challenges of Treat-to-Target in Inflammatory Bowel Disease. J Clin Med. 2023 Sep 29;12(19):6292. doi: 10.3390/jcm12196292. PMID: 37834936; PMCID: PMC10573216.

51: Ting-Ting Y, Wen-Jing T, Yi-Ting L, Wen-Jing X, Gui-Hua X. 'Eating is like experiencing a gamble': A qualitative study exploring the dietary decision-making process in adults with inflammatory bowel disease. Health Expect. 2023 Sep 20;27(1):e13873. doi: 10.1111/hex.13873. Epub ahead of print. PMID: 37731191; PMCID: PMC10726150.

52: Li Wai Suen CFD, Seah D, Choy MC, De Cruz P. Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis. 2023 Sep 19:izad183. doi: 10.1093/ibd/izad183. Epub ahead of print. PMID: 37725044.

53: van Schelt AS, Beek KJ, Wassenaar NPM, Schrauben EM, Runge JH, Gecse KB, van der Bilt JDW, Neefjes-Borst EA, Buskens CJ, Nederveen AJ, Stoker J. Viscoelastic properties of small bowel mesentery at MR elastography in Crohn's disease: a prospective cross-sectional exploratory study. Eur Radiol Exp. 2023 Sep 18;7(1):53. doi: 10.1186/s41747-023-00366-5. PMID: 37718360; PMCID: PMC10505604.

54: Guglielmi G, Crucitta S, Bertani L, Ruglioni M, Svizzero GB, Ceccarelli L, Del Re M, Danesi R, Costa F, Fogli S. Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics. Inflamm Bowel Dis. 2023 Sep 11:izad181. doi: 10.1093/ibd/izad181. Epub ahead of print. PMID: 37696681.

55: Seidemann L, Dietrich A. Newly diagnosed Crohn's disease, and hepatocellular and renal cell carcinoma in a bariatric surgery patient-dealing with the complexity of obesity-associated diseases: a case report and review of the literature. J Med Case Rep. 2023 Sep 5;17(1):379. doi:

10.1186/s13256-023-04111-9. PMID: 37667406; PMCID: PMC10478449.

56: Arif AA, Jiang SX, Byrne MF. Artificial intelligence in endoscopy: Overview, applications, and future directions. Saudi J Gastroenterol. 2023 Sep-Oct;29(5):269-277. doi: 10.4103/sjg.sjg_286_23. Epub 2023 Sep 6. PMID: 37787347; PMCID: PMC10644999.

57: Jiang S, Wang T, Zhang KH. Data-driven decision-making for precision diagnosis of digestive diseases. Biomed Eng Online. 2023 Sep 1;22(1):87. doi: 10.1186/s12938-023-01148-1. PMID: 37658345; PMCID: PMC10472739.

58: Zhdanava M, Ding Z, Manceur AM, Zhao R, Holiday C, Kachroo S, Izanec J, Pilon D. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab. Curr Med Res Opin. 2023 Sep;39(9):1215-1225. doi: 10.1080/03007995.2023.2246882. Epub 2023 Aug 26. PMID: 37563994.

59: Ayan G, Ribeiro A, Macit B, Proft F. Pharmacologic Treatment Strategies in Psoriatic Arthritis. Clin Ther. 2023 Sep;45(9):826-840. doi: 10.1016/j.clinthera.2023.05.010. Epub 2023 Jul 15. PMID: 37455227.

60: Trotta M, Patel KR, Singh S, Verma V, Ryckman J. Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review. Pract Radiat Oncol. 2023 Sep-Oct;13(5):454-465. doi: 10.1016/j.prro.2023.04.006. Epub 2023 Apr 24. PMID: 37100389; PMCID: PMC10527639.

61: Saeed S, Ekhator C, Abdelaziz AM, Naveed H, Karski A, Cook DE, Reddy SM, Affaf M, Khan SJ, Bellegarde SB, Rehman A, Hasan AH, Shehryar A. Revolutionizing Inflammatory Bowel Disease Management: A Comprehensive Narrative Review of Innovative Dietary Strategies and Future Directions. Cureus. 2023 Aug

29;15(8):e44304. doi: 10.7759/cureus.44304. PMID: 37664362; PMCID: PMC10470660.

62: Santacroce G, Zammarchi I, Tan CK, Coppola G, Varley R, Ghosh S, Iacucci M. Present and future of endoscopy precision for inflammatory bowel disease. Dig Endosc. 2023 Aug 29. doi: 10.1111/den.14672. Epub ahead of print. PMID: 37643635.

63: Dos Reis Annunciato D, Oliveira TL, Magalhães VO, de Medeiros Pinheiro M. Extra-musculoskeletal manifestations driving the therapeutic decision-making in patients with Spondyloarthritis: a 12-month follow-up prospective cohort study. Adv Rheumatol. 2023 Aug 25;63(1):44. doi: 10.1186/s42358-023-00324-0. PMID: 37626417.

64: Pal P, Ramchandani M, Patel R, Banerjee R, Kanaganti S, Gupta R, Tandan M, Reddy DN. Role of ultra-high definition endoscopy (endomicroscopy and endocytoscopy) and real-time histologic examination in inflammatory bowel disease: Scoping review. Dig Endosc. 2023 Aug 13. doi: 10.1111/den.14659. Epub ahead of print. PMID: 37573562.

65: De Gregorio M, Sidhu A, Behrenbruch C, Connor SJ, Guerra G, Johnston MJ, Keck JO, Ong EJSK, Thompson AJ, Woods R, D'Souza B, Ding NS. Preferred definitive surgical management of Crohn's perianal fistulas and factors influencing surgical decision making in Australia and New Zealand. ANZ J Surg. 2023 Aug 8. doi: 10.1111/ans.18640. Epub ahead of print. PMID: 37551939.

66: Dolinger MT, Calabrese E, Pizzolante F, Abreu MT. Current and Novel Uses of Intestinal Ultrasound in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2023 Aug;19(8):447-457. PMID: 37772159; PMCID: PMC10524432.

67: Weber F, Eger KI, March C, Croner RS, Meyer F. Manifestation of acute appendicitis as known but paradox visceral side effect of ulcerative colitis

anti-inflammatory therapy with januskinase-inhibitor Tofacitinib (Xeljanz™). Pathol Res Pract. 2023 Aug;248:154333. doi: 10.1016/j.prp.2023.154333. Epub 2023 Feb 24. PMID: 37393666.

68: Cai W, Xu J, Chen Y, Wu X, Zeng Y, Yu F. Performance of Machine Learning Algorithms for Predicting Disease Activity in Inflammatory Bowel Disease. Inflammation. 2023 Aug;46(4):1561-1574. doi: 10.1007/s10753-023-01827-0. Epub 2023 May 12. PMID: 37171693.

69: Brondfield MN, Mahadevan U. Inflammatory bowel disease in pregnancy and breastfeeding. Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):504-523. doi: 10.1038/s41575-023-00758-3. Epub 2023 Mar 31. PMID: 37002407.

70: Loveikyte R, Bourgonje AR, van der Reijden JJ, Bulthuis MLC, Hawinkels LJAC, Visschedijk MC, Festen EAM, van Dullemen HM, Weersma RK, van Goor H, van der Meulen-de Jong AE, Dijkstra G. Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Inflamm Bowel Dis. 2023 Aug 1;29(8):1272-1284. doi: 10.1093/ibd/izad010. PMID: 36748574; PMCID: PMC10393210.

71: Biamonte P, D'Amico F, Fasulo E, Barà R, Bernardi F, Allocca M, Zilli A, Danese S, Furfaro F. New Technologies in Digestive Endoscopy for Ulcerative Colitis Patients. Biomedicines. 2023 Jul 29;11(8):2139. doi: 10.3390/biomedicines11082139. PMID: 37626636; PMCID: PMC10452412.

72: Wu X, Li P, Wang W, Xu J, Ai R, Wen Q, Cui B, Zhang F. The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation. Nutrients. 2023 Jul 27;15(15):3340. doi: 10.3390/nu15153340. PMID: 37571277; PMCID: PMC10421017.

73: Noor NM, Sousa P, Bettenworth D, Gomollón F, Lobaton T, Bossuyt P, Casanova MJ, Ding NS, Dragoni G, Furfaro F, van Rheenen PF, Chaparro M, Gisbert JP, Louis E, Papamichail K. ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease. J Crohns Colitis. 2023 Jul 5;17(7):1031-1045. doi: 10.1093/ecco-jcc/jjad001. PMID: 36626338.

74: Herrlinger KR, Stange EF. Prioritization in inflammatory bowel disease therapy. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(8):753-767. doi: 10.1080/17474124.2023.2240699. Epub 2023 Jul 26. PMID: 37480322.

75: Wang EJ, Dolomisiewicz E, Karri J, Tontisirin N, Cohen SP. Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain. Korean J Pain. 2023 Jul 1;36(3):299-315. doi: 10.3344/kjp.23130. PMID: 37394273; PMCID: PMC10322666.

76: Magro F, Estevinho MM, Catalano G, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Moreira P, Santiago M, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC; GEDII (Grupo de Estudos da Doença Inflamatória Intestinal). How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study. United European Gastroenterol J. 2023 Jul;11(6):531-541. doi: 10.1002/ueg2.12420. Epub 2023 Jun 15. PMID: 37318072; PMCID: PMC10337732.

77: Chan P, Connor S, Huang V, Karimi N, Williams AJ. Letter: expanding the role for decision aids in IBD into pregnancy-related topics. Aliment Pharmacol Ther. 2023 Jul;58(1):141-142. doi: 10.1111/apt.17545. PMID: 37307542.

78: Saleh A, Abraham BP. Utility of Intestinal Ultrasound in Clinical Decision-Making for Inflammatory Bowel Disease. Crohns Colitis 360. 2023 May 15;5(3):otad027. doi: 10.1093/crocol/otad027. PMID: 37292105; PMCID:

PMC10246583.

79: Dolinger MT, Kayal M. Intestinal Ultrasound Is the Ideal Patient-Centric, Point-of-Care Tool for Clinical Decision Making in the Inflammatory Bowel Disease Practice. Crohns Colitis 360. 2023 May 26;5(3):otad029. doi: 10.1093/crocol/otad029. PMID: 37292104; PMCID: PMC10246577.

80: Lee MJ, Folan AM, Baker DM, Blackwell S, Wootton R, Robinson K, Sebastian S, Brown SR, Jones GL, Lobo AJ. A survey of patient informational preferences when choosing between medical and surgical therapy for ulcerative colitis: a sub-study from the DISCUSS project. Colorectal Dis. 2023 Jul;25(7):1479-1488. doi: 10.1111/codi.16625. Epub 2023 May 26. PMID: 37237447.

81: Cheong J, Faye A, Shaukat A. Colorectal Cancer Screening and Surveillance in the Geriatric Population. Curr Gastroenterol Rep. 2023 Jul;25(7):141-145. doi: 10.1007/s11894-023-00875-8. Epub 2023 May 23. PMID: 37219764; PMCID: PMC10330554.

82: Karimi N, Moore AR, Lukin A, Connor SJ. Health Communication Research Informs Inflammatory Bowel Disease Practice and Research: A Narrative Review. Crohns Colitis 360. 2023 Apr 21;5(3):otad021. doi: 10.1093/crocol/otad021. PMID: 37162798; PMCID: PMC10164291.

83: McHenry S. The evaluation of liver abnormalities in inflammatory bowel disease patients. Curr Opin Gastroenterol. 2023 Jul 1;39(4):287-293. doi: 10.1097/MOG.0000000000000942. Epub 2023 Apr 27. PMID: 37144524; PMCID: PMC10421594.

84: Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised

controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17. PMID: 36931693; PMCID: PMC10314011.

85: Selinger CP, Steed H, Purewal S, Homer R, Nihr BioResource, Brookes M. Factors Associated with Family Planning Status and Voluntary Childlessness in Women of Childbearing Age with Inflammatory Bowel Diseases. J Clin Med. 2023 Jun 26;12(13):4267. doi: 10.3390/jcm12134267. PMID: 37445302; PMCID: PMC10342358.

86: Shubhakar A, Jansen BC, Adams AT, Reiding KR, Ventham NT, Kalla R, Bergemalm D, Urbanowicz PA, Gardner RA; IBD-BIOM Consortium; Wuhrer M, Halfvarson J, Satsangi J, Fernandes DL, Spencer DIR. Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease. J Crohns Colitis. 2023 Jun 16;17(6):919-932. doi: 10.1093/ecco-jcc/jjad012. PMID: 36694402.

87: Baillie S, Limdi JK, Bassi A, Fraser A, Parkes G, Scott G, Raine T, Lamb CA, Kennedy NA, Fumis N, Smith MA, Nicolaou A, Emms H, Wye J, Lehmann A, Carbery I, Goodhand J, Lees R, Beshyah W, Luthra P, Pollok R, Selinger C. Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project. Frontline Gastroenterol. 2023 Jun 14;14(6):497-504. doi: 10.1136/flgastro-2023-102423. PMID: 37854782; PMCID: PMC10579551.

88: Jha D, Al-Taie Z, Krek A, Eshghi ST, Fantou A, Laurent T, Tankelevich M, Cao X, Meringer H, Livanos AE, Tokuyama M, Cossarini F, Bourreille A, Josien R, Hou R, Canales-Herrerias P, Ungaro RC, Kayal M, Marion J, Polydorides AD, Ko HM, D'souza D, Merand R, Kim-Schulze S, Hackney JA, Nguyen A, McBride JM, Yuan GC, Colombel JF, Martin JC, Argmann C, Suárez-Fariñas M, Petralia F, Mehandru S. Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis. bioRxiv [Preprint]. 2023 Jun 5:2023.06.02.542863. doi: 10.1101/2023.06.02.542863. PMID: 37333091; PMCID: PMC10274630.

89: Zhang M, Xiao E, Liu M, Mei X, Dai Y. Retrospective Cohort Study of Shear-Wave Elastography and Computed Tomography Enterography in Crohn's Disease. Diagnostics (Basel). 2023 Jun 5;13(11):1980. doi: 10.3390/diagnostics13111980. PMID: 37296832; PMCID: PMC10252205.

90: Tamir-Degabli N, Maharshak N, Cohen NA. Salvage Therapy in Acute Severe Ulcerative Colitis: Current Practice and a Look to the Future. Turk J Gastroenterol. 2023 Jun;34(6):576-583. doi: 10.5152/tjg.2023.23103. PMID: 37303244; PMCID: PMC10441136.

91: Yao J, Zhou J, Zhong Y, Zhang M, Peng X, Zhao J, Liu T, Wang W, Hu P, Meng X, Zhi M. Computed tomography-based radiomics nomogram using machine learning for predicting 1-year surgical risk after diagnosis of Crohn's disease. Med Phys. 2023 Jun;50(6):3862-3872. doi: 10.1002/mp.16402. Epub 2023 May 4. PMID: 37029097.

92: Laube R, Selinger CP, Seow CH, Christensen B, Flanagan E, Kennedy D, Mountifield R, Seeho S, Shand A, Williams AJ, Leong RW. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. Gut. 2023 Jun;72(6):1040-1053. doi: 10.1136/gutjnl-2022-329304. Epub 2023 Mar 21. PMID: 36944479.

93: Spencer EA, Abbasi S, Kayal M. Barriers to optimizing inflammatory bowel disease care in the United States. Therap Adv Gastroenterol. 2023 May 5;16:17562848231169652. doi: 10.1177/17562848231169652. PMID: 37163167; PMCID: PMC10164253.

94: Loch FN, Kamphues C, Beyer K, Schineis C, Asbach P, Reiter R, Sack I, Braun J. Ex vivo magnetic resonance elastography of the small bowel in Crohn's disease. Quant Imaging Med Surg. 2023 May 1;13(5):2895-2906. doi:

10.21037/qims-22-1071. Epub 2023 Apr 3. PMID: 37179925; PMCID: PMC10167436.

95: Dolinger MT, Kayal M. Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making. World J Gastroenterol. 2023 Apr 21;29(15):2272-2282. doi: 10.3748/wjg.v29.i15.2272. PMID: 37124889; PMCID: PMC10134421.

96: Schoefs E, Vermeire S, Ferrante M, Sabino J, Lambrechts T, Avedano L, Haaf I, De Rocchis MS, Broggi A, Sajak-Szczerba M, Saldaña R, Janssens R, Huys I. What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study. J Crohns Colitis. 2023 Apr 3;17(3):379-388. doi: 10.1093/ecco-jcc/jjac145. PMID: 36165579; PMCID: PMC10069611.

97: Liu E, Laube R, Leong RW, Fraser A, Selinger C, Limdi JK. Managing Inflammatory Bowel Disease in Pregnancy: Health Care Professionals' Involvement, Knowledge, and Decision Making. Inflamm Bowel Dis. 2023 Apr 3;29(4):522-530. doi: 10.1093/ibd/izac101. PMID: 35713620.

98: Lin WC, Chang CW, Chen MJ, Wang HY. Intestinal Ultrasound in Inflammatory Bowel Disease: A Novel and Increasingly Important Tool. J Med Ultrasound. 2023 Jan 19;31(2):86-91. doi: 10.4103/jmu.jmu_84_22. PMID: 37576427; PMCID: PMC10413392.

99: Rohatinsky N, Zelinsky S, Dolinger M, Christensen B, Wilkens R, Radford S, Dubinsky M, Novak K. Crohn's Disease Patient Experiences and Preferences With Disease Monitoring: An International Qualitative Study. Crohns Colitis 360. 2023 Feb 25;5(2):otad012. doi: 10.1093/crocol/otad012. PMID: 36937136; PMCID: PMC10022708.

100: Singh S, Boland BS, Jess T, Moore AA. Management of inflammatory bowel

diseases in older adults. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):368-382. doi: 10.1016/S2468-1253(22)00358-2. Epub 2023 Jan 17. PMID: 36669515.

101: Raja SS, Bryant RV, Costello SP, Barnett M, Schubert J, Rayner CK. Systematic review of therapies for refractory ulcerative proctitis. J Gastroenterol Hepatol. 2023 Apr;38(4):496-509. doi: 10.1111/jgh.16111. Epub 2023 Feb 6. PMID: 36644922.

102: Xu W, Wang Y, Hua Z, Hu H, Chen W, Cai Z, Cui L, Wu X, Lian L, Ding Z, Du P. Risk Factors and Quality of Life in Patients with Diffuse Pouchitis After Ileal Pouch Anal Anastomosis According to the Chicago Classification for J Pouch: a Retrospective Multicenter Cohort Study in China. J Gastrointest Surg. 2023 Apr;27(4):766-776. doi: 10.1007/s11605-022-05563-y. Epub 2023 Jan 3. PMID: 36596961.

103: Kappelman MD, Adimadhyam S, Hou L, Wolfe AE, Smith S, Simon AL, Moyneur É, Reynolds JS, Toh S, Dobes A, Parlett LE, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand JE, Dawwas GK, Lewis JD, Long MD. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. Am J Gastroenterol. 2023 Apr 1;118(4):674-684. doi: 10.14309/ajg.0000000000002068. Epub 2022 Nov 26. PMID: 36508681.

104: Ratnapradipa KL, Napit K, Ranta J, Luma LB, Dinkel D, Robinson T, Schabloske L, Watanabe-Galloway S. Qualitative Analysis of Colorectal Cancer Screening in Rural Nebraska. J Cancer Educ. 2023 Apr;38(2):652-663. doi: 10.1007/s13187-022-02170-y. Epub 2022 Apr 18. PMID: 35437633; PMCID: PMC9015281.

105: Tibi S, Ahmed S, Nizam Y, Aldoghmi M, Moosa A, Bourenane K, Yakub M, Mohsin H. Implications of Ramadan Fasting in the Setting of Gastrointestinal Disorders. Cureus. 2023 Mar 31;15(3):e36972. doi: 10.7759/cureus.36972. PMID: 37139278; PMCID: PMC10151003.

106: Looijen AEM, van Linschoten RCA, Brugma JD, Hijnen DJ, de Jong PHP, van der Kuy PHM, van Laar JAM, van der Woude CJ, Pasma A. Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry. JMIR Res Protoc. 2023 Mar 30;12:e43230. doi: 10.2196/43230. PMID: 36995758; PMCID: PMC10131723.

107: Lomazi EA, Oba J, Rodrigues M, Marmo MCDR, Sandy NS, Sdepanian VL, Imbrizi M, Baima JP, Magro DO, Albuquerque IC, Zabot GP, Cassol OS, Saad-Hossne R. BRAZILIAN CONSENSUS ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN PEDIATRIC PATIENTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB). Arq Gastroenterol. 2023 Mar 24;59(suppl 1):85-124. doi: 10.1590/S0004-2803.2022005S1-04. PMID: 36995890.

108: Baima JP, Imbrizi M, Andrade AR, Chebli LA, Argollo MC, Queiroz NSF, Azevedo MFC, Vieira A, Costa MHM, Fróes RSB, Penna FGCE, Quaresma AB, Damião AOMC, Moraes ACDS, Santos CHMD, Flores C, Zaltman C, Vilela EG, Morsoletto E, Gonçalves Filho FA, Santana GO, Zabot GP, Parente JML, Sassaki LY, Zerôncio MA, Machado MB, Cassol OS, Kotze PG, Parra RS, Miszputen SJ, Coy CSR, Ambrogini Junior O, Chebli JMF, Saad-Hossne R. SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF ULCERATIVE COLITIS IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB). Arq Gastroenterol. 2023 Mar 24;59(suppl 1):51-84. doi: 10.1590/S0004-2803.2022005S1-03. PMID: 36995889.

109: Imbrizi M, Baima JP, Azevedo MFC, Andrade AR, Queiroz NSF, Chebli JMF, Chebli LA, Argollo MC, Sassaki LY, Parra RS, Quaresma AB, Vieira A, Damião AOMC, Moraes ACDS, Flores C, Zaltman C, Vilela EG, Morsoletto EM, Gonçalves Filho FA, Penna FGCE, Santana GO, Zabot GP, Parente JML, Costa MHM, Zerôncio MA, Machado MB, Cassol OS, Kotze PG, Fróes RSB, Miszputen SJ, Ambrogini Junior O, Saad-Hossne R, Coy CSR. SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE

AND COLITIS (GEDIIB). Arq Gastroenterol. 2023 Mar 24;59(suppl 1):20-50. doi: 10.1590/S0004-2803.2022005S1-02. PMID: 36995888.

110: Zabot GP, Cassol OS, Quaresma AB, Gonçalves Filho FA, Baima JP, Imbrizi M, Rolim AS, Carmo AMD, Alves Junior AJT, Santos CHMD, Sobrado Junior CW, Miranda EF, Albuquerque IC, Souza MM, Kaiser Junior RL, Parra RS, Kotze PG, Saad-Hossne R. SURGICAL MANAGEMENT OF ADULT CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS: A CONSENSUS FROM THE BRAZILIAN ORGANIZATION OF CROHN'S DISEASE AND COLITIS (GEDIIB). Arq Gastroenterol. 2023 Mar 24;59(suppl 1):1-19. doi: 10.1590/S0004-2803.2022005S1-01. PMID: 36995887.

111: Miyatani Y, Kobayashi T. De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease. Gut Liver. 2023 Mar 15;17(2):181-189. doi: 10.5009/gnl220070. Epub 2022 Nov 14. PMID: 36375794; PMCID: PMC10018304.

112: Signore A, Bonfiglio R, Varani M, Galli F, Campagna G, Desco M, Cussó L, Mattei M, Wunder A, Borri F, Lupo MT, Bonanno E. Radioimmune Imaging of α₄β₇ Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease. Pharmaceutics. 2023 Mar 2;15(3):817. doi: 10.3390/pharmaceutics15030817. PMID: 36986677; PMCID: PMC10051745.

113: Singh S, Ananthakrishnan AN, Nguyen NH, Cohen BL, Velayos FS, Weiss JM, Sultan S, Siddique SM, Adler J, Chachu KA; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology. 2023 Mar;164(3):344-372. doi: 10.1053/j.gastro.2022.12.007. PMID: 36822736.

114: Huang JX, Lee YH, Wei JC. Patient-tailored dose reduction of tumor necrosis factor inhibitors in axial spondyloarthritis. Int Immunopharmacol. 2023 Mar;116:109804. doi: 10.1016/j.intimp.2023.109804. Epub 2023 Feb 8. PMID:

36764276.

115: Fuxman C, Sicilia B, Linares ME, García-López S, González Sueyro R, González-Lamac Y, Zabana Y, Hinojosa J, Barreiro-de Acosta M, Balderramo D, Balfour D, Bellicoso M, Daffra P, Morelli D, Orsi M, Rausch A, Ruffinengo O, Toro M, Sambuelli A, Novillo A, Gomollón F, De Paula JA. GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline. Gastroenterol Hepatol. 2023 Mar;46 Suppl 1:S1-S56. English, Spanish. doi: 10.1016/j.gastrohep.2023.01.009. Epub 2023 Jan 31. PMID: 36731724.

116: Kammermeier J, Lamb CA, Jones KDJ, Anderson CA, Baple EL, Bolton C, Braggins H, Coulter TI, Gilmour KC, Gregory V, Hambleton S, Hartley D, Hawthorne AB, Hearn S, Laurence A, Parkes M, Russell RK, Speight RA, Travis S, Wilson DC, Uhlig HH. Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):271-286. doi: 10.1016/S2468-1253(22)00337-5. Epub 2023 Jan 9. PMID: 36634696.

117: Axelrad JE, Cross RK. Surveillance for Colorectal Neoplasia in Inflammatory Bowel Disease: When to Stop. Am J Gastroenterol. 2023 Mar 1;118(3):429-431. doi: 10.14309/ajg.0000000000002168. Epub 2022 Dec 29. PMID: 36584365.

118: Adams A, Gupta V, Mohsen W, Chapman TP, Subhaharan D, Kakkadasam Ramaswamy P, Kumar S, Kedia S, McGregor CG, Ambrose T, George BD, Palmer R, Brain O, Walsh A, Ahuja V, Travis SPL, Satsangi J. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut. 2023 Mar;72(3):433-442. doi: 10.1136/gutjnl-2022-327533. Epub 2022 Sep 28. PMID: 36171080.

119: Pierre N, Huynh-Thu VA, Marichal T, Allez M, Bouhnik Y, Laharie D, Bourreille A, Colombel JF, Meuwis MA, Louis E; GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif). Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity. Gut. 2023 Mar;72(3):443-450. doi: 10.1136/gutjnl-2022-327321. Epub 2022 Aug 25. PMID: 36008101.

120: Xu W, Liu F, Hua Z, Gu Y, Lian L, Cui L, Ding Z, Du P. Comparison of The Toronto IBD Global Endoscopic Reporting (TIGER) score, Mayo endoscopic score (MES), and ulcerative colitis endoscopic index of severity (UCEIS) in predicting the need for ileal pouch-anal anastomosis in patients with ulcerative colitis. Int J Colorectal Dis. 2023 Feb 25;38(1):53. doi: 10.1007/s00384-023-04347-3. PMID: 36840832.

121: Bashir NS, Hughes A, Ungar WJ. Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review. MDM Policy Pract. 2023 Feb 24;8(1):23814683231156433. doi: 10.1177/23814683231156433. PMID: 36860664; PMCID: PMC9969457.

122: González-Lama Y, Ricart E, Cábez A, Fortes P, Gómez S, Casellas F. Medical consultation in ulcerative colitis: Key elements for improvement. World J Gastroenterol. 2023 Feb 14;29(6):917-925. doi: 10.3748/wjg.v29.i6.917. PMID: 36844134; PMCID: PMC9950864.

123: Nancey S, Fumery M, Faure M, Boschetti G, Gay C, Milot L, Roblin X. Use of imaging modalities for decision-making in inflammatory bowel disease. Therap Adv Gastroenterol. 2023 Feb 9;16:17562848231151293. doi: 10.1177/17562848231151293. PMID: 36777362; PMCID: PMC9912556.

124: Toneman M, Groenveld T, Krielen P, Hooker A, de Wilde R, Torres-de la Roche LA, Di Spiezio Sardo A, Koninckx P, Cheong Y, Nap A, van Goor H, Pargmae P, Ten Broek R. Risk Factors for Adhesion-Related Readmission and Abdominal Reoperation after Gynecological Surgery: A Nationwide Cohort Study. J Clin Med. 2023 Feb 8;12(4):1351. doi: 10.3390/jcm12041351. PMID: 36835887; PMCID: PMC9965311.

125: Lu C, Ma C, Ingram RJM, Chan M, Kheirkhahrahimabadi H, Martin ML, Seow CH, Kaplan GG, Heatherington J, Devlin SM, Panaccione R, Novak KL. Innovative Care for Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Use of Bedside Intestinal Ultrasound to Optimize Management. J Can Assoc Gastroenterol. 2022 Mar 10;6(1):e1-e6. doi: 10.1093/jcag/gwac006. PMID: 36785574; PMCID: PMC8992330.

126: Ishige T, Shimizu T, Watanabe K, Arai K, Kamei K, Kudo T, Kunisaki R, Tokuhara D, Naganuma M, Mizuochi T, Murashima A, Inoki Y, Iwata N, Iwama I, Koinuma S, Shimizu H, Jimbo K, Takaki Y, Takahashi S, Cho Y, Nambu R, Nishida D, Hagiwara SI, Hikita N, Fujikawa H, Hosoi K, Hosomi S, Mikami Y, Miyoshi J, Yagi R, Yokoyama Y, Hisamatsu T. Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. J Gastroenterol. 2023 Feb;58(2):135-157. doi: 10.1007/s00535-022-01953-w. Epub 2023 Jan 11. Erratum in: J Gastroenterol. 2023 Feb 10;: PMID: 36629948; PMCID: PMC9838549.

127: Feng Z, Kang G, Wang J, Gao X, Wang X, Ye Y, Liu L, Zhao J, Liu X, Huang H, Cao X. Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies. Biomed Pharmacother. 2023 Feb;158:114174. doi: 10.1016/j.biopha.2022.114174. Epub 2022 Dec 31. PMID: 36587559.

128: Kellar A, Dolinger M, Novak KL, Chavannes M, Dubinsky M, Huynh H. Intestinal Ultrasound for the Pediatric Gastroenterologist: A Guide for Inflammatory Bowel Disease Monitoring in Children: Expert Consensus on Behalf of

the International Bowel Ultrasound Group (IBUS) Pediatric Committee. J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):142-148. doi: 10.1097/MPG.0000000000003649. Epub 2022 Oct 28. PMID: 36306530; PMCID: PMC9848217.

129: Stibbe JA, Hoogland P, Achterberg FB, Holman DR, Sojwal RS, Burggraaf J, Vahrmeijer AL, Nagengast WB, Rogalla S. Highlighting the Undetectable - Fluorescence Molecular Imaging in Gastrointestinal Endoscopy. Mol Imaging Biol. 2023 Feb;25(1):18-35. doi: 10.1007/s11307-022-01741-1. Epub 2022 Jun 28. PMID: 35764908; PMCID: PMC9971088.

130: Lin V, Gögenur S, Pachler F, Fransgaard T, Gögenur I. Risk Prediction for Complications in Inflammatory Bowel Disease Surgery: External Validation of the American College of Surgeons' National Surgical Quality Improvement Program Surgical Risk Calculator. J Crohns Colitis. 2023 Jan 27;17(1):73-82. doi: 10.1093/ecco-jcc/jjac114. PMID: 35973971.

131: Caron B, D'Amico F, Jairath V, Netter P, Danese S, Peyrin-Biroulet L. Available Methods for Benefit-risk Assessment: Lessons for Inflammatory Bowel Disease Drugs. J Crohns Colitis. 2023 Jan 27;17(1):137-143. doi: 10.1093/ecco-jcc/jjac113. PMID: 35952722.

132: Nakase H. Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. Gut Liver. 2023 Jan 15;17(1):49-57. doi: 10.5009/gnl220017. Epub 2022 Nov 14. PMID: 36375793; PMCID: PMC9840911.

133: Deutscher D, Weil C, Chodick G, Tsukinovsky S, Bodger K, Waterman M, Kariv R. Implementing electronic patient reported outcomes in inflammatory bowel disease: patient participation, score reliability and validity. Health Qual Life Outcomes. 2023 Jan 13;21(1):2. doi: 10.1186/s12955-023-02087-0. PMID: 36639633; PMCID: PMC9837960.

134: Kurimoto N, Nishida Y, Hosomi S, Itani S, Kobayashi Y, Nakata R, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Nagami Y, Taira K, Kamata N, Fujiwara Y. Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing. PLoS One. 2023 Jan 12;18(1):e0280252. doi: 10.1371/journal.pone.0280252. PMID: 36634124; PMCID: PMC9836288.

135: Wu H, Zeng R, Qiu X, Chen K, Zhuo Z, Guo K, Xiang Y, Yang Q, Jiang R, Leung FW, Lian Q, Sha W, Chen H. Investigating regulatory patterns of NLRP3 Inflammasome features and association with immune microenvironment in Crohn's disease. Front Immunol. 2023 Jan 5;13:1096587. doi: 10.3389/fimmu.2022.1096587. PMID: 36685554; PMCID: PMC9849378.

136: Pinton P. Impact of artificial intelligence on prognosis, shared decision-making, and precision medicine for patients with inflammatory bowel disease: a perspective and expert opinion. Ann Med. 2023;55(2):2300670. doi: 10.1080/07853890.2023.2300670. Epub 2024 Jan 1. PMID: 38163336; PMCID: PMC10763920.

137: Boldovjakova D, El-Abbassy I, Alarcon I, El-Saify M, Chan JH, Harley M, Parnaby C, Watson A, Ramsay G. Management of the Rectal Stump after Subtotal Colectomy Operations for Inflammatory Bowel Disease in the Era of Immunologic Therapy: A Two-Centre Cohort Study. Dig Dis. 2023;41(6):872-878. doi: 10.1159/000533267. Epub 2023 Sep 8. PMID: 37690444.

138: Bastida Paz G, Merino Ochoa O, Aguas Peris M, Barreiro-de Acosta M, Zabana Y, Ginard Vicens D, Ceballos Santos D, Muñoz Núñez F, Monfort I Miquel D, Catalán-Serra I, García Sánchez V, Loras Alastruey C, Lucendo Villarín A, Huguet JM, de la Coba Ortiz C, Aldeguer Manté X, Palau Canós A, Domènech Morral E, Nos P; GETECCU Group (Spanish Working Group on Crohn’s Disease and Ulcerative Colitis). The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making. Dig Dis.

2023;41(6):879-889. doi: 10.1159/000531789. Epub 2023 Aug 23. PMID: 37611561.

139: Lin CC, Lin HH, Chen HC, Chen NC, Shih IL, Hung JS, Yueh TC, Chiang FF, Lin PW, Tsai YY, Wei SC. Perioperative optimization of Crohn's disease. Ann Gastroenterol Surg. 2022 Oct 13;7(1):10-26. doi: 10.1002/ags3.12621. PMID: 36643355; PMCID: PMC9831910.

140: Kann BR. Anastomotic Considerations in Crohn's Disease. Clin Colon Rectal Surg. 2022 Dec 9;36(1):63-73. doi: 10.1055/s-0042-1758770. PMID: 36619281; PMCID: PMC9815910.

141: Scribano ML. Editorial: shared decision-making intervention in patients with Crohn's disease-a personalised, patient-centred approach. Aliment Pharmacol Ther. 2023 Jan;57(2):263-264. doi: 10.1111/apt.17314. PMID: 36565000.

142: van Deen WK, Khalil C, Bonthala NN, Gale R, Patel DB, Warui E, Melmed GY, Spiegel BMR. Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study. Dig Dis. 2023;41(3):412-421. doi: 10.1159/000528586. Epub 2022 Dec 7. PMID: 36476714.

143: Miyatani Y, Kobayashi T. Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease. Digestion. 2023;104(1):66-73. doi: 10.1159/000527776. Epub 2022 Nov 30. PMID: 36450267; PMCID: PMC9843544.

144: Zisman-Ilani Y, Thompson KD, Siegel LS, Mackenzie T, Crate DJ, Korzenik JR, Melmed GY, Kozuch P, Sands BE, Rubin DT, Regueiro MD, Cross R, Wolf DC, Hanson JS, Schwartz RM, Vrabie R, Kreines MD, Scherer T, Dubinsky MC, Siegel CA. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther. 2023 Jan;57(2):205-214. doi: 10.1111/apt.17286. Epub 2022 Nov

14. PMID: 36377259; PMCID: PMC9790033.

145: Haji A. Endoscopic Submucosal Dissection in the Colon and Rectum: Indications, Techniques, and Outcomes. Gastrointest Endosc Clin N Am. 2023 Jan;33(1):83-97. doi: 10.1016/j.giec.2022.08.001. PMID: 36375889.

146: Lauricella S, Fabris S, Sylla P. Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis. Surg Endosc. 2023 Jan;37(1):48-61. doi: 10.1007/s00464-022-09462-w. Epub 2022 Aug 3. PMID: 35920906.

147: Cheon JH, Paridaens K, Awadhi SA, Begun J, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Dignass AU, Travis SP. The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intest Res. 2023 Jan;21(1):161-167. doi: 10.5217/ir.2022.00006. Epub 2022 Apr 18. PMID: 35421913; PMCID: PMC9911271.

148: VanderMeulen H, Arya S, Nersesian S, Philbert N, Sholzberg M. What have we learned about the patient's experience of von Willebrand disease? A focus on women. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):631-636. doi: 10.1182/hematology.2022000391. PMID: 36485077; PMCID: PMC9820129.

149: Peek-Kuijt NMS, Aantjes MJ, Verwey M, Van Bodegom-Vos L, van der Meulen-de Jong AE, Maljaars JPW. Treatment goals in IBD: A perspective from patients and their partners. PEC Innov. 2022 Mar 29;1:100034. doi: 10.1016/j.pecinn.2022.100034. PMID: 37213759; PMCID: PMC10194327.

150: Hans A, Battat R, Lukin DJ. Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Curr Gastroenterol Rep. 2022 Dec;24(12):157-170. doi: 10.1007/s11894-022-00853-6. Epub 2022 Nov 3. PMID: 36327029.

151: Yuasa A, Yonemoto N, Kamei K, Murofushi T, LoPresti M, Taneja A, Horgan J, Ikeda S. Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders. Adv Ther. 2022 Dec;39(12):5327-5350. doi: 10.1007/s12325-022-02321-z. Epub 2022 Oct 7. PMID: 36205907; PMCID: PMC9540264.

152: Matula KA, Minar P, Daraiseh NM, Lin L, Recker M, Lipstein EA. Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. Health Expect. 2022 Dec;25(6):3105-3113. doi: 10.1111/hex.13618. Epub 2022 Sep 26. PMID: 36161973; PMCID: PMC9700187.

153: Adolph TE, Zhang J. Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts. Gut. 2022 Dec;71(12):2574-2586. doi: 10.1136/gutjnl-2021-326575. Epub 2022 Sep 16. PMID: 36113981; PMCID: PMC9664119.

154: Iqbal N, Sackitey C, Gupta A, Tolan D, Plumb A, Godfrey E, Grierson C, Williams A, Brown S, Maxwell-Armstrong C, Anderson I, Selinger C, Lobo A, Hart A, Tozer P, Lung P. The development of a minimum dataset for MRI reporting of anorectal fistula: a multi-disciplinary, expert consensus process. Eur Radiol. 2022 Dec;32(12):8306-8316. doi: 10.1007/s00330-022-08931-z. Epub 2022 Jun 23. PMID: 35732929; PMCID: PMC9705494.

155: Patil SA, Bhat S, Limdi JK, Farraye FA, Cross RK. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022 Dec 1;28(12):1915-1923. doi: 10.1093/ibd/izac048. PMID: 35353189.

156: Zeng S, Lin Y, Guo J, Chen X, Liang Q, Zhai X, Tao J. Differential diagnosis of Crohn's disease and intestinal tuberculosis: development and assessment of a nomogram prediction model. BMC Gastroenterol. 2022 Nov 16;22(1):461. doi: 10.1186/s12876-022-02519-z. PMID: 36384447; PMCID:

PMC9670453.

157: Pugliese D, Onali S, Privitera G, Armuzzi A, Papi C. Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies. J Clin Med. 2022 Nov 13;11(22):6717. doi: 10.3390/jcm11226717. PMID: 36431194; PMCID: PMC9697479.

158: Turan M, Durmus F. UC-NfNet: Deep learning-enabled assessment of ulcerative colitis from colonoscopy images. Med Image Anal. 2022 Nov;82:102587. doi: 10.1016/j.media.2022.102587. Epub 2022 Aug 27. PMID: 36058054.

159: Brunet-Houdard S, Monmousseau F, Berthon G, Des Garets V, Laharie D, Picon L, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, Rusch E, Aubourg A; COQC-PIT Study Group. How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients. Scand J Gastroenterol. 2022 Nov;57(11):1312-1320. doi: 10.1080/00365521.2022.2085057. Epub 2022 Jun 18. PMID: 35722732.

160: Rabilloud ML, Bajeux E, Siproudhis L, Hamonic S, Pagenault M, Brochard C, Gerfaud A, Dabadie A, Viel JF, Tron I, Robaszkiewicz M, Bretagne JF, Bouguen G; (Groupe ABERMAD). Long-term outcomes and predictors of disabling disease in a population-based cohort of patients with incident Crohn's disease diagnosed between 1994 and 1997. Clin Res Hepatol Gastroenterol. 2022 Nov;46(9):101974. doi: 10.1016/j.clinre.2022.101974. Epub 2022 Jun 9. PMID: 35691599.

161: Wong C, van Oostrom J, Bossuyt P, Pittet V, Hanzel J, Samaan M, Tripathi M, Czuber-Dochan W, Burisch J, Leone S, Saldaña R, Baert F, Kopylov U, Jaghult S, Adamina M, Gecse K, Arebi N. A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence. J Crohns Colitis. 2022 Nov 1;16(10):1511-1522. doi: 10.1093/ecco-jcc/jjac057. PMID: 35512352.

162: Coates E, Wickramasekera N, Barr A, Shackley P, Lee M, Hind D, Probert C, Sebastian S, Totton N, Blackwell S, Bedford H, Dames N, Lobo A. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. Health Technol Assess. 2022 Oct;26(41):1-118. doi: 10.3310/RHXR5192. PMID: 36305390; PMCID: PMC9638891.

163: Selinger CP, Bel Kok K, Limdi JK, Kent A, Cooney R, Nelson-Piercy C. Live vaccinations for infants exposed to maternal infliximab in utero and via breast milk - the need for nuanced decision making. BMJ Open Gastroenterol. 2022 Oct;9(1):e001029. doi: 10.1136/bmjgast-2022-001029. PMID: 36216381; PMCID: PMC9557327.

164: Ten Bokkel Huinink S, de Jong DC, Nieboer D, Thomassen D, Steyerberg EW, Dijkgraaf MGW, Bodelier AGL, West RL, Römkens TEH, Hoentjen F, Mallant RC, van Tuyl BAC, Mares WGN, Wolfhagen FHJ, Dijkstra G, Reijnders JGP, de Boer NK, Tan ACITL, van Boeckel PGA, Tack GJ, van Asseldonk DP, D'Haens GRAM, van der Woude CJ, Duijvestein M, de Vries AC. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease. Eur J Gastroenterol Hepatol. 2022 Oct 1;34(10):983-992. doi: 10.1097/MEG.0000000000002403. Epub 2022 Aug 30. PMID: 36062493.

165: Duan M, Guan B, Cao L, Zhou C, Huang W, Wu Q, Zhu W, Li Y. Computed tomography enterography predicts surgical-free survival in symptomatic stricturing Crohn's disease. Abdom Radiol (NY). 2022 Oct;47(10):3414-3423. doi: 10.1007/s00261-022-03588-0. Epub 2022 Jul 27. PMID: 35896683.

166: Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, Mudombi W, Kassianides C, Katsidzira L; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol.

2022 Oct;7(10):962-972. doi: 10.1016/S2468-1253(22)00048-6. Epub 2022 Jun 30. PMID: 35779534.

167: Mullin G, Zager Y, Anteby R, Jacoby H, Kent I, Ram E, Nachmany I, Horesh N. Inflammatory markers may predict post-operative complications and recurrence in Crohn's disease patients undergoing gastrointestinal surgery. ANZ J Surg. 2022 Oct;92(10):2538-2543. doi: 10.1111/ans.17852. Epub 2022 Jun 22. PMID: 35733396; PMCID: PMC9796487.

168: Tang N, Chen H, Chen R, Tang W, Zhang H. Predicting Mucosal Healing in Crohn's Disease: A Nomogram Model Developed from a Retrospective Cohort. J Inflamm Res. 2022 Sep 23;15:5515-5525. doi: 10.2147/JIR.S378304. PMID: 36176354; PMCID: PMC9514782.

169: Chamorro-de-Vega E, Romero-Jiménez R, Escudero-Vilaplana V, Ais-Larisgoitia A, Lobato Matilla ME, González CM, Menchén L, Baniandrés O, Ibares-Frias L, Lobo-Rodríguez C, Herranz-Alonso A, Sanjurjo M. Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey. J Med Internet Res. 2022 Sep 13;24(9):e37445. doi: 10.2196/37445. PMID: 36099018; PMCID: PMC9516367.

170: Almario CV, van Deen WK, Chen M, Gale R, Sidorkiewicz S, Choi SY, Bonthala N, Ha C, Syal G, Dupuy T, Liu X, Melmed GY, Spiegel BMR. Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial. Am J Gastroenterol. 2022 Sep 1;117(9):1508-1518. doi: 10.14309/ajg.0000000000001866. Epub 2022 Jun 10. PMID: 35973146; PMCID: PMC9450884.

171: Uche-Anya E, Anyane-Yeboa A, Berzin TM, Ghassemi M, May FP. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut. 2022 Sep;71(9):1909-1915. doi:

10.1136/gutjnl-2021-326271. Epub 2022 Jun 10. PMID: 35688612; PMCID: PMC10323754.

172: Caputo A, Parente P, Cadei M, Fassan M, Rispo A, Leoncini G, Bassotti G, Del Sordo R, Metelli C, Daperno M, Armuzzi A, Villanacci V; SHMHS Study Group. Simplified Histologic Mucosal Healing Scheme (SHMHS) for inflammatory bowel disease: a nationwide multicenter study of performance and applicability. Tech Coloproctol. 2022 Sep;26(9):713-723. doi: 10.1007/s10151-022-02628-7. Epub 2022 Jun 1. Erratum in: Tech Coloproctol. 2023 Feb;27(2):167-168. PMID: 35648263; PMCID: PMC9360061.

173: Wang G, Karimi N, Willmann L, Pipicella J, Descallar J, O'Connor K, Peculis L, Leung Y, Connor S, Huang V, Williams AJ. A Novel Decision Aid Improves Quality of Reproductive Decision-Making and Pregnancy Knowledge for Women with Inflammatory Bowel Disease. Dig Dis Sci. 2022 Sep;67(9):4303-4314. doi: 10.1007/s10620-022-07494-9. Epub 2022 Apr 30. PMID: 35499712; PMCID: PMC9352739.

174: Moshirfar M, Fuhriman DA, Ali A, Odayar V, Ronquillo YC, Hoopes PC. Inflammatory Bowel Disease Guidelines for Corneal Refractive Surgery Evaluation. J Clin Med. 2022 Aug 19;11(16):4861. doi: 10.3390/jcm11164861. PMID: 36013100; PMCID: PMC9409909.

175: Kattenberg JH, Nguyen HV, Nguyen HL, Sauve E, Nguyen NTH, Chopo-Pizarro A, Trimarsanto H, Monsieurs P, Guetens P, Nguyen XX, Esbroeck MV, Auburn S, Nguyen BTH, Rosanas-Urgell A. Novel highly-multiplexed AmpliSeq targeted assay for Plasmodium vivax genetic surveillance use cases at multiple geographical scales. Front Cell Infect Microbiol. 2022 Aug 11;12:953187. doi: 10.3389/fcimb.2022.953187. PMID: 36034708; PMCID: PMC9403277.

176: Hawthorne AB, Glatter J, Blackwell J, Ainley R, Arnott I, Barrett KJ, Bell G, Brookes MJ, Fletcher M, Muhammed R, Nevill AM, Segal J, Selinger CP, St Clair

Jones A, Younge L; IBD UK Board IBD UK Task & Finish Group; Lamb CA. Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients. Aliment Pharmacol Ther. 2022 Aug;56(4):625-645. doi: 10.1111/apt.17042. Epub 2022 Jun 1. PMID: 35770866; PMCID: PMC9541797.

177: Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernández-Ávila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, O'Sullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465-479. doi: 10.1038/s41584-022-00798-0. Epub 2022 Jun 27. Erratum in: Nat Rev Rheumatol. 2022 Dec;18(12):734. PMID: 35761070; PMCID: PMC9244095.

178: Gold PA, Garbarino LJ, Ramkumar PN, Anis H, Sodhi N, Matuszak SJ, Mont MA. Psoriasis and Post-Surgical Infections in Primary Total Knee Arthroplasty: An Analysis of 10,727 Patients. J Arthroplasty. 2022 Aug;37(8):1575-1578. doi: 10.1016/j.arth.2022.03.055. Epub 2022 Mar 18. PMID: 35314284.

179: Yang L, Booth C, Speckmann C, Seidel MG, Worth AJJ, Kindle G, Lankester AC, Grimbacher B; ESID Clinical and Registry Working Parties; Gennery AR, Seppanen MRJ, Morris EC, Burns SO. Phenotype, genotype, treatment, and survival outcomes in patients with X-linked inhibitor of apoptosis deficiency. J Allergy Clin Immunol. 2022 Aug;150(2):456-466. doi: 10.1016/j.jaci.2021.10.037. Epub 2021 Dec 15. PMID: 34920033.

180: Alexdottir MS, Bourgonje AR, Karsdal MA, Pehrsson M, Loveikyte R, van Dullemen HM, Visschedijk MC, Festen EAM, Weersma RK, Faber KN, Dijkstra G,

Mortensen JH. Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn's Disease. Int J Mol Sci. 2022 Jul 23;23(15):8137. doi: 10.3390/ijms23158137. PMID: 35897710; PMCID: PMC9329899.

181: Song K, Wu D. Shared decision-making in the management of patients with inflammatory bowel disease. World J Gastroenterol. 2022 Jul 14;28(26):3092-3100. doi: 10.3748/wjg.v28.i26.3092. PMID: 36051346; PMCID: PMC9331519.

182: Freeman K, Willis BH, Ryan R, Taylor-Phillips S, Clarke A. Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease. BMC Med Res Methodol. 2022 Jul 12;22(1):192. doi: 10.1186/s12874-022-01668-9. PMID: 35820893; PMCID: PMC9275166.

183: Al-Ani A; GESA IBD Patient Information Materials Working Group*; Garg M. Development of inflammatory bowel disease patient education and medical information sheets: serving an unmet need. Intern Med J. 2022 Jul;52(7):1272-1275. doi: 10.1111/imj.15840. PMID: 35879241; PMCID: PMC9545075.

184: Johnsen JM, MacKinnon HJ. JTH in Clinic - Obstetric bleeding: VWD and other inherited bleeding disorders. J Thromb Haemost. 2022 Jul;20(7):1568-1575. doi: 10.1111/jth.15770. Epub 2022 Jun 8. PMID: 35621921.

185: Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R; International Organization for Study of Inflammatory Bowel Diseases. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):666-678. doi:

10.1016/S2468-1253(22)00021-8. Epub 2022 Apr 27. PMID: 35487235.

186: Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. J Clin Pharm Ther. 2022 Jul;47(7):851-859. doi: 10.1111/jcpt.13622. Epub 2022 Mar 6. PMID: 35253941.

187: Takishima K, Maeda Y, Ogata N, Misawa M, Mori Y, Homma M, Nemoto T, Miyata Y, Akimoto Y, Mochida K, Takashina Y, Tanaka K, Ichimasa K, Nakamura H, Sasanuma S, Kudo T, Hayashi T, Wakamura K, Miyachi H, Baba T, Ishida F, Ohtsuka K, Kudo SE. Beyond complete endoscopic healing: Goblet appearance using an endocytoscope to predict future sustained clinical remission in ulcerative colitis. Dig Endosc. 2022 Jul;34(5):1030-1039. doi: 10.1111/den.14202. Epub 2021 Dec 12. PMID: 34816494.

188: Afif W, Sattin B, Dajnowiec D, Khanna R, Seow CH, Williamson M, Karra K, Wang Y, Gao LL, Bressler B. Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial. Dig Dis Sci. 2022 Jul;67(7):3148-3157. doi: 10.1007/s10620-021-07173-1. Epub 2021 Aug 17. PMID: 34401983; PMCID: PMC9237009.

189: Li N, Zhan S, Liu C, Li T, Tu T, Chen B, He Y, Chen M, Zeng Z, Zhuang X. Development and validation of a nomogram to predict indolent course in patients with ulcerative colitis: a single-center retrospective study. Gastroenterol Rep (Oxf). 2022 Jun 30;10:goac029. doi: 10.1093/gastro/goac029. PMID: 35785264; PMCID: PMC9245125.

190: Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med (Lausanne). 2022 Jun 15;9:897936. doi: 10.3389/fmed.2022.897936. PMID: 35783628; PMCID:

PMC9241563.

191: Minnis-Lyons SE, Aiken Z, Chow S, Din S. Managing IBD in patients with previous cancers. Frontline Gastroenterol. 2022 Jun 8;13(e1):e44-e50. doi: 10.1136/flgastro-2022-102187. PMID: 35812021; PMCID: PMC9234723.

192: Yang L, Song X, Chen Y, Li Y, Gu Y, Wang X, Zhu L, Zhi M, Ouyang C, Guo H. Treatment Decision-making in Chinese Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2022 Jun 2;28(Suppl 2):S76-S84. doi: 10.1093/ibd/izab305. PMID: 34894126.

193: Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. Clin Drug Investig. 2022 Jun;42(6):477-489. doi: 10.1007/s40261-022-01162-6. Epub 2022 Jun 3. PMID: 35657560.

194: Rolak S, Kane SV. Conventional Therapies for Crohn's Disease. Gastroenterol Clin North Am. 2022 Jun;51(2):271-282. doi: 10.1016/j.gtc.2021.12.004. Epub 2022 Apr 22. PMID: 35595414.

195: Singh A, Fenton CG, Anderssen E, Paulssen RH. Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis. Int J Colorectal Dis. 2022 Jun;37(6):1321-1333. doi: 10.1007/s00384-022-04176-w. Epub 2022 May 11. PMID: 35543875; PMCID: PMC9167201.

196: Schubert S, Picker N, Cavlar T, Knop J, Kahraman A, Mohl W. Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study. Adv Ther. 2022 Jun;39(6):2889-2905. doi: 10.1007/s12325-022-02143-z. Epub 2022 Apr 22. PMID: 35451740; PMCID: PMC9023727.

197: Geldof J, Iqbal N, LeBlanc JF, Anandabaskaran S, Sawyer R, Buskens C,

Bemelman W, Gecse K, Lundby L, Lightner AL, Danese S, Spinelli A, Carvello M, Faiz O, Warusavitarne J, Lung P, De Looze D, D'Hoore A, Vermeire S, Hart A, Tozer P. Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):576-584. doi: 10.1016/S2468-1253(22)00007-3. Epub 2022 Mar 21. PMID: 35325623.

198: Daraiseh NM, Black A, Minar P, Meisman A, Saxe M, Lipstein EA. iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis. Patient Educ Couns. 2022 Jun;105(6):1628-1633. doi: 10.1016/j.pec.2021.10.023. Epub 2021 Oct 23. PMID: 34756638.

199: Stidham RW, Vickers A, Singh K, Waljee AK. From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD? Gut. 2022 Jun;71(6):1046-1047. doi: 10.1136/gutjnl-2021-324712. Epub 2021 Oct 22. PMID: 34686576; PMCID: PMC9023586.

200: Al Khoury A, Balram B, Bessissow T, Afif W, Gonczi L, Abreu M, Lakatos PL. Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review. Dig Dis Sci. 2022 Jun;67(6):1956-1974. doi: 10.1007/s10620-021-07025-y. Epub 2021 May 21. PMID: 34021425; PMCID: PMC8139371.

201: Minchenberg SB, Walradt T, Glissen Brown JR. Scoping out the future: The application of artificial intelligence to gastrointestinal endoscopy. World J Gastrointest Oncol. 2022 May 15;14(5):989-1001. doi: 10.4251/wjgo.v14.i5.989. PMID: 35646286; PMCID: PMC9124983.

202: Chiarello MM, Pepe G, Fico V, Bianchi V, Tropeano G, Altieri G, Brisinda G. Therapeutic strategies in Crohn's disease in an emergency surgical setting. World J Gastroenterol. 2022 May 14;28(18):1902-1921. doi: 10.3748/wjg.v28.i18.1902. PMID: 35664965; PMCID: PMC9150057.

203: Bots S, De Voogd F, De Jong M, Ligtvoet V, Löwenberg M, Duijvestein M, Ponsioen CY, D'Haens G, Gecse KB. Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm. J Crohns Colitis. 2022 May 10;16(4):606-615. doi: 10.1093/ecco-jcc/jjab175. PMID: 34636839; PMCID: PMC9089417.

204: Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Aliment Pharmacol Ther. 2022 May;55(10):1320-1329. doi: 10.1111/apt.16817. Epub 2022 Feb 25. PMID: 35218038.

205: Monmousseau F, Mulot L, Rusch E, Picon L, Laharie D, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, DES Garets V, Brunet-Houdard S, Aubourg A; COQC-PIT Study Group. Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics. Scand J Gastroenterol. 2022 May;57(5):566-573. doi: 10.1080/00365521.2021.2025419. Epub 2022 Feb 21. PMID: 35188859.

206: Leeds IL, Canner JK, DiBrito SR, Safar B. Do Cost Limitations of Extended Prophylaxis After Surgery Apply to Ulcerative Colitis Patients? Dis Colon Rectum. 2022 May 1;65(5):702-712. doi: 10.1097/DCR.0000000000002056. PMID: 34840290; PMCID: PMC8995329.

207: Lipstein EA, Brinkman WB, Zhang Y, Hommel KA, Ittenbach RF, Liu C, Denson LA. Decision making about anti-TNF therapy: A pilot trial of a shared decision-making intervention. Patient Educ Couns. 2022 May;105(5):1075-1081. doi: 10.1016/j.pec.2021.09.030. Epub 2021 Sep 30. PMID: 34629231.

208: Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?. Curr Res Pharmacol Drug Discov. 2022 Apr 28;3:100104. doi: 10.1016/j.crphar.2022.100104. PMID: 35570855; PMCID: PMC9092374.

209: Chandrasinghe P. Surgical Management of Small Bowel Crohn's Disease. Front Surg. 2022 Apr 15;9:759668. doi: 10.3389/fsurg.2022.759668. PMID: 35495760; PMCID: PMC9051431.

210: Porcaro K. Building responsive governance for learning networks. Learn Health Syst. 2021 Aug 5;6(2):e10288. doi: 10.1002/lrh2.10288. Erratum in: Learn Health Syst. 2022 May 26;6(3):e10322. PMID: 35434358; PMCID: PMC9006526.

211: Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Erratum in: Lancet Gastroenterol Hepatol. 2022 Apr;7(4):e8. PMID: 35120656.

212: Dignass AU, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol. 2022 Apr;57(4):424-431. doi: 10.1080/00365521.2021.2015801. Epub 2021 Dec 21. PMID: 34932423.

213: Bodini G, Demarzo MG, Djahandideh A, Ziola S, Risso P, Bertani L, Baldissarro I, Testa T, Marchi S, Savarino E, Giannini EG. Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques. Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):382-388. doi: 10.1097/MEG.0000000000002261. PMID: 34334710.

214: Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson M, East JE; Oxford IBD Cohort Study Investigators; Lindsay JO, Vega R, Thomas-Gibson S, Warusavitarne J, Wilson A, Graham TA, Hart A. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut. 2022 Apr;71(4):705-715. doi: 10.1136/gutjnl-2020-323546. Epub 2021 May 14. PMID: 33990383; PMCID: PMC8921573.

215: Plevinsky JM, Maddux MH, Fishman LN, Kahn SA, Greenley RN. Perceived effect of pediatric inflammatory bowel diseases on academics, college planning, and college adjustment. J Am Coll Health. 2022 Apr;70(3):940-947. doi: 10.1080/07448481.2020.1781869. Epub 2020 Jul 9. PMID: 32643555.

216: O'Reilly EL, Horvatić A, Kuleš J, Gelemanović A, Mrljak V, Huang Y, Brady N, Chadwick CC, Eckersall PD, Ridyard A. Faecal proteomics in the identification of biomarkers to differentiate canine chronic enteropathies. J Proteomics. 2022 Mar 15;254:104452. doi: 10.1016/j.jprot.2021.104452. Epub 2021 Dec 24. Erratum in: J Proteomics. 2022 May 15;259:104510. PMID: 34958965.

217: Daloya J, Ashraf A, Kaell A, Perera R, Korlipara G. Acute Myopericarditis in the Setting of Crohn's Colitis: Challenging Management Decisions. Cureus. 2022 Mar 3;14(3):e22794. doi: 10.7759/cureus.22794. PMID: 35399407; PMCID: PMC8980245.

218: Christian M, Giovanni M, Torsten K, Mariangela A. Ultrasonography in inflammatory bowel disease - So far we are? United European Gastroenterol J.

2022 Mar;10(2):225-232. doi: 10.1002/ueg2.12196. Epub 2022 Feb 8. Erratum in: United European Gastroenterol J. 2022 May;10(4):439. PMID: 35132795; PMCID: PMC8911535.

219: Kaneko K, Prieto-Alhambra D, Jacklin C, Bosworth A, Dickinson S, Berry S, McAteer H, Taylor PC. Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisations. BMJ Open. 2022 Feb 16;12(2):e050949. doi: 10.1136/bmjopen-2021-050949. PMID: 35172995; PMCID: PMC8852668.

220: Gorbenko KO, Riggs AR, Koeppel B, Phlegar S, Dubinsky MC, Ungaro R, Keefer L. Photovoice as a tool to improve patient-Provider communication in inflammatory bowel disease clinic: A feasibility study. J Eval Clin Pract. 2022 Feb;28(1):159-168. doi: 10.1111/jep.13609. Epub 2021 Aug 11. PMID: 34382292.

221: Carvello M, Danese S, Spinelli A. Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease. Clin Colon Rectal Surg. 2022 Jan 17;35(1):72-77. doi: 10.1055/s-0041-1740031. PMID: 35069033; PMCID: PMC8763452.

222: Fleshner P, Melmed GY. Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons. Clin Colon Rectal Surg. 2022 Jan 17;35(1):66-71. doi: 10.1055/s-0041-1740030. PMID: 35069032; PMCID: PMC8763454.

223: Alfarone L, Dal Buono A, Craviotto V, Zilli A, Fiorino G, Furfaro F, D'Amico F, Danese S, Allocca M. Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. J Clin Med. 2022 Jan 12;11(2):353. doi: 10.3390/jcm11020353. PMID: 35054047; PMCID: PMC8778036.

224: Picciarelli Z, Stransky OM, Leech MM, Michel HK, Schwartz M, Kim SC, Gray WM, Kazmerski TM. Exploring Reproductive Health Decision Experiences and Preferences of Women With Pediatric-Onset Inflammatory Bowel Diseases. Crohns

Colitis 360. 2021 Dec 29;4(1):otab083. doi: 10.1093/crocol/otab083. PMID: 36777551; PMCID: PMC9802148.

225: Tamizifar B, Ehsani M, Farzi S, Adibi P, Taleghani F, Farzi S, Shahriari M, Moladoost A. Development of a Patient Decision Aid to Help People Living with Inflammatory Bowel Disease. Middle East J Dig Dis. 2022 Jan;14(1):57-63. doi: 10.34172/mejdd.2022.256. Epub 2022 Jan 30. PMID: 36619728; PMCID: PMC9489324.

226: Radford SJ, Clarke C, Shinkins B, Leighton P, Taylor S, Moran G. Clinical utility of small bowel ultrasound assessment of Crohn's disease in adults: a systematic scoping review. Frontline Gastroenterol. 2021 Jun 23;13(4):280-286. doi: 10.1136/flgastro-2021-101897. PMID: 35722606; PMCID: PMC9186037.

227: Akhrieva KM, Kogan EA, Tertychnyi AS, Radenska-Lopovok SG, Zayratyants OV, Selivanova LS. Otsenka gistologicheskoi aktivnosti kolitov [Assessment of histologic activity in colitis]. Arkh Patol. 2022;84(2):51-57. Russian. doi: 10.17116/patol20228402151. PMID: 35417949.

228: Tica S, Alghamdi S, Tait C, Nemera B, Turmelle Y, Fleckenstein J, Stoll J, Kulkarni S. Diagnosis of Primary Sclerosing Cholangitis Beyond Childhood is Associated with Worse Outcomes. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):110-117. doi: 10.1016/j.jceh.2021.03.006. Epub 2021 Mar 26. PMID: 35068791; PMCID: PMC8766535.

229: Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol. 2021 Apr 21;13(1):77-81. doi: 10.1136/flgastro-2021-101805. PMID: 34966535; PMCID: PMC8666864.

230: Awadie H, Waterman M. Intermittent Appearance of Antibodies to Infliximab

Is Not Associated With Reduced Efficacy in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2022 Jan 1;56(1):e47-e51. doi: 10.1097/MCG.0000000000001469. PMID: 33252556.

231: Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021 Dec 9;14:17562848211059954. doi: 10.1177/17562848211059954. PMID: 34917173; PMCID: PMC8669878.

232: Jonaitis L, Marković S, Farkas K, Gheorghe L, Krznarić Ž, Salupere R, Mokricka V, Spassova Z, Gatev D, Grosu I, Lijović A, Mitrović O, Saje M, Schafer E, Uršič V, Roblek T, Drobne D. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert's and patient's perspective. BMC Proc. 2021 Dec 9;15(Suppl 17):25. doi: 10.1186/s12919-021-00230-7. PMID: 34879868; PMCID: PMC8654488.

233: Xu D, Zhang H, Chen Y. Patients' views of shared decision making in inflammatory bowel disease: a survey in China. BMC Med Inform Decis Mak. 2021 Dec 6;21(1):340. doi: 10.1186/s12911-021-01702-8. PMID: 34872536; PMCID: PMC8650369.

234: Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med. 2021 Nov 29;10(23):5642. doi: 10.3390/jcm10235642. PMID: 34884344; PMCID: PMC8658146.

235: Van Citters AD, Holthoff MM, Kennedy AM, Melmed GY, Oberai R, Siegel CA, Weaver A, Nelson EC. Point-of-care dashboards promote coproduction of healthcare services for patients with inflammatory bowel disease. Int J Qual Health Care. 2021 Nov 29;33(Supplement_2):ii40-ii47. doi: 10.1093/intqhc/mzab067. PMID:

34849970.

236: Yao L, Zhu X, Shao B, Liu R, Li Z, Wu L, Chen J, Cao Q. Reasons and Factors Contributing to Chinese Patients' Preference for Ustekinumab in Crohn's Disease: A Multicenter Cross-Sectional Study. Front Pharmacol. 2021 Nov 22;12:736149. doi: 10.3389/fphar.2021.736149. PMID: 34887751; PMCID: PMC8651007.

237: Papalia I, Tjandra D, Quah S, Tan C, Gorelik A, Sivanesan S, Macrae F. Colon Capsule Endoscopy in the Assessment of Mucosal Healing in Crohn's Disease. Inflamm Bowel Dis. 2021 Nov 15;27(Supplement_2):S25-S32. doi: 10.1093/ibd/izab180. PMID: 34791289; PMCID: PMC8690064.

238: Yanai H, Amir Barak H, Ollech JE, Avni Biron I, Goren I, Snir Y, Banai Eran H, Broitman Y, Aharoni Golan M, Didkovsky E, Amitay-Laish I, Ollech A, Hodak E, Dotan I, Pavlovsky L. Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic. Therap Adv Gastroenterol. 2021 Nov 8;14:17562848211053112. doi: 10.1177/17562848211053112. PMID: 34777576; PMCID: PMC8581781.

239: Rezazadeh Ardabili A, Goudkade D, Wintjens D, Romberg-Camps M, Winkens B, Pierik M, Grabsch HI, Jonkers D. Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn's Disease. J Crohns Colitis. 2021 Nov 8;15(11):1885-1897. doi: 10.1093/ecco-jcc/jjab087. PMID: 33987670; PMCID: PMC8575048.

240: Lucaciu LA, Ilieș M, Vesa ȘC, Seicean R, Din S, Iuga CA, Seicean A. Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. J Pers Med. 2021 Nov 2;11(11):1130. doi: 10.3390/jpm11111130. PMID: 34834482; PMCID: PMC8621192.

241: Zhang Y, Xue X, Su S, Zhou H, Jin Y, Shi Y, Lin J, Wang J, Li X, Yang G, Philpott JR, Liang J. Patients and physicians' attitudes change on fecal microbiota transplantation for inflammatory bowel disease over the past 3 years. Ann Transl Med. 2021 Nov;9(21):1619. doi: 10.21037/atm-21-3683. PMID: 34926663; PMCID: PMC8640917.

242: Lightner AL, Vogler SA, Vaidya PS, McMichael JP, Jia X, Regueiro M, Steele SR. The Fate of Unifocal Versus Multifocal Low-Grade Dysplasia at the Time of Colonoscopy in Patients With IBD. Dis Colon Rectum. 2021 Nov 1;64(11):1364-1373. doi: 10.1097/DCR.0000000000002063. Erratum in: Dis Colon Rectum. 2022 Aug 1;65(8):e825. PMID: 34623348.

243: Jorissen C, Verstockt B, Schils N, Sabino J, Ferrante M, Vermeire S. Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. Scand J Gastroenterol. 2021 Nov;56(11):1323-1327. doi: 10.1080/00365521.2021.1965207. Epub 2021 Aug 17. PMID: 34399630.

244: di Giuseppe R, Plachta-Danielzik S, Mohl W, Hoffstadt M, Krause T, Bokemeyer B, Schreiber S. Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDO_{IBD}-Study. Int J Colorectal Dis. 2021 Nov;36(11):2445-2453. doi: 10.1007/s00384-021-03943-5. Epub 2021 May 8. PMID: 33963913.

245: Nowell WB, Merkel PA, McBurney RN, Young K, Venkatachalam S, Shaw DG, Dobes A, Cerciello E, Kolaczkowski L, Curtis JR, Kappelman MD. Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. Patient. 2021 Nov;14(6):699-710. doi: 10.1007/s40271-021-00515-1. Epub 2021 Apr 27. PMID: 33904145; PMCID: PMC8075709.

246: Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, De Hertogh G, Vermeire S. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 Oct 18;27(10):1564-1575. doi: 10.1093/ibd/izab032. PMID: 33624092; PMCID: PMC8522791.

247: Kulkarni C, Murag S, Cholankeril G, Fardeen T, Mannalithara A, Lerrigo R, Kamal A, Ahmed A, Goel A, Sinha SR. Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis. Inflamm Bowel Dis. 2021 Oct 18;27(10):1602-1609. doi: 10.1093/ibd/izaa317. PMID: 33300561.

248: Patel DB, van Deen WK, Almario CV, Khalil C, Warui E, Bonthala N, Melmed GY, Spiegel BMR. Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom. Inflamm Bowel Dis. 2021 Oct 18;27(10):1593-1601. doi: 10.1093/ibd/izaa311. PMID: 33300555.

249: Fumery M, Yzet C, Chatelain D, Yzet T, Brazier F, LeMouel JP, Laharie D, Sabbagh C. Colonic Strictures in Inflammatory Bowel Disease: Epidemiology, Complications, and Management. J Crohns Colitis. 2021 Oct 7;15(10):1766-1773. doi: 10.1093/ecco-jcc/jjab068. PMID: 33844013.

250: Xu W, Ou W, Fu J, Gu Y, Cui L, Zhong J, Du P. Cut-off value of ulcerative colitis endoscopic index of severity (UCEIS) score for predicting the need for pouch construction in ulcerative colitis: results of a multicenter study with long-term follow-up. Gastroenterol Rep (Oxf). 2021 May 29;9(5):435-442. doi: 10.1093/gastro/goab022. PMID: 34733529; PMCID: PMC8560042.

251: Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised

patients. Int Immunopharmacol. 2021 Oct;99:108021. doi: 10.1016/j.intimp.2021.108021. Epub 2021 Jul 28. PMID: 34352567; PMCID: PMC8316069.

252: Alipour O, Lee V, Tejura TK, Wilson ML, Memel Z, Cho J, Cologne K, Hwang C, Shao L. The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD. Scand J Gastroenterol. 2021 Oct;56(10):1175-1181. doi: 10.1080/00365521.2021.1958368. Epub 2021 Aug 3. PMID: 34344243.

253: Visuri I, Eriksson C, Olén O, Cao Y, Mårdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P; SWIBREG study group; Ludvigsson JF, Halfvarson J. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther. 2021 Oct;54(7):931-943. doi: 10.1111/apt.16525. Epub 2021 Jul 19. PMID: 34286871.

254: Spinelli A, Carvello M, Adamina M, Panis Y, Warusavitarne J, Tulchinsky H, Bemelman WA, Kotze PG, D'Hoore A, Lastikova L, Danese S, Peyrin-Biroulet L, Avedano L, Pagnini F. Patients' perceptions of surgery for inflammatory bowel disease. Colorectal Dis. 2021 Oct;23(10):2690-2698. doi: 10.1111/codi.15813. Epub 2021 Jul 26. PMID: 34268861.

255: Feng J, Chen Y, Feng Q, Ran Z, Shen J. Novel Gene Signatures Predicting Primary Non-response to Infliximab in Ulcerative Colitis: Development and Validation Combining Random Forest With Artificial Neural Network. Front Med (Lausanne). 2021 Sep 28;8:678424. doi: 10.3389/fmed.2021.678424. PMID: 34650991; PMCID: PMC8505970.

256: Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the

Evidence. Front Pediatr. 2021 Sep 21;9:708310. doi: 10.3389/fped.2021.708310. PMID: 34621712; PMCID: PMC8490777.

257: Cohan JN, Ozanne EM, Hofer RK, Kelly YM, Kata A, Larsen C, Finlayson E. Ileostomy or ileal pouch-anal anastomosis for ulcerative colitis: patient participation and decisional needs. BMC Gastroenterol. 2021 Sep 19;21(1):347. doi: 10.1186/s12876-021-01916-0. PMID: 34538236; PMCID: PMC8451075.

258: Sagar R, Lenti MV, Clark T, Rafferty HJ, Gracie DJ, Ford AC, O'Connor A, Ahmad T, Hamlin PJ, Selinger CP. Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. Inflamm Intest Dis. 2021 Apr 13;6(3):132-139. doi: 10.1159/000515593. PMID: 34722643; PMCID: PMC8527899.

259: Park J, Park S, Lee SA, Park SJ, Cheon JH. Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management. Korean J Intern Med. 2021 Sep;36(5):1040-1048. doi: 10.3904/kjim.2021.114. Epub 2021 Aug 5. PMID: 34344146; PMCID: PMC8435511.

260: Matsuoka K, Ishikawa H, Nakayama T, Honzawa Y, Maemoto A, Hirai F, Ueno F, Sato N, Susuta Y, Hibi T. Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. J Gastroenterol. 2021 Sep;56(9):843-855. doi: 10.1007/s00535-021-01811-1. Epub 2021 Jul 27. PMID: 34313863; PMCID: PMC8370900.

261: Atia O, Gupta A, Travis S, Turner D, Koslowsky B. The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis. Scand J Gastroenterol. 2021 Sep;56(9):1049-1055. doi: 10.1080/00365521.2021.1947368. Epub 2021 Jul 14. PMID: 34261387.

262: Friedman AB, Asthana A, Knowles SR, Robbins A, Gibson PR. Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease. Aliment Pharmacol Ther. 2021 Sep;54(5):652-666. doi: 10.1111/apt.16452. Epub 2021 Jun 22. PMID: 34157157.

263: Carretero C, Carbonnel F, Ferrante M, Knudsen T, Van Lent N, Lobo AJ, Negreanu L, Vojvodic A, Oliva S. Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique. Curr Med Res Opin. 2021 Sep;37(9):1547-1554. doi: 10.1080/03007995.2021.1940910. Epub 2021 Jun 30. PMID: 34132150.

264: Correia FP, Lourenço LC. Artificial intelligence application in diagnostic gastrointestinal endoscopy - Deus ex machina? World J Gastroenterol. 2021 Aug 28;27(32):5351-5361. doi: 10.3748/wjg.v27.i32.5351. PMID: 34539137; PMCID: PMC8409168.

265: Karimi N, Kanazaki R, Lukin A, Moore AR, Williams AJ, Connor S. Clinical communication in inflammatory bowel disease: a systematic review of the study of clinician-patient dialogue to inform research and practice. BMJ Open. 2021 Aug 27;11(8):e051053. doi: 10.1136/bmjopen-2021-051053. PMID: 34452967; PMCID: PMC8404434.

266: Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore). 2021 Aug 27;100(34):e27065. doi: 10.1097/MD.0000000000027065. PMID: 34449501; PMCID: PMC8389889.

267: Okobi OE, Udoete IO, Fasehun OO, Okobi T, Evbayekha EO, Ekabua JJ, Elukeme H, Ebong IL, Ajayi OO, Olateju IV, Taiwo A, Anaya IC, Omole JA, Nkongho MB, Ojinnaka U, Ajibowo AO, Ogbeifun OE, Ugbo OO, Okorare O, Akinsola Z, Olusoji RA,

Amanze IO, Nwafor JN, Ukoha NA, Elimihele TA. A Review of Four Practice Guidelines of Inflammatory Bowel Disease. Cureus. 2021 Aug 3;13(8):e16859. doi: 10.7759/cureus.16859. PMID: 34513436; PMCID: PMC8413108.

268: Herbert A, Rafiq M, Pham TM, Renzi C, Abel GA, Price S, Hamilton W, Petersen I, Lyratzopoulos G. Predictive values for different cancers and inflammatory bowel disease of 6 common abdominal symptoms among more than 1.9 million primary care patients in the UK: A cohort study. PLoS Med. 2021 Aug 2;18(8):e1003708. doi: 10.1371/journal.pmed.1003708. PMID: 34339405; PMCID: PMC8367005.

269: Barnes EL, Holubar SD, Herfarth HH. Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis. J Crohns Colitis. 2021 Aug 2;15(8):1272-1278. doi: 10.1093/ecco-jcc/jjab025. PMID: 33544128.

270: Martín-Masot R, Ortiz Pérez P, Torcuato Rubio E, Blasco Alonso J, Herrador López M, Gallego Fernández C, Navas-López VM. The New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis: A Series of Pediatric Cases. JPGN Rep. 2021 Jul 12;2(3):e100. doi: 10.1097/PG9.0000000000000100. PMID: 37205967; PMCID: PMC10191510.

271: Ye XQ, Cai J, Yu Q, Cao XC, Chen Y, Rao MX, Chen BL, He Y, Zeng ZR, Chen H, Lin YM, Cao Q, Chen MH, Zhang SH. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study. Gastroenterol Rep (Oxf). 2020 Nov 12;9(4):329-338. doi: 10.1093/gastro/goaa069. PMID: 34567565; PMCID: PMC8460115.

272: Esen E, Keshinro A, Remzi FH. Ileoanal Pouch: Pelvic Sepsis and Poor Function-Now What? J Laparoendosc Adv Surg Tech A. 2021 Aug;31(8):867-874. doi: 10.1089/lap.2021.0030. Epub 2021 Jul 12. PMID: 34252327.

273: Sninsky J, Barnes EL. Medical Management of Aggressive Inflammatory Bowel Disease: When Is the Time to Cut Your (and the Patient's) Losses? J Laparoendosc Adv Surg Tech A. 2021 Aug;31(8):905-910. doi: 10.1089/lap.2021.0338. Epub 2021 Jun 25. PMID: 34171979.

274: Wang K, Huang L, Huang W, Liu R, Chen X, Guo Z, Qian W, Yin Y, Li Y, Zhu W. Predictive Value of CT Enterography Index for Postoperative Intra-abdominal Septic Complications in Patients With Crohn's Disease: Implications for Surgical Decision-Making. Dis Colon Rectum. 2021 Aug 1;64(8):964-976. doi: 10.1097/DCR.0000000000001796. PMID: 33951684.

275: Gong W, Guo K, Zheng T, Xie H, Li W, Li M, Hong Z, Ren H, Gu G, Wang G, Wu X, Ren J. JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease. Eur J Gastroenterol Hepatol. 2021 Aug 1;33(8):1049-1054. doi: 10.1097/MEG.0000000000001979. PMID: 33136728.

276: Ishiguro Y, Ohmori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study. Ther Apher Dial. 2021 Aug;25(4):502-512. doi: 10.1111/1744-9987.13594. Epub 2020 Nov 28. PMID: 33029920.

277: Kline BP, Weaver T, Brinton DL Jr, Harris L, Yochum GS, Berg AS, Koltun WA. Clinical and Genetic Factors Impact Time to Surgical Recurrence After Ileocolectomy for Crohn's Disease. Ann Surg. 2021 Aug 1;274(2):346-351. doi: 10.1097/SLA.0000000000003660. PMID: 31714311.

278: Williams AJ, Karimi N, Chari R, Connor S, De Vera MA, Dieleman LA, Hansen T, Ismond K, Khurana R, Kingston D, O'Connor K, Sadowski DC, Fang-Hwa F, Wine E,

Leung Y, Huang V. Shared decision making in pregnancy in inflammatory bowel disease: design of a patient orientated decision aid. BMC Gastroenterol. 2021 Jul 30;21(1):302. doi: 10.1186/s12876-021-01853-y. PMID: 34330215; PMCID: PMC8325254.

279: Matson J, Ramamoorthy S, Lopez NE. The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. J Clin Med. 2021 Jul 29;10(15):3362. doi: 10.3390/jcm10153362. PMID: 34362144; PMCID: PMC8348722.

280: Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 Jul 27;27(8):1210-1214. doi: 10.1093/ibd/izaa277. PMID: 33125058.

281: Wu Q, Wang X, Wu F, Peng D, Wu G, Yang L, Yuan L. Role of a multidisciplinary team (MDT) in the diagnosis, treatment, and outcomes of inflammatory bowel disease: a single Chinese center's experience. Biosci Trends. 2021 Jul 6;15(3):171-179. doi: 10.5582/bst.2021.01174. Epub 2021 Jun 13. PMID: 34121045.

282: Kyriakos N, Papaefthymiou A, Giakoumis M, Iatropoulos G, Mantzaris G, Liatsos C. Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. Ann Gastroenterol. 2021 Jul-Aug;34(4):466-475. doi: 10.20524/aog.2021.0635. Epub 2021 Jun 3. PMID: 34276184; PMCID: PMC8276362.

283: Fisher K, Byham-Gray L, Rothpletz-Puglia P. Characterizing the Parental Perspective of Food-Related Quality of Life in Families After Pediatric Inflammatory Bowel Disease Diagnosis. Gastroenterol Nurs. 2021 Jul-Aug 01;44(4):E69-E77. doi: 10.1097/SGA.0000000000000616. PMID: 34149042.

284: Lipstein EA, Breslin M, Dodds CM, Kappelman MD, Ollberding NJ, Margolis P,

Xu Y, Brinkman WB. Integrating shared decision making into trial consent: A nested, cluster-randomized trial. Patient Educ Couns. 2021 Jul;104(7):1575-1582. doi: 10.1016/j.pec.2020.12.018. Epub 2020 Dec 25. PMID: 33386187.

285: Rubin DT, Hart A, Panaccione R, Armuzzi A, Suvanto U, Deuring JJ, Woolcott J, Cappelleri JC, Steinberg K, Wingate L, Schreiber S. Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. Inflamm Bowel Dis. 2021 Jun 15;27(7):1096-1106. doi: 10.1093/ibd/izaa257. PMID: 33057598; PMCID: PMC8214018.

286: Wilson L, Tuson S, Yang L, Loomes D. Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel Disease. J Can Assoc Gastroenterol. 2020 Mar 4;4(3):101-109. doi: 10.1093/jcag/gwaa005. PMID: 34056527; PMCID: PMC8158651.

287: Kaimakliotis P, Ramadugu A, Kang J, McGorisk T, Polick A, Votta-Velis E, Trivedi I. Targeted housestaff intervention reduces opioid use without worsening patient-reported pain scores and improves outcomes among patients with IBD: the "IBD pain ladder". Int J Colorectal Dis. 2021 Jun;36(6):1193-1200. doi: 10.1007/s00384-021-03852-7. Epub 2021 Jan 23. PMID: 33486534.

288: Yao J, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. A Validated Prognostic Model and Nomogram to Predict Early-Onset Complications Leading to Surgery in Patients With Crohn's Disease. Dis Colon Rectum. 2021 Jun 1;64(6):697-705. doi: 10.1097/DCR.0000000000001881. PMID: 33315712; PMCID: PMC8096309.

289: Hansen R, Meade S, Beattie RM, Auth MK, Croft N, Davies P, Devadason D, Doherty C, Epstein J, Howarth L, Kiparissi F, Muhammed R, Shivamurthy V, Spray C, Stanton MP, Torrente F, Urs A, Wilson D, Irving PM, Samaan M, Kammermeier J. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND

appropriateness panel. Gut. 2021 Jun;70(6):1044-1052. doi: 10.1136/gutjnl-2020-322449. Epub 2020 Sep 1. PMID: 32873696.

290: Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1209-1217.e2. doi: 10.1016/j.cgh.2020.04.078. Epub 2020 May 4. PMID: 32376505.

291: Kapoor A, Crowley E. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Front Pediatr. 2021 May 26;9:661536. doi: 10.3389/fped.2021.661536. PMID: 34123968; PMCID: PMC8187753.

292: Sensi B, Bagaglini G, Bellato V, Cerbo D, Guida AM, Khan J, Panis Y, Savino L, Siragusa L, Sica GS. Management of Low Rectal Cancer Complicating Ulcerative Colitis: Proposal of a Treatment Algorithm. Cancers (Basel). 2021 May 13;13(10):2350. doi: 10.3390/cancers13102350. PMID: 34068058; PMCID: PMC8152518.

293: Giraud EL, Thomas PWA, van Lint JA, van Puijenbroek EP, Römkens TEH, West RL, Russel MGVM, Jansen JM, Jessurun NT, Hoentjen F; IBDREAM registry. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. Drug Saf. 2021 May;44(5):581-588. doi: 10.1007/s40264-021-01045-3. Epub 2021 Feb 4. PMID: 33538994; PMCID: PMC8053178.

294: Bourgonje AR, van Linschoten RCA, West RL, van Dijk MA, van Leer-Buter CC, Kats-Ugurlu G, Pierik MJ, Festen EAM, Weersma RK, Dijkstra G. Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. Therap Adv Gastroenterol. 2021 Apr 29;14:17562848211012595. doi: 10.1177/17562848211012595. PMID: 33995584; PMCID: PMC8111526.

295: Farkas K, Pigniczki D, Rutka M, Szántó KJ, Resál T, Bor R, Fábián A, Szepes Z, Lázár G, Molnár T. The complex relationship between viruses and inflammatory bowel disease - review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic. Therap Adv Gastroenterol. 2021 Apr 12;14:1756284820988198. doi: 10.1177/1756284820988198. PMID: 33953797; PMCID: PMC8044573.

296: Rivera K, Cabrera G, Kalivoda EJ. Point-of-Care Ultrasound Diagnosis of a Crohn's Disease-Related Intraabdominal Abscess in the Emergency Department. Cureus. 2021 Apr 4;13(4):e14290. doi: 10.7759/cureus.14290. PMID: 33968504; PMCID: PMC8096620.

297: Rohatinsky N, Boyd I, Dickson A, Fowler S, Peña-Sánchez JN, Quintin CL, Risling T, Russell B, Wicks K, Wicks M. Perspectives of health care use and access to care for individuals living with inflammatory bowel disease in rural Canada. Rural Remote Health. 2021 Apr;21(2):6358. doi: 10.22605/RRH6358. Epub 2021 Apr 6. PMID: 33820422.

298: Kabir M, Thomas-Gibson S, Hart AL, Tozer PJ, Faiz O, Warusavitarne J, Wilson A. Management of inflammatory bowel disease associated colonic dysplasia: factors predictive of patient choice and satisfaction. Colorectal Dis. 2021 Apr;23(4):882-893. doi: 10.1111/codi.15460. Epub 2020 Dec 19. PMID: 33245836.

299: Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, Vavricka SR. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021 Apr;70(4):796-802. doi: 10.1136/gutjnl-2020-322129. Epub 2020 Aug 26. PMID: 32847845; PMCID: PMC9014274.

300: Azzam N, Aljebreen A, Alharbi O, Charabaty A, Alanazi M, Alkuwaykibi N, Alfaraidi J, Bashamil A, Almansour T, Almadi M. Impact of infliximab therapeutic

drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort. Arab J Gastroenterol. 2021 Mar;22(1):66-72. doi: 10.1016/j.ajg.2021.01.001. Epub 2021 Feb 23. PMID: 33632623.

301: Arbogast JP, Urbanik S, Schmidt R, Mennigen R, Pascher A, Rijcken E. Impact of the Crohn's disease digestive damage score (Lémann Index) on the perioperative course in patients with Crohn's disease and ileocolic anastomosis. Scand J Gastroenterol. 2021 Mar;56(3):239-246. doi: 10.1080/00365521.2020.1868565. Epub 2021 Jan 7. PMID: 33410352.

302: David JG, Daly BP, Chute D, Katz-Buonincontro J, Clemente I, Lipstein EA. Use of language in the medical decision-making process for biologic therapy: Youth and parent perspectives. Child Care Health Dev. 2021 Mar;47(2):208-217. doi: 10.1111/cch.12836. Epub 2020 Dec 10. PMID: 33274460.

303: Thomas PWA, Chin PKL, Barclay ML. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Intern Med J. 2021 Mar;51(3):341-347. doi: 10.1111/imj.14778. PMID: 32043746.

304: Kim AH, Girgis A, De Cruz P, Siegel CA, Karimi N, Ruban SO, Sechi AJ, Ng WSW, Andrews JM, Connor SJ. Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. J Med Internet Res. 2021 Feb 25;23(2):e15946. doi: 10.2196/15946. PMID: 33629956; PMCID: PMC7952232.

305: Bravo F, Macpherson JA, Slack E, Patuto N, Cahenzli J, McCoy KD, Macpherson AJ, Juillerat P; SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clin Transl

Gastroenterol. 2021 Feb 15;12(2):e00298. doi: 10.14309/ctg.0000000000000298. PMID: 33735154; PMCID: PMC7886452.

306: Shamim S, Andresen YLM, Vind Thaysen H, Hovdenak Jakobsen I, Nielsen J, Kjaergaard Danielsen A, Konradsen H. Experiences of Patients Undergoing Bowel Preparation and Colonoscopy: A Qualitative Longitudinal Study. J Multidiscip Healthc. 2021 Feb 11;14:349-358. doi: 10.2147/JMDH.S290166. PMID: 33603393; PMCID: PMC7887187.

307: Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, Scharl M. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflamm Intest Dis. 2021 Feb;6(1):38-47. doi: 10.1159/000511296. Epub 2020 Nov 20. PMID: 33850838; PMCID: PMC8015259.

308: Khan R, Li J, Scaffidi MA, Gimpaya N, Pivetta B, Grover SC. Conflicts of Interest in Inflammatory Bowel Disease Articles on UpToDate. J Can Assoc Gastroenterol. 2019 Oct 11;4(1):10-14. doi: 10.1093/jcag/gwz030. PMID: 33644671; PMCID: PMC7898378.

309: Cohen-Mekelburg S, Berry S, Stidham RW, Zhu J, Waljee AK. Clinical applications of artificial intelligence and machine learning-based methods in inflammatory bowel disease. J Gastroenterol Hepatol. 2021 Feb;36(2):279-285. doi: 10.1111/jgh.15405. PMID: 33624888; PMCID: PMC8917815.

310: Nishio M, Hirasawa K, Ozeki Y, Sawada A, Ikeda R, Fukuchi T, Kobayashi R, Makazu M, Sato C, Kunisaki R, Maeda S. An endoscopic treatment strategy for superficial tumors in patients with ulcerative colitis. J Gastroenterol Hepatol. 2021 Feb;36(2):498-506. doi: 10.1111/jgh.15207. Epub 2020 Aug 27. PMID: 32754980.

311: Khan TA, Loftus TJ, Filiberto AC, Ozrazgat-Baslanti T, Ruppert MM, Bandyopadhyay S, Laiakis EC, Arnaoutakis DJ, Bihorac A. Metabolomic Profiling for Diagnosis and Prognostication in Surgery: A Scoping Review. Ann Surg. 2021 Feb 1;273(2):258-268. doi: 10.1097/SLA.0000000000003935. PMID: 32482979; PMCID: PMC7704904.

312: Kushkevych I, Martínková K, Vítězová M, Rittmann SKR. Intestinal Microbiota and Perspectives of the Use of Meta-Analysis for Comparison of Ulcerative Colitis Studies. J Clin Med. 2021 Jan 26;10(3):462. doi: 10.3390/jcm10030462. PMID: 33530381; PMCID: PMC7865400.

313: Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. medRxiv [Preprint]. 2021 Jan 20:2021.01.15.21249889. doi: 10.1101/2021.01.15.21249889. Update in: BMJ Open. 2021 Nov 12;11(11):e049740. PMID: 33501455; PMCID: PMC7836127.

314: Shen Z, Zheng K, Zou J, Gu P, Xing J, Zhang L, Zhu L, Shen H. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Trials. 2021 Jan 13;22(1):55. doi: 10.1186/s13063-020-05012-8. PMID: 33441157; PMCID: PMC7805063.

315: Allocca M, Furfaro F, Fiorino G, Peyrin-Biroulet L, Danese S. Point-of-Care Ultrasound in Inflammatory Bowel Disease. J Crohns Colitis. 2021 Jan 13;15(1):143-151. doi: 10.1093/ecco-jcc/jjaa151. PMID: 32674146.

316: Cushing K, Higgins PDR. Management of Crohn Disease: A Review. JAMA. 2021 Jan 5;325(1):69-80. doi: 10.1001/jama.2020.18936. PMID: 33399844; PMCID: PMC9183209.

317: Selinger C, Carey N, Cassere S, Nelson-Piercy C, Fraser A, Hall V, Harding K, Limdi J, Smith L, Smith M, Gunn MC, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society. Frontline Gastroenterol. 2020 May 7;12(3):182-187. doi: 10.1136/flgastro-2020-101459. PMID: 33912332; PMCID: PMC8040496.

318: Lorentsen RD, Klarskov LL, Steenholdt C. Severe ulcerative oesophagitis caused by primary Epstein-Barr virus infection in an immunocompetent individual. BMJ Open Gastroenterol. 2021 Jan;8(1):e000586. doi: 10.1136/bmjgast-2020-000586. PMID: 33495156; PMCID: PMC7839876.

319: Tański W, Świątoniowska-Lonc N, Dudek K, Jankowska-Polańska B. Benefit of Biological Drugs for Quality of Life in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Clinical Trials. Adv Exp Med Biol. 2021;1335:63-78. doi: 10.1007/5584_2020_611. PMID: 33378002.

320: Aoyama N, Shimizu T. Approach to the Seamless Management of Inflammatory Bowel Disease, Considering Special Situations, Shared Decision-Making, and Disease Burden. Digestion. 2021;102(1):12-17. doi: 10.1159/000511481. Epub 2020 Nov 25. PMID: 33238288; PMCID: PMC7949202.

321: Lee MJ, Jones GL, Lobo AJ, Brown SR; pCD collaborators. Survey to define informational needs of patients undergoing surgery for Crohn's anal fistula. Colorectal Dis. 2021 Jan;23(1):132-144. doi: 10.1111/codi.15423. Epub 2020 Dec 4. PMID: 33140914.

322: Lężyk-Ciemniak E, Tworkiewicz M, Wilczyńska D, Szaflarska-Popławska A, Krogulska A. Usefulness of Testing for Fecal Calprotectin in Pediatric

Gastroenterology Clinical Practice. Med Princ Pract. 2021;30(4):311-319. doi: 10.1159/000512631. Epub 2020 Oct 29. PMID: 33120396; PMCID: PMC8436627.

323: Crippa J, Carvello M, Kotze PG, Spinelli A. Robotic Surgery in Inflammatory Bowel Disease. Curr Drug Targets. 2021;22(1):112-116. doi: 10.2174/1389450121999200820125918. PMID: 33109059.

324: Baker DM, Folan AM, Lee MJ, Jones GL, Brown SR, Lobo AJ. A systematic review and meta-analysis of outcomes after elective surgery for ulcerative colitis. Colorectal Dis. 2021 Jan;23(1):18-33. doi: 10.1111/codi.15301. Epub 2020 Sep 1. PMID: 32777171.

325: Bisset CN, Dames N, Oliphant R, Alasadi A, Anderson D, Parson S, Cleland J, Moug SJ. Exploring shared surgical decision-making from the patient's perspective: is the personality of the surgeon important? Colorectal Dis. 2020 Dec;22(12):2214-2221. doi: 10.1111/codi.15237. Epub 2020 Jul 30. PMID: 32628311.

326: Carvello M, Di Candido F, Greco M, Foppa C, Maroli A, Fiorino G, Cecconi M, Danese S, Spinelli A. The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. Updates Surg. 2020 Dec;72(4):985-989. doi: 10.1007/s13304-020-00789-4. Epub 2020 May 13. PMID: 32406043.

327: Rumer KK, Dehghan MS, Sceats LA, Trickey AW, Morris AM, Kin C. Use of Biological Medications Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Colectomy: A Retrospective Cohort Analysis of Privately Insured Patients. Dis Colon Rectum. 2020 Nov;63(11):1524-1533. doi: 10.1097/DCR.0000000000001684. PMID: 33044293; PMCID: PMC8034550.

328: Phisalprapa P, Kositamongkol C, Limsrivilai J, Aniwan S,

Charatcharoenwitthaya P, Pisespongsa P, Kitiyakara T, Treepongkaruna S, Chaiyakunapruk N. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand. J Med Econ. 2020 Nov;23(11):1302-1310. doi: 10.1080/13696998.2020.1803889. Epub 2020 Aug 13. PMID: 32729347.

329: Pierre N, Baiwir D, Huynh-Thu VA, Mazzucchelli G, Smargiasso N, De Pauw E, Bouhnik Y, Laharie D, Colombel JF, Meuwis MA, Louis E; GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif). Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study. Gut. 2020 Oct 26:gutjnl-2020-322100. doi: 10.1136/gutjnl-2020-322100. Epub ahead of print. PMID: 33106355.

330: Zhuang X, Tian Z, Feng R, Li M, Li T, Zhou G, Qiu Y, Chen B, He Y, Chen M, Zeng Z, Zhang S. Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease. Inflamm Bowel Dis. 2020 Oct 23;26(11):1636-1647. doi: 10.1093/ibd/izaa253. PMID: 33026078.

331: Broide E, Eindor-Abarbanel A, Naftali T, Shirin H, Shalem T, Richter V, Matalon S, Leshno M. Early Surgery Versus Biologic Therapy in Limited Nonstricturing Ileocecal Crohn's Disease-A Decision-making Analysis. Inflamm Bowel Dis. 2020 Oct 23;26(11):1648-1657. doi: 10.1093/ibd/izz282. PMID: 31909420.

332: Terjung B, Schmelz R, Ehehalt R, Klaus J, Knop J, Schwind S, Wilke T, Stallmach A. Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review. Therap Adv Gastroenterol. 2020 Oct 16;13:1756284820952592. doi: 10.1177/1756284820952592. PMID: 33149762; PMCID: PMC7580131.

333: Harmand PO, Solassol J. Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT. Genes (Basel). 2020 Oct 16;11(10):1212. doi: 10.3390/genes11101212. PMID: 33081236; PMCID: PMC7602704.

334: Queiroz NSF, Teixeira FV, Parra RS, Kotze PG. INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol. 2020 Oct-Dec;57(4):507-510. doi: 10.1590/S0004-2803.202000000-76. PMID: 33331484.

335: Fiske J, Conley T, Sebastian S, Subramanian S. Infliximab in acute severe colitis: getting the right dose. Frontline Gastroenterol. 2020 Apr 3;11(6):427-429. doi: 10.1136/flgastro-2020-101407. PMID: 33104078; PMCID: PMC7569519.

336: Hawkins AT, Wise PE, Chan T, Lee JT, Glyn T, Wood V, Eglinton T, Frizelle F, Khan A, Hall J, Ilyas MIM, Michailidou M, Nfonsam VN, Cowan ML, Williams J, Steele SR, Alavi K, Ellis CT, Collins D, Winter DC, Zaghiyan K, Gallo G, Carvello M, Spinelli A, Lightner AL. Diverticulitis: An Update From the Age Old Paradigm. Curr Probl Surg. 2020 Oct;57(10):100862. doi: 10.1016/j.cpsurg.2020.100862. Epub 2020 Jul 18. PMID: 33077029; PMCID: PMC7575828.

337: Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Casén C, Moen AEF, Tannaes TM, Lindstrøm J, Detlie TE, Olbjørn C, Lindquist CM, Söderholm JD, Gomollón F, Kalla R, Satsangi J, Vatn MH, Jahnsen J, Halfvarson J, Ricanek P; IBD-Character Consortium. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scand J Gastroenterol. 2020 Oct;55(10):1146-1156. doi: 10.1080/00365521.2020.1803396. Epub 2020 Aug 11.

PMID: 32780604.

338: Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2020 Oct;69(10):1769-1777. doi: 10.1136/gutjnl-2020-321927. Epub 2020 Jun 8. PMID: 32513653; PMCID: PMC7299646.

339: Ramos López L, Hernández Camba A, Rodríguez-Lago I, Carrillo Palau M, Cejas Dorta L, Elorza A, Alonso Abreu I, Vela M, Hidalgo A, Hernández Álvarez-Builla N, Rodríguez GE, Rodríguez Y, Tardillo C, Díaz-Flórez L, Eiroa D, Aduna M, Garrido MS, Larena JA, Cabriada JL, Quintero Carrion E. Usefulness of magnetic resonance enterography in the clinical decision-making process for patients with inflammatory bowel disease. Gastroenterol Hepatol. 2020 Oct;43(8):439-445. English, Spanish. doi: 10.1016/j.gastrohep.2020.03.007. Epub 2020 Apr 27. PMID: 32349904.

340: Ko MS, Rudrapatna VA, Avila P, Mahadevan U. Safety of Flexible Sigmoidoscopy in Pregnant Patients with Known or Suspected Inflammatory Bowel Disease. Dig Dis Sci. 2020 Oct;65(10):2979-2985. doi: 10.1007/s10620-020-06122-8. Epub 2020 Feb 7. PMID: 32034603.

341: Syed S, Stidham RW. Potential for Standardization and Automation for Pathology and Endoscopy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 Sep 18;26(10):1490-1497. doi: 10.1093/ibd/izaa211. PMID: 32869844; PMCID: PMC7749192.

342: Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig G, Linggi B, Schito M, Casteele NV, Sauer JM. Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Inflamm Bowel Dis. 2020 Sep 18;26(10):1498-1508. doi: 10.1093/ibd/izaa215. PMID: 32840322; PMCID: PMC7500523.

343: van Haaften WT, Mortensen JH, Dige AK, Grønbæk H, Hvas CL, Bay-Jensen AC, Karsdal MA, Olinga P, Manon-Jensen T, Dijkstra G. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. Clin Transl Gastroenterol. 2020 Sep;11(9):e00217. doi: 10.14309/ctg.0000000000000217. PMID: 33094957; PMCID: PMC7494148.

344: Braillon A, Taiebi F. Practicing "Reflective listening" is a mandatory prerequisite for empathy. Patient Educ Couns. 2020 Sep;103(9):1866-1867. doi: 10.1016/j.pec.2020.03.024. Epub 2020 Apr 4. PMID: 32487470.

345: Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13. PMID: 31945470; PMCID: PMC8022894.

346: Malter L, Jain A, Cohen BL, Gaidos JKJ, Axisa L, Butterfield L, Rescola BJ, Sarode S, Ehrlich O, Cheifetz AS. Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey. Inflamm Bowel Dis. 2020 Aug 20;26(9):1445-1450. doi: 10.1093/ibd/izaa032. PMID: 32100018.

347: Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn; Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the

GRADE approach. Gastroenterol Hepatol. 2020 Aug;43 Suppl 1:1-57. English, Spanish. doi: 10.1016/j.gastrohep.2020.07.001. PMID: 32807301.

348: Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S761-S766. doi: 10.1093/ecco-jcc/jjaa003. PMID: 31922534; PMCID: PMC7395309.

349: Yan X, Ma F, Yu Y, Du D, Wang Z, Chen C, Zhang X, Sun X, Dong Z, Ma Y, Ma Y. Effects of herb-partitioned moxibustion for ulcerative colitis: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020 Jul 31;99(31):e21319. doi: 10.1097/MD.0000000000021319. PMID: 32756115; PMCID: PMC7402751.

350: Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol. 2020 Jul 27;13:1756284820944088. doi: 10.1177/1756284820944088. PMID: 32782481; PMCID: PMC7385848.

351: Bashir NS, Walters TD, Griffiths AM, Ito S, Ungar WJ. Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease. Inflamm Bowel Dis. 2020 Jul 17;26(8):1239-1250. doi: 10.1093/ibd/izz267. PMID: 31728510; PMCID: PMC7365807.

352: Kim AH, Girgis A, Karimi N, Sechi AJ, Descallar J, Andrews JM, Siegel CA, Connor SJ. A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc. 2020 Jul 10;9(7):e15994. doi: 10.2196/15994. PMID: 32673257; PMCID: PMC7382012.

353: Meisman A, Daraiseh NM, Minar P, Saxe M, Lipstein EA. The Gray Zone:

Adolescent and Young Adult Decision Support Needs for Ulcerative Colitis. MDM Policy Pract. 2020 Jul 7;5(2):2381468320940708. doi: 10.1177/2381468320940708. PMID: 32685687; PMCID: PMC7343374.

354: Barnes EL. Postoperative Crohn's disease management. Curr Opin Gastroenterol. 2020 Jul;36(4):277-283. doi: 10.1097/MOG.0000000000000638. PMID: 32304384.

355: Arafah K, Kriegsmann M, Renner M, Lasitschka F, Fresnais M, Kriegsmann K, von Winterfeld M, Goeppert B, Kriegsmann J, Casadonte R, Kazdal D, Bulet P, Longuespée R. Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease. Proteomics Clin Appl. 2020 Jul;14(4):e1900110. doi: 10.1002/prca.201900110. Epub 2020 Feb 16. PMID: 32003543.

356: Carpio López D, Martínez Pillado M, Salgado Barreira Á, Daponte Angueira S, Díez Lage R, Castro Ortiz E, Fernández Salgado E, Pérez Galindo P, Turnes Vázquez J. Efectividad del plan de contingencia de la Unidad de Enfermedad Inflamatoria Intestinal ante la infección de Covid-19 [Effectiveness of the contingency plan of the internal inflammatory disease unit before Covid-19 infection.]. Rev Esp Salud Publica. 2020 Jun 16;94:e202006061. Spanish. PMID: 32541647.

357: Atia O, Ledder O, Ben-Moshe T, Lev-Tzion R, Rachmen Y, Meyer EO, Beeri R, Renbaum P, Shamasneh I, Shteyer E, Turner D. Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study. J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):825-832. doi: 10.1097/MPG.0000000000002566. PMID: 32443042.

358: Louis E, Ramos-Goñi JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, Rosenfeld G, Bettenworth D, Hart A, Novak K, Donnet X, Easton D,

Saldaña R, Protze K, Tzur E, Alperovich G, Casellas F. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective. Patient. 2020 Jun;13(3):317-325. doi: 10.1007/s40271-019-00407-5. PMID: 31997116; PMCID: PMC7210247.

359: Lee MJ, Marshall JH, Jones GL, Lobo AJ, Brown SR. The informational and decisional preferences of patients undergoing surgery for Crohn's anal fistula: a qualitative study. Colorectal Dis. 2020 Jun;22(6):703-712. doi: 10.1111/codi.14936. Epub 2020 Jan 9. PMID: 31868981.

360: Piscitello A, Edwards DK 5th. Estimating the Screening-Eligible Population Size, Ages 45-74, at Average Risk to Develop Colorectal Cancer in the United States. Cancer Prev Res (Phila). 2020 May;13(5):443-448. doi: 10.1158/1940-6207.CAPR-19-0527. Epub 2020 Feb 6. PMID: 32029430.

361: Spinelli A, Armuzzi A, Ciccocioppo R, Danese S, Gionchetti P, Luglio G, Orlando A, Rispo A, Rizzello F, Sofo L, Solina G, Poggioli G. Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. Dig Liver Dis. 2020 May;52(5):506-515. doi: 10.1016/j.dld.2019.11.016. Epub 2019 Dec 31. PMID: 31901310.

362: Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, Löwenberg M, Srivastava N, Bodelier AGL, West RL, Jansen JM, de Vries AC, Haans JJL, de Jong DJ, Pierik MJ, Hoentjen F. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. Clin Pharmacol Ther. 2020 May;107(5):1189-1199. doi: 10.1002/cpt.1712. Epub 2019 Dec 11. PMID: 31677154; PMCID: PMC7232860.

363: Prasad SS, Keely S, Talley NJ, Kairuz T, Walker MM. Pharmacists' Confidence

in Managing Patients with Inflammatory Bowel Disease. Pharmacy (Basel). 2020 Apr 17;8(2):68. doi: 10.3390/pharmacy8020068. PMID: 32316504; PMCID: PMC7355482.

364: Stidham RW, Enchakalody B, Waljee AK, Higgins PDR, Wang SC, Su GL, Wasnik AP, Al-Hawary M. Assessing Small Bowel Stricturing and Morphology in Crohn's Disease Using Semi-automated Image Analysis. Inflamm Bowel Dis. 2020 Apr 11;26(5):734-742. doi: 10.1093/ibd/izz196. PMID: 31504540; PMCID: PMC7150581.

365: Meserve J, Dulai P. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne). 2020 Apr 2;7:76. doi: 10.3389/fmed.2020.00076. PMID: 32300596; PMCID: PMC7145386.

366: Fox JC, Lipstein EA. Shared Decision Making in Gastroenterology: Challenges and Opportunities. Mayo Clin Proc Innov Qual Outcomes. 2020 Mar 9;4(2):183-189. doi: 10.1016/j.mayocpiqo.2019.11.003. PMID: 32280929; PMCID: PMC7139984.

367: Rajagopalan A, Sathananthan D, An YK, Van De Ven L, Martin S, Fon J, Costello SP, Begun J, Bryant RV. Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. JGH Open. 2019 Oct 9;4(2):267-272. doi: 10.1002/jgh3.12268. PMID: 32280776; PMCID: PMC7144798.

368: Stalder T, Kapel N, Diaz S, Grenouillet F, Koch S, Limat S, Daval F, Vuitton L, Nerich V. A systematic review of economic evaluation in fecal microbiota transplantation. Infect Control Hosp Epidemiol. 2020 Apr;41(4):458-466. doi: 10.1017/ice.2019.371. Epub 2020 Jan 24. PMID: 31973773.

369: Anderson R, Burr NE, Valori R. Causes of Post-Colonoscopy Colorectal Cancers Based on World Endoscopy Organization System of Analysis. Gastroenterology. 2020 Apr;158(5):1287-1299.e2. doi: 10.1053/j.gastro.2019.12.031. Epub 2020 Jan 8. PMID: 31926170.

370: Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointest Endosc. 2020 Apr;91(4):733-745. doi: 10.1016/j.gie.2019.11.032. Epub 2019 Nov 29. Erratum in: Gastrointest Endosc. 2020 Jul;92(1):239. PMID: 31786161.

371: Hébuterne X, Peyrin-Biroulet L, Hausfater P. The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report. Dig Liver Dis. 2020 Apr;52(4):420-426. doi: 10.1016/j.dld.2019.10.015. Epub 2019 Nov 14. PMID: 31734114.

372: Del Hoyo JD, Nos P, Faubel R, Bastida G, Muñoz D, Valero-Pérez E, Garrido-Marín A, Bella P, Peña B, Savini C, Aguas M. Adaptation of TECCU App Based on Patients´ Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups. Int J Environ Res Public Health. 2020 Mar 13;17(6):1871. doi: 10.3390/ijerph17061871. PMID: 32183103; PMCID: PMC7143635.

373: Pérez de Arce E, Sedano R, Quera R. Biomarcadores en enfermedad inflamatoria intestinal: ¿sabe cómo utilizarlos? [Biomarkers in inflammatory bowel disease]. Rev Med Chil. 2020 Mar;148(3):362-370. Spanish. doi: 10.4067/S0034-98872020000300362. PMID: 32730381.

374: Cai Q, Wu L, Zhou Y. Experiences With Traditional Chinese Medicine Among Patients With Inflammatory Bowel Disease: A Qualitative Study. Gastroenterol Nurs. 2020 Mar/Apr;43(2):135-145. doi: 10.1097/SGA.0000000000000418. PMID: 32251215.

375: Waljee AK, Higgins PDR, Jensen CB, Villumsen M, Cohen-Mekelburg SA, Wallace BI, Berinstein JA, Allin KH, Jess T. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease,

rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):276-284. doi: 10.1016/S2468-1253(19)30362-0. Epub 2019 Dec 10. PMID: 31836320.

376: Roldan Munoz S, Lupattelli A, de Vries ST, Mol PGM, Nordeng H. Differences in medication beliefs between pregnant women using medication, or not, for chronic diseases: a cross-sectional, multinational, web-based study. BMJ Open. 2020 Feb 5;10(2):e034529. doi: 10.1136/bmjopen-2019-034529. PMID: 32029496; PMCID: PMC7044950.

377: Arkenbosch JHC, van Ruler O, de Vries AC. Non-obstetric surgery in pregnancy (including bowel surgery and gallbladder surgery). Best Pract Res Clin Gastroenterol. 2020 Feb-Apr;44-45:101669. doi: 10.1016/j.bpg.2020.101669. Epub 2020 Mar 6. PMID: 32359684.

378: Shen ZF, Wu HH, Zhu L, Zhou Q, Shen H. [Traditional Chinese medicine for ulcerative colitis: systematic reviews based on PRIO-harms]. Zhongguo Zhong Yao Za Zhi. 2020 Feb;45(3):674-682. Chinese. doi: 10.19540/j.cnki.cjcmm.20190624.501. PMID: 32237528.

379: Huang JS, Yueh R, Wood K, Ma S, Cruz R, Boyd N, Kruth R, Parker J. Harnessing the Electronic Health Record to Distribute Transition Services to Adolescents With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2020 Feb;70(2):200-204. doi: 10.1097/MPG.0000000000002516. PMID: 31978017.

380: Lee NK, Kim S, Hong SB, Lee SJ, Kim TU, Ryu H, Lee JW, Kim JY, Suh HB. CT diagnosis of non-traumatic gastrointestinal perforation: an emphasis on the causes. Jpn J Radiol. 2020 Feb;38(2):101-111. doi: 10.1007/s11604-019-00910-7. Epub 2019 Dec 17. PMID: 31848888.

381: Novosad SA, Mu Y, Winston LG, Johnston H, Basiliere E, Olson DM, Farley MM, Revis A, Wilson L, Perlmutter R, Holzbauer SM, Whitten T, Phipps EC, Dumyati GK, Beldavs ZG, Ocampo VLS, Davis CM, Kainer M, Gerding DN, Guh AY. Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015. J Gen Intern Med. 2020 Feb;35(2):412-419. doi: 10.1007/s11606-019-05386-9. Epub 2019 Nov 25. PMID: 31768906; PMCID: PMC7018854.

382: Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020 Jan 28;9:F1000 Faculty Rev-54. doi: 10.12688/f1000research.20928.1. PMID: 32047622; PMCID: PMC6993839.

383: Hazlewood GS, Pokharel G, Deardon R, Marshall DA, Bombardier C, Tomlinson G, Ma C, Seow CH, Panaccione R, Kaplan GG. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. PLoS One. 2020 Jan 16;15(1):e0227635. doi: 10.1371/journal.pone.0227635. PMID: 31945089; PMCID: PMC6964885.

384: Baker DM, Lee MJ, Folan AM, Blackwell S, Robinson K, Wootton R, Sebastian S, Brown SR, Jones GL, Lobo AJ. Development and evaluation of a patient decision aid for patients considering ongoing medical or surgical treatment options for ulcerative colitis using a mixed-methods approach: protocol for DISCUSS study. BMJ Open. 2020 Jan 14;10(1):e031845. doi: 10.1136/bmjopen-2019-031845. PMID: 31941765; PMCID: PMC7045112.

385: Imbrechts M, Van Stappen T, Compernolle G, Tops S, Gils A. Anti-infliximab antibodies: How to compare old and new data? J Pharm Biomed Anal. 2020 Jan 5;177:112842. doi: 10.1016/j.jpba.2019.112842. Epub 2019 Aug 27. PMID: 31526960.

386: Chuter C, Keding A, Holmes H, Turnock D, Turvill J. Getting the best out of

faecal immunochemical tests and faecal calprotectin. Frontline Gastroenterol. 2019 Dec 24;11(5):414-416. doi: 10.1136/flgastro-2019-101381. PMID: 32884634; PMCID: PMC7447280.

387: Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol. 2019 Aug 17;11(4):272-279. doi: 10.1136/flgastro-2019-101277. PMID: 32587670; PMCID: PMC7307042.

388: Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F; on be half of the Swiss IBDnet, an official working group of the Swiss Society of Gast roenterology. Treatment Algorithms for Crohn's Disease. Digestion. 2020;101 Suppl 1:43-57. doi: 10.1159/000506364. Epub 2020 Mar 13. PMID: 32172251.

389: Swann R, Boal A, Squires SI, Lamb C, Clark LL, Lamont S, Naismith G. Optimising IBD patient selection for de-escalation of anti-TNF therapy to immunomodulator maintenance. Frontline Gastroenterol. 2020 Jan;11(1):16-21. doi: 10.1136/flgastro-2018-101135. Epub 2019 May 3. PMID: 31885835; PMCID: PMC6914296.

390: Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR; on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. Digestion. 2020;101(6):683-691. doi: 10.1159/000501930. Epub 2019 Aug 28. PMID: 31461706.

391: De Felice KM. Patients Perception of Risks and Benefits of Biologic Therapy. Inflamm Bowel Dis. 2020 Jan 1;26(1):147-149. doi: 10.1093/ibd/izz122.

PMID: 31300824.

392: Burri E, Juillerat P, Maillard MH, Manz M, Michetti P, Mottet C, Rogler G, Zahnd N, Vavricka S. Position statement on the use of biosimilars in inflammatory bowel disease. Swiss Med Wkly. 2019 Dec 2;149:w20148. doi: 10.4414/smw.2019.20148. PMID: 31800086.

393: Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterol J. 2019 Dec;7(10):1285-1303. doi: 10.1177/2050640619883566. Epub 2019 Oct 17. PMID: 31839954; PMCID: PMC6894001.

394: Ghoneima AS, Flashman K, Dawe V, Baldwin E, Celentano V. High risk of septic complications following surgery for Crohn's disease in patients with preoperative anaemia, hypoalbuminemia and high CRP. Int J Colorectal Dis. 2019 Dec;34(12):2185-2188. doi: 10.1007/s00384-019-03427-7. Epub 2019 Nov 8. PMID: 31705193.

395: Goldstone RN, Steinhagen RM. Abdominal Emergencies in Inflammatory Bowel Disease. Surg Clin North Am. 2019 Dec;99(6):1141-1150. doi: 10.1016/j.suc.2019.08.007. Epub 2019 Sep 23. PMID: 31676053.

396: Pugliese D, Privitera G, Pizzolante F, Gasbarrini A, Guidi L, Armuzzi A. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterol Dietol. 2019 Dec;65(4):280-290. doi: 10.23736/S1121-421X.19.02625-4. Epub 2019 Oct 24. PMID: 31646853.

397: Schuler CL, Dodds C, Hommel KA, Ittenbach RF, Denson LA, Lipstein EA. Shared decision making in IBD: A novel approach to trial consent and timing.

Contemp Clin Trials Commun. 2019 Sep 8;16:100447. doi: 10.1016/j.conctc.2019.100447. PMID: 31538130; PMCID: PMC6745512.

398: Lai C, Sceats LA, Qiu W, Park KT, Morris AM, Kin C. Patient decision-making in severe inflammatory bowel disease: the need for improved communication of treatment options and preferences. Colorectal Dis. 2019 Dec;21(12):1406-1414. doi: 10.1111/codi.14759. Epub 2019 Jul 29. PMID: 31295766.

399: Colloca L, Panaccione R, Murphy TK. The Clinical Implications of Nocebo Effects for Biosimilar Therapy. Front Pharmacol. 2019 Nov 29;10:1372. doi: 10.3389/fphar.2019.01372. PMID: 31849647; PMCID: PMC6895996.

400: Duttenhoefer F, Fuessinger MA, Beckmann Y, Schmelzeisen R, Groetz KA, Boeker M. Dental implants in immunocompromised patients: a systematic review and meta-analysis. Int J Implant Dent. 2019 Nov 28;5(1):43. doi: 10.1186/s40729-019-0191-5. PMID: 31776815; PMCID: PMC6881487.

401: Mezones-Holguin E, Gamboa-Cardenas RV, Sanchez-Felix G, Chávez-Corrales J, Helguero-Santin LM, Laban Seminario LM, Burela-Prado PA, Castro-Reyes MM, Fiestas F. Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country. Front Pharmacol. 2019 Nov 15;10:1010. doi: 10.3389/fphar.2019.01010. PMID: 31798442; PMCID: PMC6874174.

402: Dong Y, Xu L, Fan Y, Xiang P, Gao X, Chen Y, Zhang W, Ge Q. A novel surgical predictive model for Chinese Crohn's disease patients. Medicine (Baltimore). 2019 Nov;98(46):e17510. doi: 10.1097/MD.0000000000017510. PMID: 31725605; PMCID: PMC6867775.

403: Van den Berghe N, Gils A, Thomas D. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted? Clin

Pharmacol Ther. 2019 Nov;106(5):945-954. doi: 10.1002/cpt.1609. Epub 2019 Sep 20. PMID: 31420861; PMCID: PMC6858034.

404: Mavroudis G, Magnusson MK, Isaksson S, Sundin J, Simrén M, Öhman L, Strid H. Mucosal and Systemic Immune Profiles Differ During Early and Late Phases of the Disease in Patients With Active Ulcerative Colitis. J Crohns Colitis. 2019 Oct 28;13(11):1450-1458. doi: 10.1093/ecco-jcc/jjz072. PMID: 30946450.

405: Cremer A, Ku J, Amininejad L, Bouvry MR, Brohet F, Liefferinckx C, Devière J, van Gossum A, Smet J, Stordeur P, Franchimont D. Variability of Faecal Calprotectin in Inflammatory Bowel Disease Patients: An Observational Case-control Study. J Crohns Colitis. 2019 Oct 28;13(11):1372-1379. doi: 10.1093/ecco-jcc/jjz069. PMID: 30944925.

406: Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, Amanzada A. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One. 2019 Oct 24;14(10):e0223893. doi: 10.1371/journal.pone.0223893. PMID: 31647834; PMCID: PMC6812761.

407: Grass F, Fletcher JG, Alsughayer A, Petersen M, Bruining DH, Bartlett DJ, Mathis KL, Lightner AL. Development of an Objective Model to Define Near-Term Risk of Ileocecal Resection in Patients with Terminal Ileal Crohn Disease. Inflamm Bowel Dis. 2019 Oct 18;25(11):1845-1853. doi: 10.1093/ibd/izz079. PMID: 31050733.

408: Lefevre PLC, Shackelton LM, Vande Casteele N. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. BioDrugs. 2019 Oct;33(5):453-468. doi: 10.1007/s40259-019-00366-1. PMID: 31301024.

409: Curci D, Lucafò M, Cifù A, Bramuzzo M, Martelossi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2019 Oct;69(4):474-479. doi: 10.1097/MPG.0000000000002410. PMID: 31149938.

410: van den Brink G, van Gaalen MAC, de Ridder L, van der Woude CJ, Escher JC. Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study. J Crohns Colitis. 2019 Sep 19;13(9):1163-1172. doi: 10.1093/ecco-jcc/jjz044. PMID: 30766997; PMCID: PMC7142327.

411: Di Caro S, Fragkos KC, Keetarut K, Koo HF, Sebepos-Rogers G, Saravanapavan H, Barragry J, Rogers J, Mehta SJ, Rahman F. Enteral Nutrition in Adult Crohn's Disease: Toward a Paradigm Shift. Nutrients. 2019 Sep 14;11(9):2222. doi: 10.3390/nu11092222. PMID: 31540038; PMCID: PMC6770416.

412: Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. PMID: 31555262; PMCID: PMC6743223.

413: Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019 Sep;15(9):969-979. doi: 10.1080/1744666X.2019.1646127. Epub 2019 Jul 25. PMID: 31322018; PMCID: PMC6813772.

414: Yang DH, Kim J, Song EM, Chang K, Lee SH, Hwang SW, Park SH, Ye BD, Byeon JS, Myung SJ, Yang SK. Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection. J Gastroenterol Hepatol. 2019 Sep;34(9):1581-1589. doi: 10.1111/jgh.14623. Epub 2019 Mar 3. PMID: 30724389.

415: Dalal RS, Osterman MT, Buchner AM, Praestgaard A, Lewis JD, Lichtenstein GR. A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 Aug 20;25(9):1550-1558. doi: 10.1093/ibd/izz014. PMID: 30753443.

416: Pérez-Pérez M, Pérez-Rodríguez G, Fdez-Riverola F, Lourenço A. Using Twitter to Understand the Human Bowel Disease Community: Exploratory Analysis of Key Topics. J Med Internet Res. 2019 Aug 15;21(8):e12610. doi: 10.2196/12610. PMID: 31411142; PMCID: PMC6711036.

417: Shen Z, Zhou Q, Ni Y, He W, Shen H, Zhu L. Traditional Chinese medicine for mild-to-moderate ulcerative colitis: Protocol for a network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019 Aug;98(33):e16881. doi: 10.1097/MD.0000000000016881. PMID: 31415431; PMCID: PMC6831175.

418: Schultheiss JPD, Brand EC, Lamers E, van den Berg WCM, van Schaik FDM, Oldenburg B, Fidder HH. Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Aliment Pharmacol Ther. 2019 Aug;50(4):386-396. doi: 10.1111/apt.15380. Epub 2019 Jul 16. PMID: 31310690.

419: Mason SE, Poynter L, Takats Z, Darzi A, Kinross JM. Optical Technologies for Endoscopic Real-Time Histologic Assessment of Colorectal Polyps: A Meta-Analysis. Am J Gastroenterol. 2019 Aug;114(8):1219-1230. doi: 10.14309/ajg.0000000000000156. PMID: 30848728.

420: Bollegala N, Griller N, Bannerman H, Habal M, Nguyen GC. Ultrasound vs Endoscopy, Surgery, or Pathology for the Diagnosis of Small Bowel Crohn's Disease and its Complications. Inflamm Bowel Dis. 2019 Jul 17;25(8):1313-1338. doi: 10.1093/ibd/izy392. PMID: 30883639.

421: Kotsafti A, D'Incà R, Scarpa M, Fassan M, Angriman I, Mescoli C, Bortoli N, Brun P, Bardini R, Rugge M, Savarino E, Zingone F, Castoro C, Castagliuolo I, Scarpa M. Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. Clin Transl Gastroenterol. 2019 Jul;10(7):e00061. doi: 10.14309/ctg.0000000000000061. PMID: 31343468; PMCID: PMC6708661.

422: Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, Geddes J, Goodwin G, Collins G, Travis S, Peters M. Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. Intest Res. 2019 Jul;17(3):365-374. doi: 10.5217/ir.2018.00173. Epub 2019 May 31. PMID: 31146510; PMCID: PMC6667366.

423: Tsai R, Mintz A, Lin M, Mhlanga J, Chiplunker A, Salter A, Ciorba M, Deepak P, Fowler K. Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. Br J Radiol. 2019 Jul;92(1099):20180930. doi: 10.1259/bjr.20180930. Epub 2019 May 29. PMID: 31141389; PMCID: PMC6636275.

424: Shah SC, Itzkowitz SH. Management of Inflammatory Bowel Disease-Associated Dysplasia in the Modern Era. Gastrointest Endosc Clin N Am. 2019 Jul;29(3):531-548. doi: 10.1016/j.giec.2019.02.008. Epub 2019 Apr 6. PMID: 31078251; PMCID: PMC7354094.

425: McKenna NP, Bews KA, Mathis KL, Lightner AL, Habermann EB. Surgery During Admission for an Ulcerative Colitis Flare: Should Pouch Formation Be Considered? J Surg Res. 2019 Jul;239:216-223. doi: 10.1016/j.jss.2019.02.014. Epub 2019 Mar 7. PMID: 30852448.

426: Bottigliengo D, Berchialla P, Lanera C, Azzolina D, Lorenzoni G, Martinato M, Giachino D, Baldi I, Gregori D. The Role of Genetic Factors in Characterizing Extra-Intestinal Manifestations in Crohn's Disease Patients: Are Bayesian Machine Learning Methods Improving Outcome Predictions? J Clin Med. 2019 Jun 17;8(6):865. doi: 10.3390/jcm8060865. PMID: 31212952; PMCID: PMC6617350.

427: Boeri M, Myers K, Ervin C, Marren A, DiBonaventura M, Cappelleri JC, Hauber B, Rubin DT. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol. 2019 Jun 11;12:263-278. doi: 10.2147/CEG.S206970. PMID: 31354328; PMCID: PMC6572717.

428: Lee HS, Cleynen I. Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making? Cells. 2019 Jun 4;8(6):535. doi: 10.3390/cells8060535. PMID: 31167397; PMCID: PMC6627070.

429: Rencz F, Stalmeier PFM, Péntek M, Brodszky V, Ruzsa G, Gönczi L, Palatka K, Herszényi L, Schäfer E, Banai J, Rutka M, Gulácsi L, Lakatos PL. Patient and general population values for luminal and perianal fistulising Crohn's disease health states. Eur J Health Econ. 2019 Jun;20(Suppl 1):91-100. doi: 10.1007/s10198-019-01065-y. Epub 2019 May 17. PMID: 31102158; PMCID: PMC6544586.

430: Martínez-Romero GJ, Alvariño A, Hinojosa E, Mora M, Oltra L, Maroto N, Ferrer I, Hinojosa MD, Hinojosa JE. Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2019 Jun;111(6):431-436. doi: 10.17235/reed.2019.5600/2018. PMID: 31021170.

431: Zaltman C, Amarante H, Brenner MM, Costa MHM, Flores C, Leal RF, Grain JFS, Zeroncio M. Crohn's disease - treatment with biological medication. Rev Assoc Med Bras (1992). 2019 May 2;65(4):554-567. doi: 10.1590/1806-9282.65.4.554. Erratum in: Rev Assoc Med Bras (1992). 2019 Jul 22;65(6):931. PMID: 31066809.

432: Teixeira FV, Vilela EG, Damião AOMC, Vieira A, Albuquerque IC, Parente JML, Chebli JMF, Ambrogini Junior O, Hossne RS, Miszputen SJ. Ulcerative colitis - treatment with biologicals. Rev Assoc Med Bras (1992). 2019 May 2;65(4):547-553. doi: 10.1590/1806-9282.65.4.547. PMID: 31066808.

433: Pileggi GS, Da Mota LMH, Kakehasi AM, De Souza AW, Rocha A, de Melo AKG, da Fonte CAM, Bortoletto C, Brenol CV, Marques CDL, Zaltman C, Borba EF, Reis ER, Freire EAM, Klumb EM, Christopoulos GB, Laurindo IMM, Ballalai I, Da Costa IP, Michelin L, de Azevêdo Valadares LD, Chebli LA, Lacerda M, Toscano MAF, Yazbek MA, De Abreu Vieira RMR, Magalhães R, Kfouri R, Richtmann R, Merenlender SDCS, Valim V, De Assis MR, Kowalski SC, Trevisani VFM. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Adv Rheumatol. 2019 Apr 29;59(1):17. doi: 10.1186/s42358-019-0056-x. PMID: 31036077.

434: de Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA. Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. Inflamm Bowel Dis. 2019 Apr 11;25(5):937-944. doi: 10.1093/ibd/izy325. PMID: 30329045.

435: van der Gugten JG, Bressler B, DeMarco ML. An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab. Clin Mass Spectrom. 2019 Jan 28;12:16-22. doi: 10.1016/j.clinms.2019.01.003. PMID: 34841075; PMCID: PMC8620136.

436: Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019 Apr;7(2):77-90. doi: 10.1093/gastro/goz004. Epub 2019 Mar 11. PMID: 30976420; PMCID: PMC6454839.

437: Bouchard D, Brochard C, Vinson-Bonnet B, Staumont G, Abramowitz L, Benfredj P, Fathallah N, Faucheron JL, Higuero T, Panis Y, de Parades V, Siproudhis L, Laharie D, Pigot F. How to manage anal ulcerations and anorectal stenosis in Crohn's disease: algorithm-based decision making : French National Working Group Consensus 2018. Tech Coloproctol. 2019 Apr;23(4):353-360. doi: 10.1007/s10151-019-01971-6. Epub 2019 Apr 1. PMID: 30937646.

438: McAloon CG, Roche S, Ritter C, Barkema HW, Whyte P, More SJ, O'Grady L, Green MJ, Doherty ML. A review of paratuberculosis in dairy herds - Part 2: On-farm control. Vet J. 2019 Apr;246:54-58. doi: 10.1016/j.tvjl.2019.01.009. Epub 2019 Jan 30. PMID: 30902189.

439: Khalid S, Abbass A, Khetpal N, Shen B, Navaneethan U. Endoscopic detection and resection of dysplasia in inflammatory bowel disease-techniques with videos. Int J Colorectal Dis. 2019 Apr;34(4):569-580. doi: 10.1007/s00384-019-03269-3. Epub 2019 Mar 11. PMID: 30854573.

440: Jackson B, Begun J, Gray K, Churilov L, Liew D, Knowles S, De Cruz P. Clinical decision support improves quality of care in patients with ulcerative colitis. Aliment Pharmacol Ther. 2019 Apr;49(8):1040-1051. doi: 10.1111/apt.15209. Epub 2019 Mar 7. PMID: 30847962.

441: Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, Lytras T, Bonovas S. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2. doi: 10.1016/j.cgh.2018.06.026. Epub 2018 Jun 20. PMID: 29935327.

442: Justiniano CF, Aquina CT, Becerra AZ, Xu Z, Boodry CI, Swanger AA, Monson JRT, Fleming FJ. Postoperative Mortality After Nonelective Surgery for

Inflammatory Bowel Disease Patients in the Era of Biologics. Ann Surg. 2019 Apr;269(4):686-691. doi: 10.1097/SLA.0000000000002628. PMID: 29232213.

443: Lee GC, Hodin RA. Applying Enhanced Recovery Pathways to Unique Patient Populations. Clin Colon Rectal Surg. 2019 Mar;32(2):134-137. doi: 10.1055/s-0038-1676479. Epub 2019 Feb 28. PMID: 30833863; PMCID: PMC6395174.

444: Iliás Á, Rózsa FP, Gönczi L, Lovász BD, Kürti Z, Lakatos PL. A székletkalprotektin meghatározásának szerepe a bélbetegségek diagnosztikájában és kezelésében [The role of fecal calprotectin in the diagnosis and treatment of gastrointestinal diseases]. Orv Hetil. 2019 Mar;160(9):322-328. Hungarian. doi: 10.1556/650.2019.31289. PMID: 30798622.

445: He Y, Zhu Z, Chen Y, Chen F, Wang Y, Ouyang C, Yang H, Huang M, Zhuang X, Mao R, Ben-Horin S, Wu X, Ouyang Q, Qian J, Lu N, Hu P, Chen M. Development and Validation of a Novel Diagnostic Nomogram to Differentiate Between Intestinal Tuberculosis and Crohn's Disease: A 6-year Prospective Multicenter Study. Am J Gastroenterol. 2019 Mar;114(3):490-499. doi: 10.14309/ajg.0000000000000064. PMID: 30741735.

446: Michel HK, Noll RB, Siripong N, Kim SC, Lipstein EA. Shared Decision Making About Starting Anti-TNFs: A Pediatric Perspective. J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):339-342. doi: 10.1097/MPG.0000000000002193. PMID: 30418412; PMCID: PMC7055652.

447: Sheedy SP, Bartlett DJ, Lightner AL, Trenkner SW, Bruining DH, Fidler JL, VanBuren WM, Menias CO, Reber JD, Fletcher JG. Judging the J pouch: a pictorial review. Abdom Radiol (NY). 2019 Mar;44(3):845-866. doi: 10.1007/s00261-018-1786-7. PMID: 30259096.

448: Sagami S, Kobayashi T, Kikkawa N, Umeda S, Nakano M, Toyonaga T, Okabayashi

S, Ozaki R, Hibi T. Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. PLoS One. 2019 Feb 20;14(2):e0212404. doi: 10.1371/journal.pone.0212404. PMID: 30785943; PMCID: PMC6382266.

449: Celis R, Cuervo A, Ramírez J, Cañete JD. Psoriatic Synovitis: Singularity and Potential Clinical Implications. Front Med (Lausanne). 2019 Feb 11;6:14. doi: 10.3389/fmed.2019.00014. PMID: 30805340; PMCID: PMC6378889.

450: Meserve J, Barsky M, Dulai PS. In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. Best Pract Res Clin Gastroenterol. 2019 Feb-Apr;38-39:101619. doi: 10.1016/j.bpg.2019.05.006. Epub 2019 May 29. PMID: 31327408.

451: Nguyen GC, Targownik LE, Singh H, Benchimol EI, Bitton A, Murthy SK, Bernstein CN, Lee K, Cooke-Lauder J, Kaplan GG. The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S68-S72. doi: 10.1093/jcag/gwy051. Epub 2018 Nov 2. PMID: 31294386; PMCID: PMC6512246.

452: Beaugerie L, Kirchgesner J. Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Feb;17(3):370-379. doi: 10.1016/j.cgh.2018.07.013. Epub 2018 Jul 18. PMID: 30031174.

453: Johnson CS, Kassir A, Marx DS, Soliman MK. Performance of da Vinci Stapler during robotic-assisted right colectomy with intracorporeal anastomosis. J Robot Surg. 2019 Feb;13(1):115-119. doi: 10.1007/s11701-018-0828-z. Epub 2018 May 30. PMID: 29846869.

454: Chroustová D, El-Lababidi N, Trnka J, Černa L, Lambert L. Scintigraphy with 99mTc-HMPAO labeled leukocytes is still an accurate and convenient tool to rule out suspected inflammatory bowel disease in children. Nucl Med Rev Cent East Eur. 2019;22(2):69-73. doi: 10.5603/NMR.2019.0017. PMID: 31482559.

455: Sahnan K, Adegbola SO, Fareleira A, Hart A, Warusavitarne J. Medical-surgical Combined Approach in Perianal Fistulizing Crohn's Disease (CD): Doing it Together. Curr Drug Targets. 2019;20(13):1373-1383. doi: 10.2174/1389450120666190520103454. PMID: 31109272.

456: Lindholm CR, Siegel CA. Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials? Curr Pharm Des. 2019;25(1):64-68. doi: 10.2174/1381612825666190312113935. PMID: 30864506.

457: Ansprenger C, Burri E. Diagnose und Monitoring bei chronisch-entzündlicher Darmerkrankung. Ther Umsch. 2019 Jan;75(5):316-328. German. doi: 10.1024/0040-5930/a001002. PMID: 30700246.

458: Rencz F, Lakatos PL, Gulácsi L, Brodszky V, Kürti Z, Lovas S, Banai J, Herszényi L, Cserni T, Molnár T, Péntek M, Palatka K. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. Qual Life Res. 2019 Jan;28(1):141-152. doi: 10.1007/s11136-018-2003-4. Epub 2018 Sep 17. PMID: 30225788.

459: Motaganahalli S, Beswick L, Con D, van Langenberg DR. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. Intern Med J. 2019 Jan;49(1):94-100. doi: 10.1111/imj.14027. PMID: 29962008.

460: Quezada SM, McLean LP, Cross RK. Adverse events in IBD therapy: the 2018

update. Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1183-1191. doi: 10.1080/17474124.2018.1545574. PMID: 30791788.

461: Ilias A, Lovasz BD, Gonczi L, Kurti Z, Vegh Z, Sumegi LD, Golovics PA, Rudas G, Lakatos PL. Optimizing Patient Management in Crohn's Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes. J Gastrointestin Liver Dis. 2018 Dec;27(4):391-397. doi: 10.15403/jgld.2014.1121.274.ocm. PMID: 30574621.

462: Samaan MA, Arkir Z, Ahmad T, Irving PM. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Expert Opin Biol Ther. 2018 Dec;18(12):1271-1279. doi: 10.1080/14712598.2018.1537367. Epub 2018 Oct 24. PMID: 30339466.

463: Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc. 2018 Dec;88(6):887-898. doi: 10.1016/j.gie.2018.08.018. Epub 2018 Aug 22. PMID: 30142351.

464: Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, González-Parra E, Jodar E, Joven B, Lázaro P, Olveira A, Quintero J, Rivera R. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2058-2073. doi: 10.1111/jdv.15177. Epub 2018 Aug 14. PMID: 29992631.

465: Allocca M, Fiorino G, Bonifacio C, Furfaro F, Gilardi D, Argollo M, Peyrin-Biroulet L, Danese S. Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15;12(11):1280-1287. doi: 10.1093/ecco-jcc/jjy093. PMID: 29982361.

466: Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1079-1100. doi: 10.1080/17474124.2018.1530109. Epub 2018 Oct 17. PMID: 30284911.

467: Almario CV, Chen MS, Spiegel BMR. Reply to Johnson et al. Regarding Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. Am J Gastroenterol. 2018 Nov;113(11):1721. doi: 10.1038/s41395-018-0279-1. Epub 2018 Sep 13. PMID: 30214014.

468: DiCaprio D, Lee-Kong S, Stoffels G, Shen B, Al-Mazrou A, Kiran RP, Korelitz B, Swaminath A. Management of iatrogenic perforation during colonoscopy in ulcerative colitis patients: a survey of gastroenterologists and colorectal surgeons. Int J Colorectal Dis. 2018 Nov;33(11):1607-1616. doi: 10.1007/s00384-018-3112-9. Epub 2018 Jul 5. PMID: 29978362.

469: Johnson RF, Reed S, Gonzalez JM. Letter to the Editor Regarding Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. Am J Gastroenterol. 2018 Nov;113(11):1720. doi: 10.1038/s41395-018-0186-5. Epub 2018 Jul 3. PMID: 29967477.

470: Langford T, Arkir Z, Chalkidou A, Goddard K, Kaftantzi L, Samaan M, Irving P. The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study. JMIR Res Protoc. 2018 Oct 19;7(10):e11218. doi: 10.2196/11218. PMID: 30341052; PMCID: PMC6231806.

471: Ouldali N, Hugot JP, Viala J, Damir M, Martinez-Vinson C, Meinzer U. Early

Arthritis Is Associated With Failure of Immunosuppressive Drugs and Severe Pediatric Crohn's Disease Evolution. Inflamm Bowel Dis. 2018 Oct 12;24(11):2423-2430. doi: 10.1093/ibd/izy137. PMID: 29788152.

472: Turvill J, Turnock D, Holmes H, Jones A, Mclaughlan E, Hilton V, Marriott S. Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterol. 2018 Oct;9(4):285-294. doi: 10.1136/flgastro-2018-100962. Epub 2018 Jun 7. PMID: 30245791; PMCID: PMC6145433.

473: Benlice C, Holubar SD, Gorgun E, Stocchi L, Lipman JM, Kalady MF, Champagne BJ, Steele SR. Extended Venous Thromboembolism Prophylaxis After Elective Surgery for IBD Patients: Nomogram-Based Risk Assessment and Prediction from Nationwide Cohort. Dis Colon Rectum. 2018 Oct;61(10):1170-1179. doi: 10.1097/DCR.0000000000001189. PMID: 30192325.

474: Reynolds C, Esrailian E, Hommes D. Quality Improvement in Gastroenterology: A Systematic Review of Practical Interventions for Clinicians. Dig Dis Sci. 2018 Oct;63(10):2507-2518. doi: 10.1007/s10620-018-5198-x. Epub 2018 Jul 16. PMID: 30014225.

475: Gröne J, Lorenz EM, Seifarth C, Seeliger H, Kreis ME, Mueller MH. Timing of surgery in ulcerative colitis in the biologic therapy era-the patient's perspective. Int J Colorectal Dis. 2018 Oct;33(10):1429-1435. doi: 10.1007/s00384-018-3129-0. Epub 2018 Jul 12. PMID: 30003360.

476: Fraser CG. Faecal immunochemical tests (FIT) in the assessment of patients presenting with lower bowel symptoms: Concepts and challenges. Surgeon. 2018 Oct;16(5):302-308. doi: 10.1016/j.surge.2018.01.004. Epub 2018 Mar 13. PMID: 29548552.

477: Kamel AY, Ayoub F, Banerjee D, Chaudhry N, Ader Y, Tan S, Zimmermann EM, Glover SC, Iqbal A. Effects of Preoperative Use of Biologic Agents on Operative Outcomes in Crohn's Disease Patients. Am Surg. 2018 Sep 1;84(9):1526-1530. PMID: 30268188.

478: Wren AA, Park KT. Targeted Dosing as a Precision Health Approach to Pharmacotherapy in Children with Inflammatory Bowel Disease. AMA J Ethics. 2018 Sep 1;20(9):E841-848. doi: 10.1001/amajethics.2018.841. PMID: 30242815.

479: Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018 Aug;67(2):257-291. doi: 10.1097/MPG.0000000000002035. Erratum in: J Pediatr Gastroenterol Nutr. 2020 Dec;71(6):794. PMID: 30044357.

480: Nowacki TM, Bettenworth D, Meister T, Heidemann J, Lenze F, Schmidt HH, Heinzow HS. Novel score predicts risk for cytomegalovirus infection in ulcerative colitis. J Clin Virol. 2018 Aug;105:103-108. doi: 10.1016/j.jcv.2018.06.002. Epub 2018 Jun 9. PMID: 29940421.

481: Celentano V. Decision making in primary Crohn's enteritis complicated by ileosigmoid fistula: laparoscopic approach - a video vignette. Colorectal Dis. 2018 Jul;20(7):642. doi: 10.1111/codi.14223. Epub 2018 May 7. PMID: 29673036.

482: Hoekstra J, van Roon AHC, Bekkering FC, van Tilburg AJP, West RL. Decision making and outcome of pregnancies in female patients with inflammatory bowel disease: findings from a community-based practice. Eur J Gastroenterol Hepatol.

2018 Jul;30(7):704-708. doi: 10.1097/MEG.0000000000001117. PMID: 29543610.

483: Chohno T, Uchino M, Sasaki H, Bando T, Takesue Y, Ikeuchi H. Associations Between the Prognostic Nutritional Index and Morbidity/Mortality During Intestinal Resection in Patients with Ulcerative Colitis. World J Surg. 2018 Jul;42(7):1949-1959. doi: 10.1007/s00268-017-4411-y. PMID: 29270654.

484: Boehncke WH, Brembilla NC. Immunogenicity of biologic therapies: causes and consequences. Expert Rev Clin Immunol. 2018 Jun;14(6):513-523. doi: 10.1080/1744666X.2018.1468753. Epub 2018 Apr 25. PMID: 29683362.

485: Kamp KJ, Brittain K. Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review. Patient. 2018 Jun;11(3):271-284. doi: 10.1007/s40271-017-0294-0. PMID: 29313266.

486: Piekkala M, Alfthan H, Merras-Salmio L, Puustinen Wikström A, Heiskanen K, Jaakkola T, Klemetti P, Färkkilä M, Kolho KL. Fecal Calprotectin Test Performed at Home: A Prospective Study of Pediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):926-931. doi: 10.1097/MPG.0000000000001861. PMID: 29240011.

487: Jackson BD, Con D, De Cruz P. Design considerations for an eHealth decision support tool in inflammatory bowel disease self-management. Intern Med J. 2018 Jun;48(6):674-681. doi: 10.1111/imj.13677. PMID: 29136332.

488: Vaughn DA, van Deen WK, Kerr WT, Meyer TR, Bertozzi AL, Hommes DW, Cohen MS. Using insurance claims to predict and improve hospitalizations and biologics use in members with inflammatory bowel diseases. J Biomed Inform. 2018 May;81:93-101. doi: 10.1016/j.jbi.2018.03.015. Epub 2018 Apr 3. PMID: 29625187.

489: Lam D, Yong E, D'Souza B, Woods R. Three-Dimensional Modeling for Crohn's Fistula-in-Ano: A Novel, Interactive Approach. Dis Colon Rectum. 2018 May;61(5):567-572. doi: 10.1097/DCR.0000000000001084. PMID: 29624551.

490: Martín Fernández C, Maroto Martín C, Fernández Salazar L. Using the internet to evaluate the opinion of patients with inflammatory bowel disease with regard to the available information. Rev Esp Enferm Dig. 2018 May;110(5):274-284. doi: 10.17235/reed.2018.5331/2017. PMID: 29527904.

491: Bryant RV, Friedman AB, Wright EK, Taylor KM, Begun J, Maconi G, Maaser C, Novak KL, Kucharzik T, Atkinson NSS, Asthana A, Gibson PR. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut. 2018 May;67(5):973-985. doi: 10.1136/gutjnl-2017-315655. Epub 2018 Feb 3. PMID: 29437914.

492: Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018 May;74(5):655-661. doi: 10.1007/s00228-018-2418-4. Epub 2018 Jan 24. PMID: 29368188; PMCID: PMC5893662.

493: Sherwin LB. Layperson's knowledge and perceptions of irritable bowel syndrome as potential barriers to care. J Adv Nurs. 2018 May;74(5):1199-1207. doi: 10.1111/jan.13521. Epub 2018 Jan 30. PMID: 29319900.

494: Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2018 May;67(5):818-826. doi: 10.1136/gutjnl-2016-313071. Epub 2017 Apr 27. PMID: 28450388.

495: Marlicz W, Skonieczna-Żydecka K, Dabos KJ, Łoniewski I, Koulaouzidis A. Emerging concepts in non-invasive monitoring of Crohn's disease. Therap Adv Gastroenterol. 2018 Apr 18;11:1756284818769076. doi: 10.1177/1756284818769076. PMID: 29707039; PMCID: PMC5912292.

496: Kedia S, Limdi JK, Ahuja V. Management of inflammatory bowel disease in older persons: evolving paradigms. Intest Res. 2018 Apr;16(2):194-208. doi: 10.5217/ir.2018.16.2.194. Epub 2018 Apr 30. PMID: 29743832; PMCID: PMC5934592.

497: Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, Cimino L, Costanzo A, Cristaudo A, D'Angelo S, Daperno M, Fostini AC, Galeazzi M, Gilio M, Gionchetti P, Gisondi P, Lubrano E, Marchesoni A, Offidani A, Orlando A, Pugliese D, Salvarani C, Scarpa R, Vecchi M, Girolomoni G. Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Adv Ther. 2018 Apr;35(4):545-562. doi: 10.1007/s12325-018-0672-6. Epub 2018 Mar 7. PMID: 29516409; PMCID: PMC5910456.

498: Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP, Wollina U, Marzano AV, Wallach D, Kim K, Schadt C, Ormerod A, Fung MA, Steel A, Patel F, Qin R, Craig F, Williams HC, Powell F, Merleev A, Cheng MY. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018 Apr 1;154(4):461-466. doi: 10.1001/jamadermatol.2017.5980. PMID: 29450466.

499: Hodgson R, Walton M, Biswas M, Mebrahtu T, Woolacott N. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018 Apr;36(4):387-398. doi: 10.1007/s40273-017-0593-2. PMID: 29192397.

500: Jain S, Kedia S, Sethi T, Bopanna S, Yadav DP, Goyal S, Padhan R, Venigalla

PM, Sahni P, Dash NR, Pal S, Makharia G, Travis SPL, Ahuja V. Predictors of long-term outcomes in patients with acute severe colitis: A northern Indian cohort study. J Gastroenterol Hepatol. 2018 Mar;33(3):615-622. doi: 10.1111/jgh.13921. PMID: 28801987.

501: Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018 Mar;16(3):343-356.e3. doi: 10.1016/j.cgh.2017.06.016. Epub 2017 Jun 16. PMID: 28625817; PMCID: PMC6658168.

502: Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. J Crohns Colitis. 2018 Feb 28;12(3):289-297. doi: 10.1093/ecco-jcc/jjx146. PMID: 29121178.

503: Gumidyala AP, Greenley RN, Plevinsky JM, Poulopoulos N, Cabrera J, Lerner D, Noe JD, Walkiewicz D, Werlin S, Kahn SA. Moving On: Transition Readiness in Adolescents and Young Adults With IBD. Inflamm Bowel Dis. 2018 Feb 15;24(3):482-489. doi: 10.1093/ibd/izx051. PMID: 29462383.

504: Liu W, Zhou W, Xiang J, Cao Q, Zhu J, Qi W, Chen P, Xie Q. Lémann Index at Diagnosis Predicts the Risk of Early Surgery in Crohn's Disease. Dis Colon Rectum. 2018 Feb;61(2):207-213. doi: 10.1097/DCR.0000000000000930. PMID: 29337776.

505: Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. doi: 10.1111/apt.14452. Epub 2017 Dec 11. PMID: 29226370.

506: Mui M, An V, Lovell J, D'Souza B, Woods R. Patients' perspective on bowel resection for inflammatory bowel disease. Int J Colorectal Dis. 2018 Feb;33(2):219-222. doi: 10.1007/s00384-017-2941-2. Epub 2017 Dec 4. PMID: 29204696.

507: Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018 Feb;19(1):1-13. doi: 10.1007/s40257-017-0328-3. PMID: 29080066.

508: Veilleux S, Noiseux I, Lachapelle N, Kohen R, Vachon L, Guay BW, Bitton A, Rioux JD; iGenoMed Consortium. Patients' perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease. Patient Educ Couns. 2018 Feb;101(2):331-339. doi: 10.1016/j.pec.2017.07.028. Epub 2017 Jul 25. PMID: 28760459.

509: Derwa Y, Williams CJM, Sood R, Mumtaz S, Bholah MH, Selinger CP, Hamlin PJ, Ford AC, Gracie DJ. Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. Therap Adv Gastroenterol. 2018 Jan 18;11:1756283X17744739. doi: 10.1177/1756283X17744739. PMID: 29383026; PMCID: PMC5784497.

510: Dibley L, Czuber-Dochan W, Wade T, Duncan J, Burch J, Warusavitarne J, Norton C, Artom M, O'Sullivan L, Verjee A, Cann D; members of the stoma PPI team. Patient Decision-Making About Emergency and Planned Stoma Surgery for IBD: A Qualitative Exploration of Patient and Clinician Perspectives. Inflamm Bowel Dis. 2018 Jan 18;24(2):235-246. doi: 10.1093/ibd/izx043. PMID: 29361098.

511: Kato S, Kani K, Ishibashi A, Oka M, Nagoshi S, Yakabi K. RETRACTED: P444 Shared decision making for switching from oral mesalazine tablets to granules in low adherent inflammatory bowel disease patients. J Crohns Colitis. 2018 Jan 16;12(suppl_1):S329. doi: 10.1093/ecco-jcc/jjx180.571. PMID: 31135895.

512: Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jan 5;12(1):17-31. doi: 10.1093/ecco-jcc/jjx101. PMID: 28981623.

513: Roldán ÚB, Badia X, Marcos-Rodríguez JA, de la Cruz-Merino L, Gómez-González J, Melcón-de Dios A, Caraballo-Camacho MO, Cordero-Ramos J, Alvarado-Fernández MD, Galiana-Auchel JM, Calleja-Hernández MÁ. MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING. Int J Technol Assess Health Care. 2018 Jan;34(5):519-526. doi: 10.1017/S0266462318000569. Epub 2018 Oct 23. PMID: 30348241.

514: Signore A, Anzola KL, Auletta S, Varani M, Petitti A, Pacilio M, Galli F, Lauri C. Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders. Curr Pharm Des. 2018;24(7):743-753. doi: 10.2174/1381612824666180130115153. PMID: 29384051.

515: Kluthe C, Isaac DM, Hiller K, Carroll M, Wine E, van Manen M, Huynh HQ. Qualitative Analysis of Pediatric Patient and Caregiver Perspectives After Recent Diagnosis With Inflammatory Bowel Disease. J Pediatr Nurs. 2018 Jan-Feb;38:106-113. doi: 10.1016/j.pedn.2017.11.011. Epub 2017 Dec 7. PMID: 29357985.

516: Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, Melmed GY, Spiegel BMR. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. Am J Gastroenterol. 2018 Jan;113(1):58-71. doi: 10.1038/ajg.2017.470. Epub 2017 Dec 5. PMID: 29206816.

517: Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan;47(2):162-175. doi: 10.1111/apt.14422. Epub 2017 Dec 4. PMID: 29205406.

518: Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, Queiro R, Bassas-Vila J, Martorell A, García-Campayo J. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):129-144. doi: 10.1111/jdv.14517. Epub 2017 Sep 12. PMID: 28796920.

519: Mosli M, Sabbahi H, Alyousef H, Abdulhaq M, Hadadi A, Aljahdali E, Jawa H, Bazarah S, Qari Y. Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome. Dig Dis. 2018;36(1):49-55. doi: 10.1159/000477613. Epub 2017 Jun 28. PMID: 28654928.

520: Jones I, Ramani P, Spray C, Cusick E. How Secure Is the Diagnosis of Ulcerative Colitis in Children, Even After Colectomy? J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):69-72. doi: 10.1097/MPG.0000000000001644. PMID: 28562521.

521: Pai RK, Geboes K. Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology? Virchows Arch. 2018 Jan;472(1):99-110. doi: 10.1007/s00428-017-2156-5. Epub 2017 May 30. PMID: 28555281.

522: Allocca M, Fiorino G, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S. Biologic Therapies in Ulcerative Colitis: Primi Inter Pares? Curr Drug Targets. 2018;19(7):748-756. doi: 10.2174/1389450117666160527142719. PMID: 27231106.

523: Mücke MM, Bettenworth D, Geyer C, Schwegmann K, Poremba C, Schäfers M, Domagk D, Höltke C, Lenz P. Targeting Mucosal Endothelin-A-Receptor Expression by Fluorescence Endoscopy is Feasible to Detect and Characterize Colitis-Associated Cancer in Mice. Inflamm Bowel Dis. 2017 Dec 19;24(1):111-122. doi: 10.1093/ibd/izx032. Erratum in: Inflamm Bowel Dis. 2018 Oct 12;24(11):2477. PMID: 29272493.

524: Baker DM, Lee MJ, Jones GL, Brown SR, Lobo AJ. The Informational Needs and Preferences of Patients Considering Surgery for Ulcerative Colitis: Results of a Qualitative Study. Inflamm Bowel Dis. 2017 Dec 19;24(1):179-190. doi: 10.1093/ibd/izx026. PMID: 29272489.

525: Waljee AK, Lipson R, Wiitala WL, Zhang Y, Liu B, Zhu J, Wallace B, Govani SM, Stidham RW, Hayward R, Higgins PDR. Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning. Inflamm Bowel Dis. 2017 Dec 19;24(1):45-53. doi: 10.1093/ibd/izx007. PMID: 29272474; PMCID: PMC5931801.

526: Baker DM, Marshall JH, Lee MJ, Jones GL, Brown SR, Lobo AJ. YouTube as a source of information for patients considering surgery for ulcerative colitis. J Surg Res. 2017 Dec;220:133-138. doi: 10.1016/j.jss.2017.06.094. Epub 2017 Jul 26. PMID: 29180175.

527: Selinger CP, Lenti MV, Clark T, Rafferty H, Gracie D, Ford AC, O'Connor A, Ahmad T, Hamlin PJ. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Dec;23(12):2083-2088. doi: 10.1097/MIB.0000000000001258. PMID: 29140939.

528: Stewart D. Surgical care of the pediatric Crohn's disease patient. Semin Pediatr Surg. 2017 Dec;26(6):373-378. doi: 10.1053/j.sempedsurg.2017.10.007.

Epub 2017 Oct 5. PMID: 29126506.

529: Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-1053. doi: 10.1111/apt.14368. Epub 2017 Oct 13. PMID: 29027257.

530: Stein J, Aksan A, Farrag K, Dignass A, Radeke HH. Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother. 2017 Nov;18(16):1721-1737. doi: 10.1080/14656566.2017.1391790. Epub 2017 Nov 5. PMID: 29019427.

531: Diederen K, Sahami SS, Tabbers MM, Benninga MA, Kindermann A, Tanis PJ, Oomen MW, de Jong JR, Bemelman WA. Outcome after restorative proctocolectomy and ileal pouch-anal anastomosis in children and adults. Br J Surg. 2017 Nov;104(12):1640-1647. doi: 10.1002/bjs.10678. Epub 2017 Sep 20. PMID: 28940230.

532: Deora V, Kozak J, El-Kalla M, Huynh HQ, El-Matary W. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease. Acta Paediatr. 2017 Nov;106(11):1863-1867. doi: 10.1111/apa.14008. Epub 2017 Aug 24. PMID: 28779489.

533: Lesnovska KP, Hollman Frisman G, Hjortswang H, Hjelm K, Börjeson S. Health care as perceived by persons with inflammatory bowel disease - a focus group study. J Clin Nurs. 2017 Nov;26(21-22):3677-3687. doi: 10.1111/jocn.13740. Epub

2017 Mar 29. PMID: 28122403.

534: Chongthammakun V, Fialho A, Fialho A, Lopez R, Shen B. Correlation of the Rutgeerts score and recurrence of Crohn's disease in patients with end ileostomy. Gastroenterol Rep (Oxf). 2017 Nov;5(4):271-276. doi: 10.1093/gastro/gow043. Epub 2016 Dec 30. PMID: 28039168; PMCID: PMC5691374.

535: Eck A, Zintgraf LM, de Groot EFJ, de Meij TGJ, Cohen TS, Savelkoul PHM, Welling M, Budding AE. Interpretation of microbiota-based diagnostics by explaining individual classifier decisions. BMC Bioinformatics. 2017 Oct 4;18(1):441. doi: 10.1186/s12859-017-1843-1. PMID: 28978318; PMCID: PMC5628491.

536: Holtman GA, Lisman-van Leeuwen Y, Day AS, Fagerberg UL, Henderson P, Leach ST, Perminow G, Mack D, van Rheenen PF, van de Vijver E, Wilson DC, Reitsma JB, Berger MY. Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data. JAMA Pediatr. 2017 Oct 1;171(10):984-991. doi: 10.1001/jamapediatrics.2017.1736. PMID: 28806445; PMCID: PMC5710621.

537: Milovanovic S, Scaldaferri F, Canarecci S, Kheiraoui F, Ciancarella G, de Waure C, Collamati A, Schiavoni E, Gasbarrini A, Boccia S, Poscia A. Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease. Dig Liver Dis. 2017 Oct;49(10):1098-1103. doi: 10.1016/j.dld.2017.06.015. Epub 2017 Jul 5. PMID: 28778820.

538: Picoraro JA, Rosh JR. Communicating the benefits and risks of inflammatory bowel disease therapy to patients and families. Curr Opin Pediatr. 2017 Oct;29(5):572-577. doi: 10.1097/MOP.0000000000000524. PMID: 28692447.

539: Vasudevan A, Gibson PR, van Langenberg DR. Time to clinical response and

remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol. 2017 Sep 21;23(35):6385-6402. doi: 10.3748/wjg.v23.i35.6385. PMID: 29085188; PMCID: PMC5643264.

540: Cooper J, Blake I, Lindsay JO, Hawkey CJ. Living with Crohn's disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study). BMJ Open. 2017 Sep 11;7(9):e015201. doi: 10.1136/bmjopen-2016-015201. PMID: 28893742; PMCID: PMC5595183.

541: Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology. 2017 Sep;153(3):835-857.e6. doi: 10.1053/j.gastro.2017.07.031. Epub 2017 Jul 31. PMID: 28774547.

542: Yanai H, Ben-Shachar S, Mlynarsky L, Godny L, Leshno M, Tulchinsky H, Dotan I. The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors. Aliment Pharmacol Ther. 2017 Sep;46(5):508-515. doi: 10.1111/apt.14205. Epub 2017 Jun 30. PMID: 28664992.

543: Oyaert M, Boel A, Jacobs J, Van den Bremt S, De Sloovere M, Vanpoucke H, Van Hoovels L. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med. 2017 Aug 28;55(10):1564-1573. doi: 10.1515/cclm-2016-1012. PMID: 28222018.

544: Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. BMC Gastroenterol. 2017 Aug

8;17(1):97. doi: 10.1186/s12876-017-0654-1. PMID: 28789636; PMCID: PMC5549364.

545: Baker DM, Marshall JH, Lee MJ, Jones GL, Brown SR, Lobo AJ. A Systematic Review of Internet Decision-Making Resources for Patients Considering Surgery for Ulcerative Colitis. Inflamm Bowel Dis. 2017 Aug;23(8):1293-1300. doi: 10.1097/MIB.0000000000001198. PMID: 28708807.

546: Aguas Peris M, Bosó V, Navarro B, Marqués-Miñana MR, Bastida G, Beltrán B, Iborra M, Sáez-González E, Monte-Boquet E, Poveda-Andrés JL, Nos P. Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflamm Bowel Dis. 2017 Aug;23(8):1454-1460. doi: 10.1097/MIB.0000000000001182. PMID: 28708805.

547: Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8. PMID: 28612180; PMCID: PMC5548814.

548: Restall GJ, Simms AM, Walker JR, Haviva C, Graff LA, Sexton KA, Miller N, Targownik LE, Bernstein CN. Coping with Inflammatory Bowel Disease: Engaging with Information to Inform Health-Related Decision Making in Daily Life. Inflamm Bowel Dis. 2017 Aug;23(8):1247-1256. doi: 10.1097/MIB.0000000000001141. PMID: 28498156.

549: Turvill J, Rook L, Rawle M, Robins G, Smale S, Kant P, Phillips A. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterol. 2017 Jul;8(3):183-188. doi: 10.1136/flgastro-2016-100780. Epub 2017 Jan 30. PMID: 28839907; PMCID: PMC5558279.

550: De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of

iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. Eur J Intern Med. 2017 Jul;42:16-23. doi: 10.1016/j.ejim.2017.04.018. Epub 2017 May 18. PMID: 28528999.

551: Kelly OB, Donnell SO, Stempak JM, Steinhart AH, Silverberg MS. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Jul;23(7):1202-1209. doi: 10.1097/MIB.0000000000001126. PMID: 28498155.

552: Martinez B, Dailey F, Almario CV, Keller MS, Desai M, Dupuy T, Mosadeghi S, Whitman C, Lasch K, Ursos L, Spiegel BMR. Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms. Inflamm Bowel Dis. 2017 Jul;23(7):1057-1064. doi: 10.1097/MIB.0000000000001110. PMID: 28410343.

553: Clarke K, Bilal M, Abdul-Baki H, Lebovitz P, El-Hachem S. College inflammatory bowel disease (C-IBD) day: a targeted approach to shared decision-making in college age students with IBD-a 2-year pilot project. Int J Colorectal Dis. 2017 Jul;32(7):1019-1023. doi: 10.1007/s00384-017-2763-2. Epub 2017 Feb 13. PMID: 28194494.

554: Mihes Y, Hogan NM, Egan L, Joyce MR. Completion Proctectomy for Crohn's Colitis: Lessons Learned. J Crohns Colitis. 2017 Jul 1;11(7):894-897. doi: 10.1093/ecco-jcc/jjx011. PMID: 28158506.

555: Day AS, Adamji M. Commentary: Impact of Fecal Calprotectin Measurement on Decision-Making in Children with Inflammatory Bowel Disease. Front Pediatr. 2017 Jun 6;5:133. doi: 10.3389/fped.2017.00133. PMID: 28634577; PMCID: PMC5459887.

556: Marshall JH, Baker DM, Lee MJ, Jones GL, Lobo AJ, Brown SR. Assessing

internet-based information used to aid patient decision-making about surgery for perianal Crohn's fistula. Tech Coloproctol. 2017 Jun;21(6):461-469. doi: 10.1007/s10151-017-1648-2. Epub 2017 Jun 22. PMID: 28643034; PMCID: PMC5495846.

557: Kariburyo MF, Xie L, Teeple A, Tan H, Ingham M. Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers. Adv Ther. 2017 Jun;34(6):1398-1410. doi: 10.1007/s12325-017-0545-4. Epub 2017 May 8. PMID: 28484953; PMCID: PMC5487867.

558: Campos C, Perrey A, Lambert C, Pereira B, Goutte M, Dubois A, Goutorbe F, Dapoigny M, Bommelaer G, Hordonneau C, Buisson A. Medical Therapies for Stricturing Crohn's Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure. Dig Dis Sci. 2017 Jun;62(6):1628-1636. doi: 10.1007/s10620-017-4572-4. Epub 2017 Apr 11. PMID: 28401425.

559: Bhatnagar G, Von Stempel C, Halligan S, Taylor SA. Utility of MR enterography and ultrasound for the investigation of small bowel Crohn's disease. J Magn Reson Imaging. 2017 Jun;45(6):1573-1588. doi: 10.1002/jmri.25569. Epub 2016 Dec 9. PMID: 27943484.

560: Lofland JH, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence. 2017 May 18;11:947-958. doi: 10.2147/PPA.S133222. PMID: 28572722; PMCID: PMC5441672.

561: Rodriguez A, Yokomizo L, Christofferson M, Barnes D, Khavari N, Park KT. Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):127-130. doi: 10.4292/wjgpt.v8.i2.127. PMID:

28533922; PMCID: PMC5421111.

562: Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. PLoS One. 2017 Apr 14;12(4):e0175826. doi: 10.1371/journal.pone.0175826. PMID: 28410403; PMCID: PMC5391967.

563: Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):317-328. doi: 10.1080/17474124.2017.1292128. Epub 2017 Feb 22. PMID: 28276813.

564: Mege D, Monsinjon M, Zappa M, Stefanescu C, Treton X, Maggiori L, Bouhnik Y, Panis Y. Is abdominal CT useful for the management of patients with severe acute colitis complicating inflammatory bowel disease? A study in 54 consecutive patients. Colorectal Dis. 2017 Apr;19(4):O97-O102. doi: 10.1111/codi.13640. PMID: 28238232.

565: Dias CC, Rodrigues PP, Coelho R, Santos PM, Fernandes S, Lago P, Caetano C, Rodrigues Â, Portela F, Oliveira A, Ministro P, Cancela E, Vieira AI, Barosa R, Cotter J, Carvalho P, Cremers I, Trabulo D, Caldeira P, Antunes A, Rosa I, Moleiro J, Peixe P, Herculano R, Gonçalves R, Gonçalves B, Sousa HT, Contente L, Morna H, Lopes S, Magro F; on behalf GEDII. Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions. J Crohns Colitis. 2017 Apr 1;11(4):445-453. doi: 10.1093/ecco-jcc/jjw171. Erratum in: J Crohns Colitis. 2017 Apr 1;11(4):515. PMID: 27683799.

566: Sánchez-Martínez MA, Garcia-Planella E, Laiz A, Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermosifiliogr. 2017 Apr;108(3):184-191. English, Spanish. doi: 10.1016/j.ad.2016.07.007. Epub 2016 Aug 28. PMID: 27576452.

567: Bolge SC, Eldridge HM, Lofland JH, Ravin C, Hart PJ, Ingham MP. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Prefer Adherence. 2017 Mar 28;11:661-669. doi: 10.2147/PPA.S121032. PMID: 28405158; PMCID: PMC5378465.

568: Kanamori A, Sugaya T, Tominaga K, Takahashi F, Takenaka K, Hoshino A, Koike T, Nakano M, Hiraishi H. Endoscopic balloon dilation for stenotic lesions in Crohn's disease. Turk J Gastroenterol. 2017 Mar;28(2):117-124. doi: 10.5152/tjg.2017.16598. Epub 2017 Feb 14. PMID: 28195539.

569: Bojic D, Bodger K, Travis S. Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. J Crohns Colitis. 2017 Mar 1;11(suppl_2):S576-S585. doi: 10.1093/ecco-jcc/jjw187. PMID: 27797917.

570: El-Matary W, Abej E, Deora V, Singh H, Bernstein CN. Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease. Front Pediatr. 2017 Jan 25;5:7. doi: 10.3389/fped.2017.00007. PMID: 28180127; PMCID: PMC5263122.

571: Veilleux S, Villeneuve M, Lachapelle N, Kohen R, Vachon L, White Guay B, Rioux JD, Bitton A; IBD Genomic Medicine Consortium (iGenoMed). Exploring the Use of a Participative Design in the Early Development of a Predictive Test: The Importance of Physician Involvement. Public Health Genomics. 2017;20(3):174-187. doi: 10.1159/000479289. Epub 2017 Aug 17. PMID: 28813717.

572: Mahlich J, Matsuoka K, Sruamsiri R. Shared Decision Making and Treatment Satisfaction in Japanese Patients with Inflammatory Bowel Disease. Dig Dis. 2017;35(5):454-462. doi: 10.1159/000471795. Epub 2017 Apr 6. PMID: 28380481.

573: Higgins PD. Measurement of Fibrosis in Crohn's Disease Strictures with Imaging and Blood Biomarkers to Inform Clinical Decisions. Dig Dis. 2017;35(1-2):32-37. doi: 10.1159/000449080. Epub 2017 Feb 1. PMID: 28147365.

574: Cha JM, Park DI, Park SH, Shin JE, Kim WS, Yang SK. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients. J Korean Med Sci. 2017 Jan;32(1):85-94. doi: 10.3346/jkms.2017.32.1.85. PMID: 27914136; PMCID: PMC5143303.

575: Morishige R, Nakajima H, Yoshizawa K, Mahlich J, Sruamsiri R. Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients. Adv Ther. 2017 Jan;33(12):2242-2256. doi: 10.1007/s12325-016-0436-0. Epub 2016 Nov 2. PMID: 27807816; PMCID: PMC5126200.

576: Hou JK, Gasche C, Drazin NZ, Weaver SA, Ehrlich OG, Oberai R, Zapala S, Siegel CA, Melmed G. Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2017 Jan;23(1):35-43. doi: 10.1097/MIB.0000000000000953. PMID: 27749376.

577: Peyrin-Biroulet L, Lönnfors S, Roblin X, Danese S, Avedano L. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. J Crohns Colitis. 2017 Jan;11(1):128-133. doi: 10.1093/ecco-jcc/jjw138. Epub 2016 Jul 31. PMID: 27481878.

578: Hernández-Breijo B, Chaparro M, Cano-Martínez D, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Gisbert JP, Guijarro LG; PREDICROHN study group from GETECCU. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. Biochem Pharmacol. 2016 Dec 15;122:33-41. doi:

10.1016/j.bcp.2016.09.019. Epub 2016 Sep 21. PMID: 27664854.

579: Jacobs I, Petersel D, Isakov L, Lula S, Lea Sewell K. Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence. BioDrugs. 2016 Dec;30(6):525-570. doi: 10.1007/s40259-016-0201-6. PMID: 27885553; PMCID: PMC5126192.

580: Lipstein EA, Lovell DJ, Denson LA, Kim SC, Spencer C, Ittenbach RF, Britto MT. High Levels of Decisional Conflict and Decision Regret When Making Decisions About Biologics. J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):e176-e181. doi: 10.1097/MPG.0000000000001425. PMID: 27749390; PMCID: PMC5123667.

581: Gudlaugsdottir K, Valsdottir EB, Stefansson TB. [Quality of Life after colectomy due to ulcerative colitis]. Laeknabladid. 2016 Nov;102(11):482-489. Icelandic. doi: 10.17992/lbl.2016.11.105. PMID: 27813487.

582: Bager P, Julsgaard M, Vestergaard T, Christensen LA, Dahlerup JF. Adherence and quality of care in IBD. Scand J Gastroenterol. 2016 Nov;51(11):1326-31. doi: 10.1080/00365521.2016.1195870. Epub 2016 Jun 16. PMID: 27311071.

583: Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in pregnancy: current perspectives. Clin Exp Gastroenterol. 2016 Oct 14;9:325-335. doi: 10.2147/CEG.S96676. PMID: 27789969; PMCID: PMC5072556.

584: Clarke T, Lusher J. Transitioning patients with inflammatory bowel disease (IBD) from adolescent to adult services: a systematic review. Frontline Gastroenterol. 2016 Oct;7(4):264-270. doi: 10.1136/flgastro-2015-100575. Epub 2015 Jun 16. PMID: 28839867; PMCID: PMC5369483.

585: Jossen J, Dubinsky M. Therapeutic drug monitoring in inflammatory bowel disease. Curr Opin Pediatr. 2016 Oct;28(5):620-5. doi:

10.1097/MOP.0000000000000393. PMID: 27583410.

586: Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. Eur J Clin Invest. 2016 Oct;46(10):825-32. doi: 10.1111/eci.12660. Epub 2016 Sep 6. PMID: 27438629.

587: Waddell L, Rajić A, Stärk K, McEwen SA. Mycobacterium avium ssp. paratuberculosis detection in animals, food, water and other sources or vehicles of human exposure: A scoping review of the existing evidence. Prev Vet Med. 2016 Sep 15;132:32-48. doi: 10.1016/j.prevetmed.2016.08.003. Epub 2016 Aug 18. PMID: 27664446.

588: Lipstein EA, Lovell DJ, Denson LA, Kim SC, Spencer C, Britto MT. Parents' information needs and influential factors when making decisions about TNF-α inhibitors. Pediatr Rheumatol Online J. 2016 Sep 15;14(1):53. doi: 10.1186/s12969-016-0113-5. PMID: 27641835; PMCID: PMC5024421.

589: Jansen I, Prager M, Valentini L, Büning C. Inflammation-driven malnutrition: a new screening tool predicts outcome in Crohn's disease. Br J Nutr. 2016 Sep;116(6):1061-7. doi: 10.1017/S0007114516003044. Epub 2016 Aug 22. PMID: 27546478.

590: Turvill J, O'Connell S, Brooks A, Bradley-Wood K, Laing J, Thiagarajan S, Hammond D, Turnock D, Jones A, Sood R, Ford A. Evaluation of a faecal calprotectin care pathway for use in primary care. Prim Health Care Res Dev. 2016 Sep;17(5):428-36. doi: 10.1017/S1463423616000049. Epub 2016 Feb 22. PMID: 26899214.

591: Mowat C, Digby J, Strachan JA, Wilson R, Carey FA, Fraser CG, Steele RJ. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in

patients presenting to primary care with bowel symptoms. Gut. 2016 Sep;65(9):1463-9. doi: 10.1136/gutjnl-2015-309579. Epub 2015 Aug 20. PMID: 26294695; PMCID: PMC5036251.

592: Stidham RW, Higgins PD. Imaging of intestinal fibrosis: current challenges and future methods. United European Gastroenterol J. 2016 Aug;4(4):515-22. doi: 10.1177/2050640616636620. Epub 2016 Mar 2. PMID: 27536361; PMCID: PMC4971796.

593: Barned C, Stinzi A, Mack D, O'Doherty KC. To tell or not to tell: A qualitative interview study on disclosure decisions among children with inflammatory bowel disease. Soc Sci Med. 2016 Aug;162:115-23. doi: 10.1016/j.socscimed.2016.06.023. Epub 2016 Jun 19. PMID: 27344353.

594: Subramanian S, Asher R, Weston W, Rimmer M, McConville A, Malin A, Jackson R, Collins P, Probert C, Dibb M, Rhodes JM. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use. Inflamm Bowel Dis. 2016 Aug;22(8):1902-7. doi: 10.1097/MIB.0000000000000803. PMID: 27243590.

595: Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis. 2016 Aug;22(8):1999-2015. doi: 10.1097/MIB.0000000000000772. PMID: 27135483.

596: Chernavskaia O, Heuke S, Vieth M, Friedrich O, Schürmann S, Atreya R, Stallmach A, Neurath MF, Waldner M, Petersen I, Schmitt M, Bocklitz T, Popp J. Beyond endoscopic assessment in inflammatory bowel disease: real-time histology of disease activity by non-linear multimodal imaging. Sci Rep. 2016 Jul 13;6:29239. doi: 10.1038/srep29239. PMID: 27406831; PMCID: PMC4942779.

597: Tomás CC, Oliveira E, Sousa D, Uba-Chupel M, Furtado G, Rocha C, Teixeira

A, Ferreira P, Alves C, Gisin S, Catarino E, Carvalho N, Coucelo T, Bonfim L, Silva C, Franco D, González JA, Jardim HG, Silva R, Baixinho CL, Presado MªH, Marques MªF, Cardoso ME, Cunha M, Mendes J, Xavier A, Galhardo A, Couto M, Frade JG, Nunes C, Mesquita JR, Nascimento MS, Gonçalves G, Castro C, Mártires A, Monteiro MªJ, Rainho C, Caballero FP, Monago FM, Guerrero JT, Monago RM, Trigo AP, Gutierrez ML, Milanés GM, Reina MG, Villanueva AG, Piñero AS, Aliseda IR, Ramirez FB, Ribeiro A, Quelhas A, Manso C, Caballero FP, Guerrero JT, Monago FM, Santos RB, Jimenez NR, Nuñez CG, Gomez IR, Fernandez MªJL, Marquez LA, Moreno AL, Huertas MªJT, Ramirez FB, Seabra D, Salvador MªC, Braga L, Parreira P, Salgueiro-Oliveira A, Arreguy-Sena C, Oliveira BF, Henriques MªA, Santos J, Lebre S, Marques A, Festas C, Rodrigues S, Ribeiro A, Lumini J, Figueiredo AG, Hernandez-Martinez FJ, Campi L, Quintana-Montesdeoca MªP, Jimenez-Diaz JF, Rodriguez-De-Vera BC, Parente A, Mata MªA, Pereira AMª, Fernandes A, Brás M, Pinto MªR, Parreira P, Basto ML, Rei AC, Mónico LM, Sousa G, Morna C, Freitas O, Freitas G, Jardim A, Vasconcelos R, Horta LG, Rosa RS, Kranz LF, Nugem RC, Siqueira MS, Bordin R, Kniess R, Lacerda JT, Guedes J, Machado I, Almeida S, Zilhão A, Alves H, Ribeiro Ó, Amaral AP, Santos A, Monteiro J, Rocha MªC, Cruz R, Amaral AP, Lourenço M, Rocha MªC, Cruz R, Antunes S, Mendonça V, Andrade I, Osório N, Valado A, Caseiro A, Gabriel A, Martins AC, Mendes F, Cabral L, Ferreira M, Gonçalves A, Luz TD, Luz L, Martins R, Morgado A, Vale-Dias ML, Porta-Nova R, Fleig TC, Reuter ÉM, Froemming MB, Guerreiro SL, Carvalho LL, Guedelha D, Coelho P, Pereira A, Calha A, Cordeiro R, Gonçalves A, Certo A, Galvão A, Mata MªA, Welter A, Pereira E, Ribeiro S, Kretzer M, Jiménez-Díaz JF, Jiménez-Rodríguez C, Hernández-Martínez FJ, Rodríguez-De-Vera BDC, Marques-Rodrigues A, Coelho P, Bernardes T, Pereira A, Sousa P, Filho JG, Nazario N, Kretzer M, Amaral O, Garrido A, Veiga N, Nunes C, Pedro AR, Pereira C, Almeia A, Fernandes HM, Vasconcelos C, Sousa N, Reis VM, Monteiro MJ, Mendes R, Pinto IC, Pires T, Gama J, Preto V, Silva N, Magalhães C, Martins M, Duarte M, Paúl C, Martín I, Pinheiro AA, Xavier S, Azevedo J, Bento E, Marques C, Marques M, Macedo A, Pereira AT, Almeida JP, Almeida A, Alves J, Sousa N, Saavedra F, Mendes R, Maia AS, Oliveira MT, Sousa AR, Ferreira PP, Lopes LS, Santiago EC,

Monteiro S, Jesus Â, Colaço A, Carvalho A, Silva RP, Cruz A, Ferreira A, Marques C, Figueiredo JP, Paixão S, Ferreira A, Lopes C, Moreira F, Figueiredo JP, Ferreira A, Ribeiro D, Moreira F, Figueiredo JP, Paixão S, Fernandes T, Amado D, Leal J, Azevedo M, Ramalho S, Mangas C, Ribeiro J, Gonçalves R, Nunes AF, Tuna AR, Martins CR, Forte HD, Costa C, Tenedório JA, Santana P, Andrade JA, Pinto JL, Campofiorito C, Nunes S, Carmo A, Kaliniczenco A, Alves B, Mendes F, Jesus C, Fonseca F, Gehrke F, Albuquerque C, Batista R, Cunha M, Madureira A, Ribeiro O, Martins R, Madeira T, Peixoto-Plácido C, Santos N, Santos O, Bergland A, Bye A, Lopes C, Alarcão V, Goulão B, Mendonça N, Nicola P, Clara JG, Gomes J, Querido A, Tomás C, Carvalho D, Cordeiro M, Rosa MC, Marques A, Brandão D, Ribeiro Ó, Araújo L, Paúl C, Minghelli B, Richaud S, Mendes AL, Marta-Simões J, Trindade IA, Ferreira C, Carvalho T, Cunha M, Pinto-Gouveia J, Fernandes MC, Rosa RS, Nugem RC, Kranz LF, Siqueira MS, Bordin R, Martins AC, Medeiros A, Pimentel R, Fernandes A, Mendonça C, Andrade I, Andrade S, Menezes RL, Bravo R, Miranda M, Ugartemendia L, Tena JMª, Pérez-Caballero FL, Fuentes-Broto L, Rodríguez AB, Carmen B, Carneiro MA, Domingues JN, Paixão S, Figueiredo J, Nascimento VB, Jesus C, Mendes F, Gehrke F, Alves B, Azzalis L, Fonseca F, Martins AR, Nunes A, Jorge A, Veiga N, Amorim A, Silva A, Martinho L, Monteiro L, Silva R, Coelho C, Amaral O, Coelho I, Pereira C, Correia A, Rodrigues D, Marante N, Silva P, Carvalho S, Araujo AR, Ribeiro M, Coutinho P, Ventura S, Roque F, Calvo C, Reses M, Conde J, Ferreira A, Figueiredo J, Silva D, Seiça L, Soares R, Mourão R, Kraus T, Abreu AC, Padilha JM, Alves JM, Sousa P, Oliveira M, Sousa J, Novais S, Mendes F, Pinto J, Cruz J, Marques A, Duarte H, Dixe MDA, Sousa P, Cruz I, Bastos F, Pereira F, Carvalho FL, Oliveira TT, Raposo VR, Rainho C, Ribeiro JC, Barroso I, Rodrigues V, Neves C, Oliveira TC, Oliveira B, Morais MªC, Baylina P, Rodrigues R, Azeredo Z, Vicente C, Dias H, Sim-Sim M, Parreira P, Salgueiro-Oliveira A, Castilho A, Melo R, Graveto J, Gomes J, Vaquinhas M, Carvalho C, Mónico L, Brito N, Sarroeira C, Amendoeira J, Cunha F, Cândido A, Fernandes P, Silva HR, Silva E, Barroso I, Lapa L, Antunes C, Gonçalves A, Galvão A, Gomes MªJ, Escanciano SR, Freitas M, Parreira P, Marôco J, Fernandes AR, Cabral C, Alves S, Sousa P, Ferreira A, Príncipe F, Seppänen

UM, Ferreira M, Carvalhais M, Silva M, Ferreira M, Silva J, Neves J, Costa D, Santos B, Duarte S, Marques S, Ramalho S, Mendes I, Louro C, Menino E, Dixe M, Dias SS, Cordeiro M, Tomás C, Querido A, Carvalho D, Gomes J, Valim FC, Costa JO, Bernardes LG, Prebianchi H, Rosa MC, Gonçalves N, Martins MM, Kurcgant P, Vieira A, Bento S, Deodato S, Rabiais I, Reis L, Torres A, Soares S, Ferreira M, Graça P, Leitão C, Abreu R, Bellém F, Almeida A, Ribeiro-Varandas E, Tavares A, Frade JG, Henriques C, Menino E, Louro C, Jordão C, Neco S, Morais C, Ferreira P, Silva CR, Brito A, Silva A, Duarte H, Dixe MDA, Sousa P, Postolache G, Oliveira R, Moreira I, Pedro L, Vicente S, Domingos S, Postolache O, Silva D, Filho JG, Nazario N, Kretzer M, Schneider D, Marques FM, Parreira P, Carvalho C, Mónico LM, Pinto C, Vicente S, Breda SJ, Gomes JH, Melo R, Parreira P, Salgueiro A, Graveto J, Vaquinhas M, Castilho A, Jesus Â, Duarte N, Lopes JC, Nunes H, Cruz A, Salgueiro-Oliveira A, Parreira P, Basto ML, Braga LM, Ferreira A, Araújo B, Alves JM, Ferreira M, Carvalhais M, Silva M, Novais S, Sousa AS, Ferrito C, Ferreira PL, Rodrigues A, Ferreira M, Oliveira I, Ferreira M, Neves J, Costa D, Duarte S, Silva J, Santos B, Martins C, Macedo AP, Araújo O, Augusto C, Braga F, Gomes L, Silva MA, Rosário R, Pimenta L, Carreira D, Teles P, Barros T, Tomás C, Querido A, Carvalho D, Gomes J, Cordeiro M, Carvalho D, Querido A, Tomás C, Gomes J, Cordeiro M, Jácome C, Marques A, Capelas S, Hall A, Alves D, Lousada M, Loureiro MªH, Camarneiro A, Silva M, Mendes A, Pedreiro A, G.Silva A, Coelho ES, Melo F, Ribeiro F, Torres R, Costa R, Pinho T, Jácome C, Marques A, Cruz B, Seabra D, Carreiras D, Ventura M, Cruz X, Brooks D, Marques A, Pinto MR, Parreira P, Lima-Basto M, Neves M, Mónico LM, Bizarro C, Cunha M, Galhardo A, Margarida C, Amorim AP, Silva E, Cruz S, Padilha JM, Valente J, Guerrero JT, Caballero FP, Santos RB, Gonzalez EP, Monago FM, Ugalde LU, Vélez MM, Tena MJ, Guerrero JT, Bravo R, Pérez-Caballero FL, Becerra IA, Agudelo MªE, Acedo G, Bajo R, Malheiro I, Gaspar F, Barros L, Furtado G, Uba-Chupel M, Marques M, Rama L, Braga M, Ferreira JP, Teixeira AMª, Cruz J, Barbosa T, Simões Â, Coelho L, Rodrigues A, Jiménez-Díaz JF, Martinez-Hernandez F, Rodriguez-De-Vera B, Ferreira P, Rodrigues A, Ramalho A, Petrica J, Mendes P, Serrano J, Santo I, Rosado A, Mendonça P, Freitas K, Ferreira D, Brito A, Fernandes R, Gomes S,

Moreira F, Pinho C, Oliveira R, Oliveira AI, Mendonça P, Casimiro AP, Martins P, Silva I, Evangelista D, Leitão C, Velosa F, Carecho N, Coelho L, Menino E, Dixe A, Catarino H, Soares F, Gama E, Gordo C, Moreira E, Midões C, Santos M, Machado S, Oliveira VP, Santos M, Querido A, Dixe A, Marques R, Charepe Z, Antunes A, Santos S, Rosa MC, Rosa MC, Marques SF, Minghelli B, CaroMinghelli E, Luís MªJ, Brandão T, Mendes P, Marinho D, Petrica J, Monteiro D, Paulo R, Serrano J, Santo I, Monteiro L, Ramalho F, Santos-Rocha R, Morgado S, Bento T, Sousa G, Freitas O, Silva I, Freitas G, Morna C, Vasconcelos R, Azevedo T, Soares S, Pisco J, Ferreira PP, Olszewer EO, Oliveira MT, Sousa AR, Maia AS, Oliveira ST, Santos E, Oliveira AI, Maia C, Moreira F, Santos J, Mendes MF, Oliveira RF, Pinho C, Barreira E, Pereira A, Vaz JA, Novo A, Silva LD, Maia B, Ferreira E, Pires F, Andrade R, Camarinha L, Silva LD, Maia B, Ferreira E, Pires F, Andrade R, Camarinha L, César AF, Poço M, Ventura D, Loura R, Gomes P, Gomes C, Silva C, Melo E, Lindo J, Domingos J, Mendes Z, Poeta S, Carvalho T, Tomás C, Catarino H, Dixe MªA, Ramalho A, Rosado A, Mendes P, Paulo R, Garcia I, Petrica J, Rodrigues S, Meneses R, Afonso C, Faria L, Seixas A, Cordeiro M, Granjo P, Gomes JC, Souza NR, Furtado GE, Rocha SV, Silva P, Carvalho J, Morais MA, Santos S, Lebre P, Antunes A, Calha A, Xavier A, Cunha M, Pinto-Gouveia J, Alencar L, Cunha M, Madureira A, Cardoso I, Galhardo A, Daniel F, Rodrigues V, Luz L, Luz T, Ramos MR, Medeiros DC, Carmo BM, Seabra A, Padez C, Silva MC, Rodrigues A, Coelho P, Coelho A, Caminha M, Matheus F, Mendes E, Correia J, Kretzer M, Hernandez-Martinez FJ, Jimenez-Diaz JF, Rodriguez-De-Vera BC, Jimenez-Rodriguez C, Armas-Gonzalez Y, Rodrigues C, Pedroso R, Apolinário-Hagen J, Vehreschild V, Veloso M, Magalhães C, Cabral I, Ferraz M, Nave F, Costa E, Matos F, Pacheco J, Dias A, Pereira C, Duarte J, Cunha M, Silva D, Mónico LM, Alferes VR, Brêda MªSJ, Carvalho C, Parreira PM, Morais MªC, Ferreira P, Pimenta R, Boavida J, Pinto IC, Pires T, Silva C, Ribeiro M, Viega-Branco M, Pereira F, Pereira AMª, Almeida FM, Estevez GL, Ribeiro S, Kretzer MR, João PV, Nogueira P, Novais S, Pereira A, Carneiro L, Mota M, Cruz R, Santiago L, Fontes-Ribeiro C, Furtado G, Rocha SV, Coutinho AP, Neto JS, Vasconcelos LR, Souza NR, Dantas E, Dinis A, Carvalho S, Castilho P, Pinto-Gouveia J, Sarreira-Santos A, Figueiredo A, Medeiros-Garcia L,

Seabra P, Rodrigues R, Morais MªC, Fernandes PO, Santiago C, Figueiredo MªH, Basto ML, Guimarães T, Coelho A, Graça A, Silva AM, Fonseca AR, Vale-Dias L, Minas B, Franco-Borges G, Simões C, Santos S, Serra A, Matos M, Jesus L, Tavares AS, Almeida A, Leitão C, Varandas E, Abreu R, Bellém F, Trindade IA, Ferreira C, Pinto-Gouveia J, Marta-Simões J, Amaral O, Miranda C, Guimarães P, Gonçalves R, Veiga N, Pereira C, Fleig TC, San-Martin EA, Goulart CL, Schneiders PB, Miranda NF, Carvalho LL, Silva AG, Topa J, Nogueira C, Neves S, Ventura R, Nazaré C, Brandão D, Freitas A, Ribeiro Ó, Paúl C, Mercê C, Branco M, Almeida P, Nascimento D, Pereira J, Catela D, Rafael H, Reis AC, Mendes A, Valente AR, Lousada M, Sousa D, Baltazar AL, Loureiro MªH, Oliveira A, Aparício J, Marques A, Marques A, Oliveira A, Neves J, Ayoub R, Sousa L, Marques-Vieira C, Severino S, José H, Cadorio I, Lousada M, Cunha M, Andrade D, Galhardo A, Couto M, Mendes F, Domingues C, Schukg S, Abrantes AM, Gonçalves AC, Sales T, Teixo R, Silva R, Estrela J, Laranjo M, Casalta-Lopes J, Rocha C, Simões PC, Sarmento-Ribeiro AB, Botelho MªF, Rosa MS, Fonseca V, Colaço D, Neves V, Jesus C, Hesse C, Rocha C, Osório N, Valado A, Caseiro A, Gabriel A, Svensson L, Mendes F, Siba WA, Pereira C, Tomaz J, Carvalho T, Pinto-Gouveia J, Cunha M, Duarte D, Lopes NV, Fonseca-Pinto R, Duarte D, Lopes NV, Fonseca-Pinto R, Martins AC, Brandão P, Martins L, Cardoso M, Morais N, Cruz J, Alves N, Faria P, Mateus A, Morouço P, Alves N, Ferreira N, Mateus A, Faria P, Morouço P, Malheiro I, Gaspar F, Barros L, Parreira P, Cardoso A, Mónico L, Carvalho C, Lopes A, Salgueiro-Oliveira A, Seixas A, Soares V, Dias T, Vardasca R, Gabriel J, Rodrigues S, Paredes H, Reis A, Marinho S, Filipe V, Lains J, Barroso J, Da Motta C, Carvalho CB, Pinto-Gouveia J, Peixoto E, Gomes AA, Costa V, Couto D, Marques DR, Leitão JA, Tavares J, Azevedo MH, Silva CF, Freitas J, Parreira P, Marôco J, Garcia-Gordillo MA, Collado-Mateo D, Chen G, Iezzi A, Sala JA, Parraça JA, Gusi N, Sousa J, Marques M, Jardim J, Pereira A, Simões S, Cunha M, Sardo P, Guedes J, Lindo J, Machado P, Melo E, Carvalho CB, Benevides J, Sousa M, Cabral J, Da Motta C, Pereira AT, Xavier S, Azevedo J, Bento E, Marques C, Carvalho R, Marques M, Macedo A, Silva AM, Alves J, Gomes AA, Marques DR, Azevedo MªH, Silva C, Mendes A, Lee HD, Spolaôr N, Oliva JT, Chung WF, Fonseca-Pinto R, Bairros K, Silva CD, Souza CA,

Schroeder SS, Araújo E, Monteiro H, Costa R, Dias SS, Torgal J, Henriques CG, Santos L, Caceiro EF, Ramalho SA, Oliveira R, Afreixo V, Santos J, Mota P, Cruz A, Pimentel F, Marques R, Dixe MªA, Querido A, Sousa P, Benevides J, Da Motta C, Sousa M, Caldeira SN, Carvalho CB, Querido A, Tomás C, Carvalho D, Gomes J, Cordeiro M, Costa JO, Valim FC, Ribeiro LC, Charepe Z, Querido A, Figueiredo MªH, Aquino PS, Ribeiro SG, Pinheiro AB, Lessa PA, Oliveira MF, Brito LS, Pinto ÍN, Furtado AS, Castro RB, Aquino CQ, Martins ES, Pinheiro AB, Aquino PS, Oliveira LL, Pinheiro PC, Sousa CR, Freitas VA, Silva TM, Lima AS, Aquino CQ, Andrade KV, Oliveira CA, Vidal EF, Ganho-Ávila A, Moura-Ramos M, Gonçalves Ó, Almeida J, Silva A, Brito I, Amado J, Rodrigo A, Santos S, Gomes F, Rosa MC, Marques SF, Luís S, Cavalheiro L, Ferreira P, Gonçalves R, Lopes RS, Cavalheiro L, Ferreira P, Gonçalves R, Fiorin BH, Santos MS, Oliveira ES, Moreira RL, Oliveira EA, Filho BL, Palmeira L, Garcia T, Pinto-Gouveia J, Cunha M, Cardoso S, Palmeira L, Cunha M, Pinto-Gouveia J, Marta-Simões J, Mendes AL, Trindade IA, Oliveira S, Ferreira C, Mendes AL, Marta-Simões J, Trindade IA, Ferreira C, Nave F, Campos M, Gaudêncio I, Martins F, Ferreira L, Lopes N, Fonseca-Pinto R, Rodrigues R, Azeredo Z, Vicente C, Silva J, Sousa P, Marques R, Mendes I, Rodrigues R, Azeredo Z, Vicente C, Vardasca R, Marques AR, Seixas A, Carvalho R, Gabriel J, Ferreira PP, Oliveira MT, Sousa AR, Maia AS, Oliveira ST, Costa PO, Silva MM, Arreguy-Sena C, Alvarenga-Martins N, Pinto PF, Oliveira DC, Parreira PD, Gomes AT, Braga LM, Araújo O, Lage I, Cabrita J, Teixeira L, Marques R, Dixe MªA, Querido A, Sousa P, Silva S, Cordeiro E, Pimentel J, Ferro-Lebres V, Souza JA, Tavares M, Dixe MªA, Sousa P, Passadouro R, Peralta T, Ferreira C, Lourenço G, Serrano J, Petrica J, Paulo R, Honório S, Mendes P, Simões A, Carvalho L, Pereira A, Silva S, Sousa P, Padilha JM, Figueiredo D, Valente C, Marques A, Ribas P, Sousa J, Brandão F, Sousa C, Martins M, Sousa P, Marques R, Mendes F, Fernandes R, Martins E, Magalhães C, Araújo P, Grande C, Mata MªA, Vieitez JG, Bianchini B, Nazario N, Filho JG, Kretzer M, Costa T, Almeida A, Baffour G, Almeida A, Costa T, Baffour G, Azeredo Z, Laranjeira C, Guerra M, Barbeiro AP, Ferreira R, Lopes S, Nunes L, Mendes A, Martins J, Schneider D, Kretzer M, Magajewski F, Soares C, Marques A, Batista M, Castuera RJ, Mesquita H, Faustino

A, Santos J, Honório S, Vizzotto BP, Frigo L, Pivetta HF, Sardo D, Martins C, Abreu W, Figueiredo MªC, Batista M, Jimenez-Castuera R, Petrica J, Serrano J, Honório S, Paulo R, Mendes P, Sousa P, Marques R, Faustino A, Silveira P, Serrano J, Paulo R, Mendes P, Honório S, Oliveira C, Bastos F, Cruz I, Rodriguez CK, Kretzer MR, Nazário NO, Cruz P, Vaz DC, Ruben RB, Avelelas F, Silva S, Campos MªJ, Almeida M, Gonçalves L, Antunes L, Sardo P, Guedes J, Simões J, Machado P, Melo E, Cardoso S, Santos O, Nunes C, Loureiro I, Santos F, Alves G, Soar C, Marsi TO, Silva E, Pedrosa D, Leça A, Silva D, Galvão A, Gomes M, Fernandes P, Noné A, Combadão J, Ramalhete C, Figueiredo P, Caeiro P, Fontana KC, Lacerda JT, Machado PO, Borges R, Barbosa F, Sá D, Brunhoso G, Aparício G, Carvalho A, Garcia AP, Fernandes PO, Santos A, Veiga N, Brás C, Carvalho I, Batalha J, Glória M, Bexiga F, Coelho I, Amaral O, Pereira C, Pinho C, Paraíso N, Oliveira AI, Lima CF, Dias AP, Silva P, Espada M, Marques M, Pereira A, Pereira AMª, Veiga-Branco Mª, Pereira F, Ribeiro M, Lima V, Oliveira AI, Pinho C, Cruz G, Oliveira RF, Barreiros L, Moreira F, Camarneiro A, Loureiro MªH, Silva M, Duarte C, Jesus Â, Cruz A, Mota M, Novais S, Nogueira P, Pereira A, Carneiro L, João PV, Lima TM, Salgueiro-Oliveira A, Vaquinhas M, Parreira P, Melo R, Graveto J, Castilho A, Gomes JH, Medina MS, Blanco VG, Santos O, Lopes E, Virgolino A, Dinis A, Ambrósio S, Almeida I, Marques T, Heitor MªJ, Garcia-Gordillo MA, Collado-Mateo D, Olivares PR, Parraça JA, Sala JA, Castilho A, Graveto J, Parreira P, Oliveira A, Gomes JH, Melo R, Vaquinhas M, Cheio M, Cruz A, Pereira OR, Pinto S, Oliveira A, Manso MC, Sousa C, Vinha AF, Machado MªM, Vieira M, Fernandes B, Tomás T, Quirino D, Desouzart G, Matos R, Bordini M, Mouroço P, Matos AR, Serapioni M, Guimarães T, Fonseca V, Costa A, Ribeiro J, Lobato J, Martin IZ, Björklund A, Tavares AI, Ferreira P, Passadouro R, Morgado S, Tavares N, Valente J, Martins AC, Araújo P, Fernandes R, Mendes F, Magalhães C, Martins E, Mendes P, Paulo R, Faustino A, Mesquita H, Honório S, Batista M, Lacerda JT, Ortiga AB, Calvo MªC, Natal S, Pereira M, Ferreira M, Prata AR, Nelas P, Duarte J, Carneiro J, Oliveira AI, Pinho C, Couto C, Oliveira RF, Moreira F, Maia AS, Oliveira MT, Sousa AR, Ferreira PP, Souza GM, Almada LF, Conceição MA, Santiago EC, Rodrigues S, Domingues G, Ferreira I, Faria L, Seixas

A, Costa AR, Jesus Â, Cardoso A, Meireles A, Colaço A, Cruz A, Vieira VL, Vincha KR, Cervato-Mancuso AMª, Faria M, Reis C, Cova MP, Ascenso RT, Almeida HA, Oliveira EG, Santana M, Pereira R, Oliveira EG, Almeida HA, Ascenso RT, Jesus R, Tapadas R, Tim-Tim C, Cezanne C, Lagoa M, Dias SS, Torgal J, Lopes J, Almeida H, Amado S, Carrão L, Cunha M, Saboga-Nunes L, Albuquerque C, Ribeiro O, Oliveira S, Morais MªC, Martins E, Mendes F, Fernandes R, Magalhães C, Araújo P, Pedro AR, Amaral O, Escoval A, Assunção V, Luís H, Luís L, Apolinário-Hagen J, Vehreschild V, Fotschl U, Lirk G, Martins AC, Andrade I, Mendes F, Mendonça V, Antunes S, Andrade I, Osório N, Valado A, Caseiro A, Gabriel A, Martins AC, Mendes F, Silva PA, Mónico LM, Parreira PM, Carvalho C, Carvalho C, Parreira PM, Mónico LM, Ruivo J, Silva V, Sousa P, Padilha JM, Ferraz V, Aparício G, Duarte J, Vasconcelos C, Almeida A, Neves J, Correia T, Amorim H, Mendes R, Saboga-Nunes L, Cunha M, Albuquerque C, Pereira ES, Santos LS, Reis AS, Silva HR, Rombo J, Fernandes JC, Fernandes P, Ribeiro J, Mangas C, Freire A, Silva S, Francisco I, Oliveira A, Catarino H, Dixe MªA, Louro MªC, Lopes S, Dixe A, Dixe MªA, Menino E, Catarino H, Soares F, Oliveira AP, Gordo S, Kraus T, Tomás C, Queirós P, Rodrigues T, Sousa P, Frade JG, Lobão C, Moura CB, Dreyer LC, Meneghetti V, Cabral PP, Pinto F, Sousa P, Esteves MªR, Galvão S, Tytgat I, Andrade I, Osório N, Valado A, Caseiro A, Gabriel A, Martins AC, Mendes F, Casas-Novas M, Bernardo H, Andrade I, Sousa G, Sousa AP, Rocha C, Belo P, Osório N, Valado A, Caseiro A, Gabriel A, Martins AC, Mendes F, Martins F, Pulido-Fuentes M, Barroso I, Cabral G, Monteiro MJ, Rainho C, Prado A, Carvalho YM, Campos M, Moreira L, Ferreira J, Teixeira A, Rama L, Campos M, Moreira L, Ferreira J, Teixeira A, Rama L. Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016. BMC Health Serv Res. 2016 Jul 6;16 Suppl 3(Suppl 3):200. doi: 10.1186/s12913-016-1423-5. PMID: 27409075; PMCID: PMC4943498.

598: Murphy J, Kalkbrenner KA, Blas JV, Pemberton JH, Landmann RG, Young-Fadok TM, Etzioni DA. What is the likelihood of colorectal cancer when surgery for ulcerative-colitis-associated dysplasia is deferred? Colorectal Dis. 2016 Jul;18(7):703-9. doi: 10.1111/codi.13312. PMID: 26921877.

599: Sahami S, Bartels SA, D'Hoore A, Fadok TY, Tanis PJ, Lindeboom R, de Buck van Overstraeten A, Wolthuis AM, Bemelman WA, Buskens CJ. A Multicentre Evaluation of Risk Factors for Anastomotic Leakage After Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease. J Crohns Colitis. 2016 Jul;10(7):773-8. doi: 10.1093/ecco-jcc/jjv170. Epub 2015 Sep 27. PMID: 26417046.

600: Cohan JN, Ozanne EM, Sewell JL, Hofer RK, Mahadevan U, Varma MG, Finlayson E. A Novel Decision Aid for Surgical Patients with Ulcerative Colitis: Results of a Pilot Study. Dis Colon Rectum. 2016 Jun;59(6):520-8. doi: 10.1097/DCR.0000000000000572. PMID: 27145309.

601: Roblin X, Williet N, Peyrin-Biroulet L. Thiopurine Metabolism in the Era of Combotherapy. Inflamm Bowel Dis. 2016 Jun;22(6):1496-501. doi: 10.1097/MIB.0000000000000737. PMID: 26978723.

602: Patel D, Madani S, Patel S, Guglani L. Review of pulmonary adverse effects of infliximab therapy in Crohn's disease. Expert Opin Drug Saf. 2016 Jun;15(6):769-75. doi: 10.1517/14740338.2016.1160053. Epub 2016 Mar 16. PMID: 26923135.

603: Lipstein EA, Dodds CM, Lovell DJ, Denson LA, Britto MT. Making decisions about chronic disease treatment: a comparison of parents and their adolescent children. Health Expect. 2016 Jun;19(3):716-26. doi: 10.1111/hex.12210. Epub 2014 Jun 3. PMID: 24889468; PMCID: PMC5055230.

604: Adler J, Saeed SA, Eslick IS, Provost L, Margolis PA, Kaplan HC. Appreciating the Nuance of Daily Symptom Variation to Individualize Patient Care. EGEMS (Wash DC). 2016 May 4;4(1):1247. doi: 10.13063/2327-9214.1247. PMID: 27376097; PMCID: PMC4909374.

605: Carlberg DJ, Lee SD, Dubin JS. Lower Abdominal Pain. Emerg Med Clin North Am. 2016 May;34(2):229-49. doi: 10.1016/j.emc.2015.12.003. PMID: 27133242.

606: Trivedi I, Holl JL, Hanauer S, Keefer L. Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. Curr Gastroenterol Rep. 2016 May;18(5):21. doi: 10.1007/s11894-016-0495-z. PMID: 27086002.

607: Dillman JR, Trout AT, Smith EA. MR enterography: how to deliver added value. Pediatr Radiol. 2016 May;46(6):829-37. doi: 10.1007/s00247-016-3555-5. Epub 2016 Mar 3. PMID: 26939974.

608: Thompson KD, Connor SJ, Walls DM, Gollins J, Stewart SK, Bewtra M, Baumblatt GL, Holubar SD, Greenup AJ, Sechi A, Girgis A, Rubin DT, Siegel CA. Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis. 2016 Apr;22(4):940-7. doi: 10.1097/MIB.0000000000000740. PMID: 26950308.

609: Targownik LE, Coneys JG, Dhillon AS. Emerging issues in the medical management of Crohn's disease. Curr Opin Gastroenterol. 2016 Mar;32(2):103-9. doi: 10.1097/MOG.0000000000000242. PMID: 26839964.

610: Tormey LK, Farraye FA, Paasche-Orlow MK. Understanding Health Literacy and its Impact on Delivering Care to Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Mar;22(3):745-51. doi: 10.1097/MIB.0000000000000622. PMID: 26595554.

611: Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016 Mar;10(3):286-95. doi: 10.1093/ecco-jcc/jjv210.

Epub 2015 Nov 17. PMID: 26581895; PMCID: PMC4957474.

612: McHale P, Keenan A, Ghebrehewet S. Reasons for measles cases not being vaccinated with MMR: investigation into parents' and carers' views following a large measles outbreak. Epidemiol Infect. 2016 Mar;144(4):870-5. doi: 10.1017/S0950268815001909. Epub 2015 Aug 12. PMID: 26265115.

613: Martin J, Kane SV, Feagins LA. Fertility and Contraception in Women With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2016 Feb;12(2):101-9. PMID: 27182211; PMCID: PMC4865770.

614: Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016 Feb;43(4):482-513. doi: 10.1111/apt.13491. Epub 2016 Jan 4. PMID: 26725569.

615: Wallenhorst T, Brochard C, Bretagne JF, Bouguen G, Siproudhis L. Crohn's disease: is there any link between anal and luminal phenotypes? Int J Colorectal Dis. 2016 Feb;31(2):307-11. doi: 10.1007/s00384-015-2390-8. Epub 2015 Sep 26. PMID: 26410258.

616: Siegel CA, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients' Perspectives on Shared Decision Making. Patient. 2016 Feb;9(1):79-89. doi: 10.1007/s40271-015-0126-z. PMID: 25963447.

617: Bell RD, Moriarty KJ. Synchronous colonic lymphoma and adenocarcinoma in a patient with Crohn's disease, treated with thiopurine therapy and a TNFα inhibitor: a challenge to Occam's razor. BMJ Case Rep. 2016 Jan 20;2016:bcr2015212464. doi: 10.1136/bcr-2015-212464. PMID: 26791118; PMCID: PMC4735391.

618: Mitchell RA, Shuster C, Shahidi N, Galorport C, DeMarco ML, Rosenfeld G, Enns RA, Bressler B. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Can J Gastroenterol Hepatol. 2016;2016:5203898. doi: 10.1155/2016/5203898. Epub 2016 Nov 10. PMID: 27957480; PMCID: PMC5121455.

619: Abej E, El-Matary W, Singh H, Bernstein CN. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol. 2016;2016:2483261. doi: 10.1155/2016/2483261. Epub 2016 Sep 28. PMID: 27774443; PMCID: PMC5059522.

620: Lee J, Clarke K. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management. Int J Colorectal Dis. 2015 Dec;30(12):1595-602. doi: 10.1007/s00384-015-2344-1. Epub 2015 Sep 8. PMID: 26349591.

621: Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015 Dec;27(12):1418-24. doi: 10.1097/MEG.0000000000000461. PMID: 26308711.

622: Bennett AL, Buckton S, Lawrance I, Leong RW, Moore G, Andrews JM. Ulcerative colitis outpatient management: development and evaluation of tools to support primary care practitioners. Intern Med J. 2015 Dec;45(12):1254-66. doi: 10.1111/imj.12872. Erratum in: Intern Med J. 2016 Feb;46(2):244. PMID: 26256445.

623: Appenzeller S, Gilissen C, Rijntjes J, Tops BB, Kastner-van Raaij A, Hebeda KM, Nissen L, Dutilh BE, van Krieken JH, Groenen PJ. Immunoglobulin rearrangement analysis from multiple lesions in the same patient using next-generation sequencing. Histopathology. 2015 Dec;67(6):843-58. doi:

10.1111/his.12714. Epub 2015 Jun 26. PMID: 25891511.

624: Oh SH, Baek J, Kim KM, Lee EJ, Jung Y, Lee YJ, Jin HS, Ye BD, Yang SK, Lee JK, Seo EJ, Lim HT, Lee I, Song K. Is Whole Exome Sequencing Clinically Practical in the Management of Pediatric Crohn's Disease? Gut Liver. 2015 Nov 23;9(6):767-75. doi: 10.5009/gnl15176. PMID: 26503572; PMCID: PMC4625707.

625: Fraquelli M, Branchi F, Cribiù FM, Orlando S, Casazza G, Magarotto A, Massironi S, Botti F, Contessini-Avesani E, Conte D, Basilisco G, Caprioli F. The Role of Ultrasound Elasticity Imaging in Predicting Ileal Fibrosis in Crohn's Disease Patients. Inflamm Bowel Dis. 2015 Nov;21(11):2605-12. doi: 10.1097/MIB.0000000000000536. PMID: 26230861.

626: Dayama A, Sugano D, Stone ME, McNelis J. Predictive factors associated with adverse events in patients with toxic colitis: an analysis of the National Surgical Quality Improvement Project. Am J Surg. 2015 Nov;210(5):852-8.e1. doi: 10.1016/j.amjsurg.2015.03.026. Epub 2015 Jun 1. PMID: 26120026.

627: Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, Fidder HH, Schwartz MP, Oldenburg B. Predicting Endoscopic Disease Activity in Crohn's Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index). Inflamm Bowel Dis. 2015 Oct;21(10):2453-9. doi: 10.1097/MIB.0000000000000507. PMID: 26181428.

628: Gawron LM, Goldberger AR, Gawron AJ, Hammond C, Keefer L. Disease-related pregnancy concerns and reproductive planning in women with inflammatory bowel diseases. J Fam Plann Reprod Health Care. 2015 Oct;41(4):272-7. doi: 10.1136/jfprhc-2014-101000. Epub 2015 Apr 22. PMID: 25902816; PMCID: PMC8451967.

629: Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):537-45. doi:

10.1038/nrgastro.2015.135. Epub 2015 Aug 18. PMID: 26284562.

630: Novak K, Tanyingoh D, Petersen F, Kucharzik T, Panaccione R, Ghosh S, Kaplan GG, Wilson A, Kannengiesser K, Maaser C. Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. J Crohns Colitis. 2015 Sep;9(9):795-801. doi: 10.1093/ecco-jcc/jjv105. Epub 2015 Jun 16. PMID: 26079723.

631: Siegel CA, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2015 Sep;60(9):2636-45. doi: 10.1007/s10620-015-3675-z. Epub 2015 May 5. PMID: 25939543; PMCID: PMC4541702.

632: Plevinsky JM, Gumidyala AP, Fishman LN. Transition experience of young adults with inflammatory bowel diseases (IBD): a mixed methods study. Child Care Health Dev. 2015 Sep;41(5):755-61. doi: 10.1111/cch.12213. Epub 2014 Nov 6. PMID: 25376979.

633: Hardt J, Kienle P. Occult and Manifest Colorectal Carcinoma in Ulcerative Colitis: How Does It Influence Surgical Decision Making? Viszeralmedizin. 2015 Aug;31(4):252-7. doi: 10.1159/000438811. Epub 2015 Jul 31. PMID: 26557833; PMCID: PMC4608634.

634: Louis E, Dotan I, Ghosh S, Mlynarsky L, Reenaers C, Schreiber S. Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations. J Crohns Colitis. 2015 Aug;9(8):685-91. doi: 10.1093/ecco-jcc/jjv085. Epub 2015 May 18. PMID: 25987349; PMCID: PMC4584566.

635: D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut. 2015 Aug;64(8):1227-35. doi:

10.1136/gutjnl-2014-307118. Epub 2014 Oct 3. PMID: 25281416; PMCID: PMC4515993.

636: Kistler CE, Hess TM, Howard K, Pignone MP, Crutchfield TM, Hawley ST, Brenner AT, Ward KT, Lewis CL. Older adults' preferences for colorectal cancer-screening test attributes and test choice. Patient Prefer Adherence. 2015 Jul 15;9:1005-16. doi: 10.2147/PPA.S82203. PMID: 26203233; PMCID: PMC4508065.

637: Rogler G, Biedermann L. Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015 Jul;17(7):26. doi: 10.1007/s11894-015-0449-x. PMID: 26122247.

638: Allen P, Shaw E, Jong A, Behrens H, Skinner I. Severity and duration of pain after colonoscopy and gastroscopy: a cohort study. J Clin Nurs. 2015 Jul;24(13-14):1895-903. doi: 10.1111/jocn.12817. Epub 2015 May 6. PMID: 25950449.

639: Huang VW, Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflamm Bowel Dis. 2015 Jun;21(6):1359-67. doi: 10.1097/MIB.0000000000000376. PMID: 25989340; PMCID: PMC4450916.

640: Cross RK. Which patients with inflammatory bowel disease should receive combination therapy? Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):715-7. doi: 10.1586/17474124.2015.1039989. Epub 2015 Apr 25. PMID: 25912620.

641: Xie F. The economics of adalimumab for ulcerative colitis. Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):373-7. doi: 10.1586/14737167.2015.1031113. Epub 2015 Mar 30. PMID: 25817776.

642: Malgras B, Pautrat K, Dray X, Pasquier P, Valleur P, Pocard M, Soyer P.

Multidisciplinary management of gastrointestinal fibrotic stenosis in Crohn's disease. Dig Dis Sci. 2015 May;60(5):1152-68. doi: 10.1007/s10620-014-3421-y. Epub 2014 Nov 8. PMID: 25381203.

643: Wolff MJ, Balzora S, Poles M, Zabar S, Mintah A, Wong L, Weinshel E, Malter LB. Objective structured clinical examination as a novel tool in inflammatory bowel disease fellowship education. Inflamm Bowel Dis. 2015 Apr;21(4):759-65. doi: 10.1097/MIB.0000000000000317. PMID: 25633560.

644: Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015 Apr;9(4):497-505. doi: 10.1586/17474124.2015.983079. Epub 2015 Jan 20. PMID: 25600263.

645: Gabbani T, Manetti N, Bonanomi AG, Annese AL, Annese V. New endoscopic imaging techniques in surveillance of inflammatory bowel disease. World J Gastrointest Endosc. 2015 Mar 16;7(3):230-6. doi: 10.4253/wjge.v7.i3.230. PMID: 25789093; PMCID: PMC4360441.

646: Kim M, Katz S, Green J. Drug Management in the Elderly IBD Patient. Curr Treat Options Gastroenterol. 2015 Mar;13(1):90-104. doi: 10.1007/s11938-014-0039-2. PMID: 25617139.

647: Atreja A, Khan S, Rogers JD, Otobo E, Patel NP, Ullman T, Colombel JF, Moore S, Sands BE; HealthPROMISE Consortium Group. Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc. 2015 Feb 18;4(1):e23. doi: 10.2196/resprot.4042. PMID: 25693610; PMCID: PMC4376196.

648: van Mierlo T, Fournier R, Fedorak R. Don't Forget the Doctor:

Gastroenterologists' Preferences on the Development of mHealth Tools for Inflammatory Bowel Disease. JMIR Mhealth Uhealth. 2015 Jan 21;3(1):e5. doi: 10.2196/mhealth.3987. PMID: 25608628; PMCID: PMC4319145.

649: Triantafillidis JK, Vagianos C, Papalois AE. The role of enteral nutrition in patients with inflammatory bowel disease: current aspects. Biomed Res Int. 2015;2015:197167. doi: 10.1155/2015/197167. Epub 2015 Feb 22. PMID: 25793189; PMCID: PMC4352452.

650: Wang ED, Conkling N, Xu X, Chern H, Finlayson E, Varma MG, Hansen SL, Foster RD, Hoffman WY, Sbitany H. Perineal flap reconstruction following oncologic anorectal extirpation: an outcomes assessment. Plast Reconstr Surg. 2015 Jan;135(1):176e-184e. doi: 10.1097/PRS.0000000000000837. PMID: 25539325.

651: Affronti A, Orlando A, Cottone M. An update on medical management on Crohn's disease. Expert Opin Pharmacother. 2015 Jan;16(1):63-78. doi: 10.1517/14656566.2015.981525. Epub 2014 Nov 24. PMID: 25418125.

652: Lundy JB. A primer on wound healing in colorectal surgery in the age of bioprosthetic materials. Clin Colon Rectal Surg. 2014 Dec;27(4):125-33. doi: 10.1055/s-0034-1394086. PMID: 25435821; PMCID: PMC4226754.

653: Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin exposure and risk of inflammatory bowel disease. JAMA Dermatol. 2014 Dec;150(12):1322-6. doi: 10.1001/jamadermatol.2014.1540. PMID: 25207875.

654: Thai H, Guerron AD, Bencsath KP, Liu X, Loor M. Fulminant Clostridium difficile enteritis causing abdominal compartment syndrome. Surg Infect (Larchmt). 2014 Dec;15(6):821-5. doi: 10.1089/sur.2013.026. PMID: 24824419.

655: Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis.

World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):579-88. doi: 10.4291/wjgp.v5.i4.579. PMID: 25401001; PMCID: PMC4231522.

656: Bringiotti R, Ierardi E, Lovero R, Losurdo G, Di Leo A, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):550-9. doi: 10.4291/wjgp.v5.i4.550. PMID: 25400998; PMCID: PMC4231519.

657: Kammermeier J, Drury S, James CT, Dziubak R, Ocaka L, Elawad M, Beales P, Lench N, Uhlig HH, Bacchelli C, Shah N. Targeted gene panel sequencing in children with very early onset inflammatory bowel disease--evaluation and prospective analysis. J Med Genet. 2014 Nov;51(11):748-55. doi: 10.1136/jmedgenet-2014-102624. Epub 2014 Sep 5. PMID: 25194001.

658: Gerlach UA, Vrakas G, Reddy S, Baumgart DC, Neuhaus P, Friend PJ, Pascher A, Vaidya A. Chronic intestinal failure after Crohn disease: when to perform transplantation. JAMA Surg. 2014 Oct;149(10):1060-6. doi: 10.1001/jamasurg.2014.1072. Erratum in: JAMA Surg. 2014 Dec;149(12):1313. Baumgar, Daniel C [Corrected to Baumgart, Daniel C]. PMID: 25162284.

659: Maltz R, Podberesky DJ, Saeed SA. Imaging modalities in pediatric inflammatory bowel disease. Curr Opin Pediatr. 2014 Oct;26(5):590-6. doi: 10.1097/MOP.0000000000000131. PMID: 25029227.

660: Wunder A, Thiele A, Koslowski M, Gantner F, Niessen H. Nuclear imaging to support anti-inflammatory drug discovery and development. Q J Nucl Med Mol Imaging. 2014 Sep;58(3):290-8. PMID: 25265250.

661: Glauser J, Siff J, Emerman C. Emergency department experience with nonoral contrast computed tomography in the evaluation of patients for appendicitis. J Patient Saf. 2014 Sep;10(3):154-8. doi: 10.1097/PTS.0b013e31829a07ba. PMID:

24080721.

662: Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Aug;10(8):478-489. PMID: 28845139; PMCID: PMC5566190.

663: Murphy J, Kalkbrenner KA, Pemberton JH, Landmann RG, Heppell JP, Young-Fadok TM, Etzioni DA. Dysplasia in ulcerative colitis as a predictor of unsuspected synchronous colorectal cancer. Dis Colon Rectum. 2014 Aug;57(8):993-8. doi: 10.1097/DCR.0000000000000172. PMID: 25003294.

664: Mountifield R, Andrews JM, Bampton P. It IS worth the effort: Patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session. J Crohns Colitis. 2014 Aug;8(8):796-801. doi: 10.1016/j.crohns.2013.12.019. Epub 2014 Jan 25. PMID: 24467964.

665: Lahat A, Neuman S, Eliakim R, Ben-Horin S. Partners of patients with inflammatory bowel disease: how important is their support? Clin Exp Gastroenterol. 2014 Jul 30;7:255-9. doi: 10.2147/CEG.S62173. PMID: 25114579; PMCID: PMC4122224.

666: Philpott HL, Nandurkar S, Lubel J, Gibson PR. Drug-induced gastrointestinal disorders. Postgrad Med J. 2014 Jul;90(1065):411-9. doi: 10.1136/postgradmedj-2013-100316rep. PMID: 24942356.

667: Cypers H, Van Praet L, Varkas G, Elewaut D. Relevance of the gut/joint axis for the management of spondyloarthritis in daily clinical practice. Curr Opin Rheumatol. 2014 Jul;26(4):371-6. doi: 10.1097/BOR.0000000000000070. PMID: 24841232.

668: Bemelman WA, Allez M. The surgical intervention: earlier or never? Best Pract Res Clin Gastroenterol. 2014 Jun;28(3):497-503. doi: 10.1016/j.bpg.2014.04.013. Epub 2014 May 10. PMID: 24913388.

669: Connelly TM, Berg AS, Hegarty JP, Deiling S, Brinton D, Poritz LS, Koltun WA. The TNFSF15 gene single nucleotide polymorphism rs7848647 is associated with surgical diverticulitis. Ann Surg. 2014 Jun;259(6):1132-7. doi: 10.1097/SLA.0000000000000232. PMID: 24814505.

670: Wunder A, Thiele A, Koslowski M, Gantner F, Niessen H. Nuclear imaging to support anti-inflammatory drug discovery and development. Q J Nucl Med Mol Imaging. 2014 May 15. Epub ahead of print. PMID: 24829127.

671: Byrne CM, Tan KK, Young JM, Selby W, Solomon MJ. Patient and clinician preferences for surgical and medical treatment options in ulcerative colitis. Colorectal Dis. 2014 Apr;16(4):285-92. doi: 10.1111/codi.12538. PMID: 24373392.

672: Bressenot A, Cahn V, Danese S, Peyrin-Biroulet L. Microscopic features of colorectal neoplasia in inflammatory bowel diseases. World J Gastroenterol. 2014 Mar 28;20(12):3164-72. doi: 10.3748/wjg.v20.i12.3164. PMID: 24696602; PMCID: PMC3964388.

673: Harrison E, Allan P, Ramu A, Vaidya A, Travis S, Lal S. Management of intestinal failure in inflammatory bowel disease: small intestinal transplantation or home parenteral nutrition? World J Gastroenterol. 2014 Mar 28;20(12):3153-63. doi: 10.3748/wjg.v20.i12.3153. PMID: 24696601; PMCID: PMC3964387.

674: Khanna R, Feagan BG. Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. Curr Treat Options Gastroenterol. 2014 Mar;12(1):76-89. doi: 10.1007/s11938-013-0005-4. PMID: 24395613.

675: Ha CY. Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy. Clin Geriatr Med. 2014 Feb;30(1):67-78. doi: 10.1016/j.cger.2013.10.007. PMID: 24267603.

676: Rimola J, Ordás I. MR colonography in inflammatory bowel disease. Magn Reson Imaging Clin N Am. 2014 Feb;22(1):23-33. doi: 10.1016/j.mric.2013.07.011. Epub 2013 Aug 30. PMID: 24238130.

677: Al-Hawary MM, Zimmermann EM, Hussain HK. MR imaging of the small bowel in Crohn disease. Magn Reson Imaging Clin N Am. 2014 Feb;22(1):13-22. doi: 10.1016/j.mric.2013.09.001. PMID: 24238129.

678: Siao D, Velayos F. Avoiding rash decision making: skin cancer screening of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014 Feb;12(2):274-6. doi: 10.1016/j.cgh.2013.10.018. Epub 2013 Oct 29. PMID: 24183955.

679: Philpott HL, Nandurkar S, Lubel J, Gibson PR. Drug-induced gastrointestinal disorders. Frontline Gastroenterol. 2014 Jan;5(1):49-57. doi: 10.1136/flgastro-2013-100316. Epub 2013 Jun 19. PMID: 28839751; PMCID: PMC5369702.

680: Colombel JF. IBD therapy: new targets and unmet needs. Nestle Nutr Inst Workshop Ser. 2014;79:153-60. doi: 10.1159/000360720. Epub 2014 Sep 5. PMID: 25227303.

681: Roblin X, Rinaudo M, Sparrow MP, Moreau A, Phelip JM, Genin C, Lamarque D, Paul S. Pharmacokinetics in IBD: ready for prime time? Curr Drug Targets. 2014;15(11):1049-55. doi: 10.2174/1389450115666140829153509. PMID: 25173707.

682: Spinelli A, Fiorino G, Bazzi P, Sacchi M, Bonifacio C, De Bastiani S, Malesci A, Balzarini L, Peyrin-Biroulet L, Montorsi M, Danese S. Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. J Gastrointest Surg. 2014 Jan;18(1):83-90; discussion 90-1. doi: 10.1007/s11605-013-2404-1. Epub 2013 Nov 20. PMID: 24254837.

683: Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2013 Dec;19(13):2927-36. doi: 10.1097/MIB.0b013e31829aad16. PMID: 23867874; PMCID: PMC3938311.

684: Wine E, Mack DR, Hyams J, Otley AR, Markowitz J, Crandall WV, Leleiko N, Muise AM, Griffiths AM, Turner D. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013 Dec;7(11):916-22. doi: 10.1016/j.crohns.2012.12.012. Epub 2013 Jan 20. PMID: 23339932.

685: Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: what does it mean? World J Gastroenterol. 2013 Nov 21;19(43):7552-60. doi: 10.3748/wjg.v19.i43.7552. PMID: 24282345; PMCID: PMC3837253.

686: Lannon CM, Peterson LE. Pediatric collaborative networks for quality improvement and research. Acad Pediatr. 2013 Nov-Dec;13(6 Suppl):S69-74. doi: 10.1016/j.acap.2013.07.004. PMID: 24268088.

687: Allison M, Lindsay J, Gould D, Kelly D. Surgery in young adults with inflammatory bowel disease: a narrative account. Int J Nurs Stud. 2013 Nov;50(11):1566-75. doi: 10.1016/j.ijnurstu.2013.04.003. Epub 2013 May 14. PMID: 23684395.

688: Flor N, Rigamonti P, Pisani Ceretti A, Romagnoli S, Balestra F, Sardanelli F, Cornalba G, Pickhardt PJ. Diverticular disease severity score based on CT colonography. Eur Radiol. 2013 Oct;23(10):2723-9. doi: 10.1007/s00330-013-2882-2. Epub 2013 May 10. PMID: 23660775.

689: Batz MB, Henke E, Kowalcyk B. Long-term consequences of foodborne infections. Infect Dis Clin North Am. 2013 Sep;27(3):599-616. doi: 10.1016/j.idc.2013.05.003. Epub 2013 Jul 25. PMID: 24011832.

690: Kevans D, Van Assche G. Is there a therapeutic window of opportunity in early inflammatory bowel disease? Early stage inflammatory bowel disease: the actual management. Minerva Gastroenterol Dietol. 2013 Sep;59(3):299-312. PMID: 23867949.

691: Min SB, Le-Carlson M, Singh N, Nylund CM, Gebbia J, Haas K, Lo S, Mann N, Melmed GY, Rabizadeh S, Dubinsky MC. Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience. Inflamm Bowel Dis. 2013 Sep;19(10):2139-45. doi: 10.1097/MIB.0b013e31829a749c. PMID: 23867872.

692: Lamousé-Smith ES, Weber S, Rossi RF, Neinstedt LJ, Mosammaparast N, Sandora TJ, McAdam AJ, Bousvaros A. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013 Sep;57(3):293-7. doi: 10.1097/MPG.0b013e3182999990. PMID: 23698022.

693: Papay P, Ignjatovic A, Karmiris K, Amarante H, Milheller P, Feagan B, D'Haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel JF, Panaccione R. Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis. 2013 Sep;7(8):653-69. doi: 10.1016/j.crohns.2013.02.005. Epub 2013 Apr 4. PMID: 23562672.

694: Kreps GL, Neuhauser L. Artificial intelligence and immediacy: designing health communication to personally engage consumers and providers. Patient Educ Couns. 2013 Aug;92(2):205-10. doi: 10.1016/j.pec.2013.04.014. Epub 2013 May 15. PMID: 23683341.

695: Ananthakrishnan AN, Xavier RJ. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis. 2013 Aug;19(9):2021-30. doi: 10.1097/MIB.0b013e318281f5c5. PMID: 23644824; PMCID: PMC3720704.

696: Lipstein EA, Muething KA, Dodds CM, Britto MT. "I'm the one taking it": adolescent participation in chronic disease treatment decisions. J Adolesc Health. 2013 Aug;53(2):253-9. doi: 10.1016/j.jadohealth.2013.02.004. Epub 2013 Apr 3. PMID: 23561895.

697: Kim YG, Jang BI. The role of colonoscopy in inflammatory bowel disease. Clin Endosc. 2013 Jul;46(4):317-20. doi: 10.5946/ce.2013.46.4.317. Epub 2013 Jul 31. PMID: 23964327; PMCID: PMC3746135.

698: Gotthardt DN, Gauss A, Zech U, Mehrabi A, Weiss KH, Sauer P, Stremmel W, Büchler MW, Schemmer P. Indications for intestinal transplantation: recognizing the scope and limits of total parenteral nutrition. Clin Transplant. 2013 Jul-Aug;27 Suppl 25:49-55. doi: 10.1111/ctr.12161. PMID: 23909502.

699: Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol. 2013 Jul;6(4):269-93. doi: 10.1177/1756283X13479826. PMID: 23814608; PMCID: PMC3667472.

700: Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group. Predictors for

hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. Eur J Gastroenterol Hepatol. 2013 Jul;25(7):790-7. doi: 10.1097/MEG.0b013e32836019b9. PMID: 23571609.

701: Mesko B, Poliska S, Váncsa A, Szekanecz Z, Palatka K, Hollo Z, Horvath A, Steiner L, Zahuczky G, Podani J, Nagy AL. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med. 2013 Jun 28;5(6):59. doi: 10.1186/gm463. PMID: 23809696; PMCID: PMC4064310.

702: Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):345-51. doi: 10.1038/nrgastro.2013.31. Epub 2013 Mar 5. Erratum in: Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):ii. PMID: 23458890.

703: Robertson J, Walkom EJ, Bevan MD, Newby DA. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia. BMC Public Health. 2013 May 21;13:489. doi: 10.1186/1471-2458-13-489. PMID: 23687910; PMCID: PMC3702435.

704: Kerner C, Carey K, Baillie C, Mills AM, Yang W, Hilton S, Synnestvedt MB, Weiner MG, Lewis JD. Clinical predictors of urgent findings on abdominopelvic CT in emergency department patients with Crohn's disease. Inflamm Bowel Dis. 2013 May;19(6):1179-85. doi: 10.1097/MIB.0b013e31828133ad. PMID: 23552763; PMCID: PMC3733456.

705: Ha C, Katz S. Elderly-onset IBD: a milder disease? Nat Rev Gastroenterol Hepatol. 2013 May;10(5):264-5. doi: 10.1038/nrgastro.2013.56. Epub 2013 Apr 2. PMID: 23545521.

706: Alarcón-Fernández O, Ramos L, Adrián-de-Ganzo Z, Gimeno-García AZ, Nicolás-Pérez D, Jiménez A, Quintero E. Effects of colon capsule endoscopy on medical decision making in patients with incomplete colonoscopies. Clin Gastroenterol Hepatol. 2013 May;11(5):534-40.e1. doi: 10.1016/j.cgh.2012.10.016. Epub 2012 Oct 16. PMID: 23078891.

707: Kruis W, Leifeld L, Morgenstern J, Pfützer R, Reimers B, Ceplis-Kastner S; CARE study group. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study. J Crohns Colitis. 2013 May;7(4):e125-32. doi: 10.1016/j.crohns.2012.07.004. Epub 2012 Aug 27. PMID: 22951030.

708: Katicić M. Indeksi aktivnosti upalnih bolesti crijeva [Activity indices in IBD]. Acta Med Croatica. 2013 Apr;67(2):93-110. Croatian. PMID: 24471293.

709: Lipstein EA, Lovell DJ, Denson LA, Moser DW, Saeed SA, Dodds CM, Britto MT. Parents' information needs in tumor necrosis factor-α inhibitor treatment decisions. J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):244-50. doi: 10.1097/MPG.0b013e31827496c3. PMID: 23059648.

710: Nasir BF, Griffiths L, Nasir A, Roberts R, Barclay M, Gearry R, Lea RA. Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. J Clin Gastroenterol. 2013 Mar;47(3):242-5. doi: 10.1097/MCG.0b013e318258314d. PMID: 22739221.

711: Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013 Feb 12;13:27. doi: 10.1186/1471-230X-13-27. PMID: 23399416;

PMCID: PMC3583683.

712: Vogt BA. Inflammatory bowel disease: perspectives from cingulate cortex in the first brain. Neurogastroenterol Motil. 2013 Feb;25(2):93-8. doi: 10.1111/nmo.12067. PMID: 23336589.

713: Mendoza JL, González-Lama Y, Taxonera C, Suárez-Ferrer C, Matute F, Vera MI, López-Palacios N, Rodríguez P, Calvo M, Méndez R, Pastrana M, González C, Lana R, Rodríguez R, Abreu L. Using of magnetic resonance enterography in the management of Crohn's disease of the small intestine: first year of experience. Rev Esp Enferm Dig. 2012 Dec;104(11):578-83. doi: 10.4321/s1130-01082012001100005. PMID: 23368649.

714: Hagymási K, Miheller P, Tulassay Z. Adatok az "önként vállalt gyermektelenség" csökkentésére gyulladásos bélbetegségben [Data for the decrease of "voluntary childlessness" in inflammatory bowel disease]. Orv Hetil. 2012 Nov 25;153(47):1855-62. Hungarian. doi: 10.1556/OH.2012.29492. PMID: 23160076.

715: Islam MS, Grainger SL. Do we know how to use corticosteroids in acute severe ulcerative colitis? Frontline Gastroenterol. 2012 Oct;3(4):248-251. doi: 10.1136/flgastro-2012-100211. Epub 2012 Aug 11. PMID: 28839676; PMCID: PMC5369831.

716: Saito K, Katsuno T, Nakagawa T, Saito M, Sazuka S, Sato T, Matsumura T, Arai M, Miyauchi H, Matsubara H, Yokosuka O. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther. 2012 Oct;36(8):744-54. doi: 10.1111/apt.12033. Epub 2012 Sep 7. PMID: 22957944.

717: Jung SA. Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy? Clin Endosc. 2012 Sep;45(3):254-62. doi:

10.5946/ce.2012.45.3.254. Epub 2012 Aug 22. PMID: 22977813; PMCID: PMC3429747.

718: Ordas I, Rimola J, Rodriguez S, Gallego M, Ricart E, Panes J. Imaging of the colon in inflammatory bowel disease: ready for prime time? Curr Drug Targets. 2012 Sep 1;13(10):1252-60. doi: 10.2174/138945012802429714. PMID: 22664082.

719: Löwenberg M, D'Haens G. Mucosal healing in Crohn's disease: relevance for clinical outcomes. Curr Drug Targets. 2012 Sep 1;13(10):1248-51. doi: 10.2174/138945012802429688. PMID: 22664081.

720: Vermeire S, Carbonnel F, Coulie PG, Geenen V, Hazes JM, Masson PL, De Keyser F, Louis E. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis. 2012 Sep;6(8):811-23. doi: 10.1016/j.crohns.2012.04.009. Epub 2012 May 16. PMID: 22595185.

721: Schoultz M. The role of psychological factors in inflammatory bowel disease. Br J Community Nurs. 2012 Aug;17(8):370-4. doi: 10.12968/bjcn.2012.17.8.370. PMID: 22875212.

722: Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012 Aug 1;10:82. doi: 10.1186/1741-7015-10-82. PMID: 22853635; PMCID: PMC3414735.

723: Masoomi H, Kang CY, Chen A, Mills S, Dolich MO, Carmichael JC, Stamos MJ. Predictive factors of in-hospital mortality in colon and rectal surgery. J Am Coll Surg. 2012 Aug;215(2):255-61. doi: 10.1016/j.jamcollsurg.2012.04.019. Epub 2012 May 27. PMID: 22640532.

724: Rimola J, Rodríguez S, Cabanas ML, Ayuso C, Panés J, Cuatrecasas M. MRI of

Crohn's disease: from imaging to pathology. Abdom Imaging. 2012 Jun;37(3):387-96. doi: 10.1007/s00261-011-9797-7. PMID: 21879316.

725: Brown J, Meyer F, Klapproth JM. Aspects in the interdisciplinary decision-making for surgical intervention in ulcerative colitis and its complications. Z Gastroenterol. 2012 May;50(5):468-74. doi: 10.1055/s-0031-1299467. Epub 2012 May 11. PMID: 22581702.

726: Smith JJ, Netuveli G, Sleight SP, Das P, Tekkis PP, Gabe SM, Clark SK, Nicholls RJ. Development of a social morbidity score in patients with chronic ulcerative colitis as a potential guide to treatment. Colorectal Dis. 2012 May;14(5):e250-7. doi: 10.1111/j.1463-1318.2012.02880.x. PMID: 22469481.

727: Conrad S, Hüppe A, Raspe H. Zu welchen Themen wünschen Patientinnen und Patienten mit Morbus Crohn oder Colitis ulcerosa mehr Informationen und welche eigene Rolle bevorzugen sie bei medizinischen Behandlungsentscheidungen? Ergebnisse einer Betroffenenbefragung in Deutschland [Preference of patients with inflammatory bowel disease regarding information and shared decision-making: results from a cross-sectional survey in Germany]. Z Gastroenterol. 2012 Apr;50(4):364-72. German. doi: 10.1055/s-0031-1281949. Epub 2012 Apr 1. PMID: 22467539.

728: Manilich E, Remzi FH, Fazio VW, Church JM, Kiran RP. Prognostic modeling of preoperative risk factors of pouch failure. Dis Colon Rectum. 2012 Apr;55(4):393-9. doi: 10.1097/DCR.0b013e3182452594. PMID: 22426262.

729: Sehgal R, Berg A, Polinski JI, Hegarty JP, Lin Z, McKenna KJ, Stewart DB, Poritz LS, Koltun WA. Genetic risk profiling and gene signature modeling to predict risk of complications after IPAA. Dis Colon Rectum. 2012 Mar;55(3):239-48. doi: 10.1097/DCR.0b013e31823e2d18. PMID: 22469789.

730: Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012 Mar;35(5):501-15. doi: 10.1111/j.1365-2036.2011.04967.x. Epub 2012 Jan 5. PMID: 22221203.

731: Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012 Mar;61(3):459-65. doi: 10.1136/gutjnl-2011-300988. Epub 2011 Dec 20. PMID: 22187072.

732: Ghosh S, D'Haens G, Feagan BG, Silverberg MS, Szigethy EM. What do changes in inflammatory bowel disease management mean for our patients? J Crohns Colitis. 2012 Feb;6 Suppl 2:S243-9. doi: 10.1016/S1873-9946(12)60504-2. PMID: 22463931.

733: Sehgal R, Berg A, Polinski JI, Hegarty JP, Lin Z, McKenna KJ, Stewart DB, Poritz LS, Koltun WA. Mutations in IRGM are associated with more frequent need for surgery in patients with ileocolonic Crohn's disease. Dis Colon Rectum. 2012 Feb;55(2):115-21. doi: 10.1097/DCR.0b013e31823ccea8. PMID: 22228152.

734: Gralnek IM, Cohen SA, Ephrath H, Napier A, Gobin T, Sherrod O, Lewis J. Small bowel capsule endoscopy impacts diagnosis and management of pediatric inflammatory bowel disease: a prospective study. Dig Dis Sci. 2012 Feb;57(2):465-71. doi: 10.1007/s10620-011-1894-5. Epub 2011 Sep 8. PMID: 21901253.

735: Van VQ, Baba N, Rubio M, Wakahara K, Panzini B, Richard C, Soucy G, Franchimont D, Fortin G, Torres AC, Cabon L, Susin S, Sarfati M. CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. PLoS One. 2012;7(8):e41972. doi: 10.1371/journal.pone.0041972. Epub 2012 Aug 1. PMID: 22870271; PMCID:

PMC3411572.

736: Rutgeerts P. How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD? Dig Dis. 2012;30(4):396-9. doi: 10.1159/000338137. Epub 2012 Jul 12. PMID: 22796804.

737: Racz JM, Davies W. Severe stricturing Crohn's disease of the duodenum: A case report and review of surgical options. Int J Surg Case Rep. 2012;3(7):242-5. doi: 10.1016/j.ijscr.2012.03.012. Epub 2012 Mar 23. PMID: 22503915; PMCID: PMC3356554.

738: Ussui VM, Wallace MB. Confocal endomicroscopy of colorectal polyps. Gastroenterol Res Pract. 2012;2012:545679. doi: 10.1155/2012/545679. Epub 2012 Jan 26. PMID: 22319524; PMCID: PMC3272798.

739: Bastida G, Sánchez Montes C, Aguas M. Adhesión a los tratamientos: un punto crítico [Treatment adherence: a key element]. Gastroenterol Hepatol. 2011 Dec;34 Suppl 3:12-7. Spanish. doi: 10.1016/S0210-5705(11)70093-0. Epub 2014 Oct 30. PMID: 25443221.

740: Flasar MH, Cross RK, Doman DB. Current and future role of serogenomics in ulcerative colitis. Gastroenterol Hepatol (N Y). 2011 Nov;7(11):720-7. PMID: 22298968; PMCID: PMC3264925.

741: Gilmour J, Harrison C, Asadi L, Cohen MH, Vohra S. Treating teens: considerations when adolescents want to use complementary and alternative medicine. Pediatrics. 2011 Nov;128 Suppl 4:S161-6. doi: 10.1542/peds.2010-2720D. PMID: 22045858.

742: Shukla R, Abidi WM, Richards-Kortum R, Anandasabapathy S. Endoscopic imaging: How far are we from real-time histology? World J Gastrointest Endosc.

2011 Oct 16;3(10):183-94. doi: 10.4253/wjge.v3.i10.183. PMID: 22013499; PMCID: PMC3196726.

743: Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011 Oct;13(5):409-15. doi: 10.1007/s11926-011-0198-2. PMID: 21744132.

744: Rini C, Jandorf L, Goldsmith RE, Manne SL, Harpaz N, Itzkowitz SH. Interpersonal influences on patients' surgical decision making: the role of close others. J Behav Med. 2011 Oct;34(5):396-407. doi: 10.1007/s10865-011-9323-y. Epub 2011 Feb 10. PMID: 21308408; PMCID: PMC3113663.

745: Jáuregui-Amézaga A, Ricart E, Panés J. Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis. Curr Drug Targets. 2011 Sep;12(10):1467-77. doi: 10.2174/138945011796818162. PMID: 21466495.

746: Burger DC, Travis S. Colon salvage therapy for acute severe colitis: cyclosporine or infliximab? Curr Opin Gastroenterol. 2011 Jul;27(4):358-62. doi: 10.1097/MOG.0b013e32834586e3. PMID: 21423006.

747: Waljee AK, Morris AM, Waljee JF, Higgins PD. Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis. 2011 Jun;17(6):1328-32. doi: 10.1002/ibd.21515. Epub 2010 Nov 16. PMID: 21560195; PMCID: PMC4813665.

748: Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011 May;60(5):571-607. doi: 10.1136/gut.2010.224154. PMID: 21464096.

749: Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. Aliment Pharmacol Ther. 2011 May;33(9):1028-35. doi: 10.1111/j.1365-2036.2011.04620.x. Epub 2011 Mar 8. PMID: 21385195.

750: Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr;106(4):685-98. doi: 10.1038/ajg.2011.103. Epub 2011 Mar 22. PMID: 21427713.

751: Jellema P, van Tulder MW, van der Horst HE, Florie J, Mulder CJ, van der Windt DA. Inflammatory bowel disease: a systematic review on the value of diagnostic testing in primary care. Colorectal Dis. 2011 Mar;13(3):239-54. doi: 10.1111/j.1463-1318.2009.02131.x. PMID: 19912290.

752: Teeuwen PH, Bremers AJ, Groenewoud JM, van Laarhoven CJ, Bleichrodt RP. Predictive value of POSSUM and ACPGBI scoring in mortality and morbidity of colorectal resection: a case-control study. J Gastrointest Surg. 2011 Feb;15(2):294-303. doi: 10.1007/s11605-010-1354-0. Epub 2010 Oct 9. PMID: 20936370; PMCID: PMC3035786.

753: Pulimood AB, Amarapurkar DN, Ghoshal U, Phillip M, Pai CG, Reddy DN, Nagi B, Ramakrishna BS. Differentiation of Crohn's disease from intestinal tuberculosis in India in 2010. World J Gastroenterol. 2011 Jan 28;17(4):433-43. doi: 10.3748/wjg.v17.i4.433. PMID: 21274372; PMCID: PMC3027009.

754: Sejdinovic R, Salihefendic N, Pandza H, Zildzic M. Characteristics of acute abdominal pain in lower abdomen in patients hospitalized in general hospital Tesanj. Med Arh. 2011;65(3):145-8. doi: 10.5455/medarh.2011.65.145-148. PMID: 21776874.

755: Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clin Exp Gastroenterol. 2011;4:127-40. doi: 10.2147/CEG.S18187. Epub 2011 Jun 2. PMID: 21753895; PMCID: PMC3132855.

756: Zitomersky NL, Verhave M, Trenor CC 3rd. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis. 2011 Jan;17(1):458-70. doi: 10.1002/ibd.21334. PMID: 20848518.

757: Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis. 2011 Jan;17(1):30-8. doi: 10.1002/ibd.21386. Epub 2010 Sep 1. PMID: 20812335; PMCID: PMC2998586.

758: Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis. 2011 Jan;17(1):440-9. doi: 10.1002/ibd.21383. PMID: 20645317.

759: Glaudemans AW, Dierckx RA, Kallenberg CG, Fuentes KL. The role of radiolabelled anti-TNFa monoclonal antibodies for diagnostic purposes and therapy evaluation. Q J Nucl Med Mol Imaging. 2010 Dec;54(6):639-53. PMID: 21221071.

760: Sehgal R, Berg A, Hegarty JP, Kelly AA, Lin Z, Poritz LS, Koltun WA. NOD2/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. Dis Colon Rectum. 2010 Nov;53(11):1487-94. doi: 10.1007/DCR.0b013e3181f22635. PMID: 20940596.

761: Baars JE, Siegel CA, van't Spijker A, Markus T, Kuipers EJ, van der Woude CJ. Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Dig Liver Dis. 2010 Nov;42(11):777-84. doi: 10.1016/j.dld.2010.03.023. Epub 2010 May 15. PMID: 20472518.

762: Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010 Nov;16(11):1898-904. doi: 10.1002/ibd.21259. PMID: 20310016.

763: Wibmer AG, Kroesen AJ, Gröne J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease--review of the literature. Int J Colorectal Dis. 2010 Oct;25(10):1149-57. doi: 10.1007/s00384-010-1010-x. Epub 2010 Jul 14. PMID: 20628881.

764: Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn's disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010 Aug;16(8):1431-42. doi: 10.1002/ibd.21261. PMID: 20310013.

765: Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul;6(4):621-31. doi: 10.1586/eci.10.36. PMID: 20594135; PMCID: PMC2925472.

766: Lakatos PL. Prediction of disease course in inflammatory bowel diseases. World J Gastroenterol. 2010 Jun 7;16(21):2589-90. doi: 10.3748/wjg.v16.i21.2589. PMID: 20518078; PMCID: PMC2880769.

767: Messaris E, Chandolias N, Grand D, Pricolo V. Role of magnetic resonance enterography in the management of Crohn disease. Arch Surg. 2010 May;145(5):471-5. doi: 10.1001/archsurg.2010.68. PMID: 20479346.

768: Eshuis EJ, Stokkers PC, Bemelman WA. Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy. Expert Rev Gastroenterol Hepatol. 2010 Apr;4(2):181-9. doi: 10.1586/egh.10.3. PMID: 20350265.

769: Greenley RN, Doughty A, Stephens M, Kugathasan S. Brief report: development of the inflammatory bowel disease family responsibility questionnaire. J Pediatr Psychol. 2010 Mar;35(2):183-7. doi: 10.1093/jpepsy/jsp052. Epub 2009 Jun 29. PMID: 19564243.

770: Kiss LS, Lakatos PL. A betegség lefolyásának elôrejelzése gyulladásos bélbetegségekben [Prediction of the disease course in inflammatory bowel diseases]. Orv Hetil. 2010 Feb 21;151(8):293-301. Hungarian. doi: 10.1556/OH.2010.28813. PMID: 20154000.

771: Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28(3):418-23. doi: 10.1159/000320396. Epub 2010 Sep 30. PMID: 20926866.

772: Baars JE, Markus T, Kuipers EJ, van der Woude CJ. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion. 2010;81(2):113-9. doi: 10.1159/000253862. Epub 2010 Jan 9. PMID: 20093836.

773: Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrügger R, Angelucci E, Seibold F, Michetti P, Pittet V; EPACT II Study Group. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy

and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis. 2009 Dec;3(4):257-63. doi: 10.1016/j.crohns.2009.03.008. Epub 2009 May 14. PMID: 21172284.

774: Camacho Martel L. Apoyo y tratamiento psicológico en la enfermedad inflamatoria intestinal: relación médico-paciente [Psychological support and treatment in inflammatory bowel disease: the physician-patient relationship]. Gastroenterol Hepatol. 2009 Oct;32 Suppl 2:13-8. Spanish. doi: 10.1016/S0210-5705(09)72600-7. PMID: 19900623.

775: Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009 Aug;15(8):1264-75. doi: 10.1002/ibd.20899. PMID: 19235918.

776: Bourreille A, Ignjatovic A, Aabakken L, Loftus EV Jr, Eliakim R, Pennazio M, Bouhnik Y, Seidman E, Keuchel M, Albert JG, Ardizzone S, Bar-Meir S, Bisschops R, Despott EJ, Fortun PF, Heuschkel R, Kammermeier J, Leighton JA, Mantzaris GJ, Moussata D, Lo S, Paulsen V, Panés J, Radford-Smith G, Reinisch W, Rondonotti E, Sanders DS, Swoger JM, Yamamoto H, Travis S, Colombel JF, Van Gossum A; World Organisation of Digestive Endoscopy (OMED) and the European Crohn's and Colitis Organisation (ECCO). Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy. 2009 Jul;41(7):618-37. doi: 10.1055/s-0029-1214790. Epub 2009 Jul 8. PMID: 19588292.

777: Wagnon JH, Leiman DA, Ayers GD, Schwartz DA. Survey of gastroenterologists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use? Inflamm Bowel Dis. 2009 Jul;15(7):1082-9. doi: 10.1002/ibd.20857. PMID: 19137605.

778: Raspe H, Conrad S, Muche-Borowski C. Evidenzbasierte und interdisziplinär konsentierte Versorgungspfade für Patientinnen und Patienten mit Morbus Crohn oder Colitis ulcerosa [Evidence-based and consented pathways for patients with inflammatory bowel diseases (IBD)]. Z Gastroenterol. 2009 Jun;47(6):541-62. German. doi: 10.1055/s-0028-1109323. Epub 2009 Jun 16. PMID: 19533545.

779: Braithwaite RS, Fiellin D, Justice AC. The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines. Med Care. 2009 Jun;47(6):610-7. doi: 10.1097/MLR.0b013e31819748d5. PMID: 19433991; PMCID: PMC3077952.

780: Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009 May;15(5):720-5. doi: 10.1002/ibd.20839. PMID: 19067431.

781: Schneider MA, Jamieson A, Fletcher PC. 'One sip won't do any harm . . .': temptation among women with inflammatory bowel disease/irritable bowel syndrome to engage in negative dietary behaviours, despite the consequences to their health. Int J Nurs Pract. 2009 Apr;15(2):80-90. doi: 10.1111/j.1440-172X.2009.01729.x. PMID: 19335525.

782: Di Fabio F, Obrand D, Satin R, Gordon PH. Intra-abdominal venous and arterial thromboembolism in inflammatory bowel disease. Dis Colon Rectum. 2009 Feb;52(2):336-42. doi: 10.1007/DCR.0b013e31819a235d. PMID: 19279432.

783: Spiegel BM, Ho W, Esrailian E, Targan S, Higgins PD, Siegel CA, Dubinsky M, Melmed GY. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol. 2009 Feb;7(2):168-74, 174.e1. doi: 10.1016/j.cgh.2008.08.029. Epub 2008

Sep 4. PMID: 18952199; PMCID: PMC3804428.

784: Schwenter F, Gervaz P, de Saussure P, McKee T, Morel P. Perforated Meckel's diverticulitis complicating active Crohn's ileitis: a case report. J Med Case Rep. 2009 Jan 13;3:12. doi: 10.1186/1752-1947-3-12. PMID: 19144118; PMCID: PMC2630308.

785: Klement E, Shpigel N, Balicer RD, Baneth G, Grotto I, Davidovitch N. 'One Health', from science to policy: examples from the Israeli experience. Vet Ital. 2009 Jan-Mar;45(1):45-53. PMID: 20391389.

786: Joyce MR, Fazio VW. Can ileal pouch anal anastomosis be used in Crohn's disease? Adv Surg. 2009;43:111-37. doi: 10.1016/j.yasu.2009.02.008. PMID: 19845173.

787: Habal FM, Kapila V. Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making. Can J Gastroenterol. 2009 Jan;23(1):49-53. doi: 10.1155/2009/531638. PMID: 19172209; PMCID: PMC2695148.

788: Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009 Jan;29(1):121-36. doi: 10.1111/j.1539-6924.2008.01135.x. Epub 2008 Sep 26. PMID: 18826414; PMCID: PMC2847437.

789: Esteve M, Gisbert JP. Severe ulcerative colitis: at what point should we define resistance to steroids? World J Gastroenterol. 2008 Sep 28;14(36):5504-7. doi: 10.3748/wjg.14.5504. PMID: 18810766; PMCID: PMC2746335.

790: Assadian A, Senekowitsch C, Assadian O, Hartleb H, Hagmüller GW. Diagnostic accuracy of sigmoidoscopy compared with histology for ischemic colitis after aortic aneurysm repair. Vascular. 2008 Sep-Oct;16(5):243-7. doi:

10.2310/6670.2008.00038. PMID: 19238863.

791: Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008 Aug;51(8):1202-7; discussion 1207-10. doi: 10.1007/s10350-008-9364-7. Epub 2008 Jun 7. PMID: 18536964.

792: Moshkovska T, Stone M, Baker R, Mayberry J. Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis. Inflamm Bowel Dis. 2008 Jun;14(6):763-8. doi: 10.1002/ibd.20404. PMID: 18286644.

793: Wen XH, Lu XH. [Diagnostic and therapeutic values of capsule endoscopy in Crohn's disease]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Apr;30(2):175-7. Chinese. PMID: 18505120.

794: Sachdev MS, Ismail MK. Capsule endoscopy: a review. South Med J. 2008 Apr;101(4):407-14. doi: 10.1097/SMJ.0b013e3181683eff. PMID: 18360329.

795: Saibil F, Lai E, Hayward A, Yip J, Gilbert C. Self-management for people with inflammatory bowel disease. Can J Gastroenterol. 2008 Mar;22(3):281-7. doi: 10.1155/2008/428967. PMID: 18354757; PMCID: PMC2662203.

796: Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment Pharmacol Ther. 2008 Mar;27 Suppl 1:1-8. doi: 10.1111/j.1365-2036.2008.03605.x. PMID: 18307643.

797: Kennedy ED, To T, Steinhart AH, Detsky A, Llewellyn-Thomas HA, McLeod RS. Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile? Inflamm Bowel Dis. 2008 Feb;14(2):224-35. doi: 10.1002/ibd.20300.

PMID: 17932964.

798: Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver. 2007 Dec;1(2):118-25. doi: 10.5009/gnl.2007.1.2.118. Epub 2007 Dec 31. PMID: 20485627; PMCID: PMC2871624.

799: Esrailian E, Spiegel BM, Targownik LE, Dubinsky MC, Targan SR, Gralnek IM. Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther. 2007 Oct 1;26(7):1005-18. doi: 10.1111/j.1365-2036.2007.03445.x. PMID: 17877507.

800: Heetun ZS, Byrnes C, Neary P, O'Morain C. Review article: Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther. 2007 Aug 15;26(4):513-33. doi: 10.1111/j.1365-2036.2007.03397.x. PMID: 17661756.

801: Tilg H, Feichtenschlager T, Knoflach P, Petritsch W, Schöfl R, Vogelsang H, Reinisch W. Infliximab in der Therapie der Colitis ulcerosa [Use of infliximab in ulcerative colitis]. Z Gastroenterol. 2007 Aug;45(8):907-11. German. doi: 10.1055/s-2007-963393. PMID: 17701864.

802: Ravishankar HR, Armstrong GR, Scott NA. Intra-operative pathological diagnosis of chronic ulcerative colitis in the two stage ileal pouch anal anastomosis. Colorectal Dis. 2007 Jul;9(6):540-2. doi: 10.1111/j.1463-1318.2007.01113.x. PMID: 17573749.

803: Warrington JC, Charron M. Pediatric gastrointestinal nuclear medicine. Semin Nucl Med. 2007 Jul;37(4):269-85. doi: 10.1053/j.semnuclmed.2007.02.005. PMID: 17544627.

804: Hotokezaka M, Jimi SI, Hidaka H, Maehara N, Eto TA, Chijiiwa K. Role of

intraoperative enteroscopy for surgical decision making with Crohn's disease. Surg Endosc. 2007 Jul;21(7):1238-42. doi: 10.1007/s00464-006-9154-z. Epub 2007 Feb 7. PMID: 17285372.

805: Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007 Jun;5(6):729-35. doi: 10.1016/j.cgh.2007.02.016. Epub 2007 May 4. PMID: 17481964.

806: Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn's disease. Dis Colon Rectum. 2007 May;50(5):586-97. doi: 10.1007/s10350-006-0847-0. PMID: 17380368.

807: Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007 Mar 15;25(6):657-68. doi: 10.1111/j.1365-2036.2007.03241.x. PMID: 17311598.

808: Siegel CA, Bensen SP, Ely P. Should rare complications of treatment influence decision-making in ulcerative colitis? Inflamm Bowel Dis. 2007 Feb;13(2):242. doi: 10.1002/ibd.20064. PMID: 17206713.

809: Van Vlodrop V, Pattyn P, Ceelen W. Management of the 'normal' appendix during surgery for right fossa syndrome: proposed clinical algorithm. Acta Chir Belg. 2007 Jan-Feb;107(1):8-11. doi: 10.1080/00015458.2007.11680004. PMID: 17405592.

810: Pennazio M. Capsule endoscopy: where are we after 6 years of clinical use? Dig Liver Dis. 2006 Dec;38(12):867-78. doi: 10.1016/j.dld.2006.09.007. Epub 2006 Oct 11. PMID: 17045557.

811: Sonnenberg A, Collins JF. Vicious circles in inflammatory bowel disease.

Inflamm Bowel Dis. 2006 Oct;12(10):944-9. doi: 10.1097/01.mib.0000231577.19301.95. PMID: 17012965.

812: Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Aug;12(8):797-813. doi: 10.1097/00054725-200608000-00016. PMID: 16917235.

813: Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. doi: 10.1016/j.cgh.2006.05.020. Epub 2006 Jul 14. PMID: 16843733.

814: Jakobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull. 2006 Jul 17;75-76:131-44. doi: 10.1093/bmb/ldl001. PMID: 16847166.

815: Ros LH, Crespo AM, Giménez F, Marcuello T, Galbe R. Diagnóstico por imagen en la enfermedad inflamatoria intestinal [Diagnostic imaging of inflammatory bowel disease]. Radiologia. 2006 Jul-Aug;48(4):205-15. Spanish. doi: 10.1016/s0033-8338(06)73157-5. PMID: 17058647.

816: Lipska MA, Bissett IP, Parry BR, Merrie AE. Anastomotic leakage after lower gastrointestinal anastomosis: men are at a higher risk. ANZ J Surg. 2006 Jul;76(7):579-85. doi: 10.1111/j.1445-2197.2006.03780.x. PMID: 16813622.

817: Konda V, Huo D, Hermes G, Liu M, Patel R, Rubin DT. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006 Jun;12(6):497-502. doi: 10.1097/00054725-200606000-00009. PMID: 16775494.

818: Travis SP. New thinking: theory vs practice. A case study illustrating evidence-based therapeutic decision making. Colorectal Dis. 2006 May;8 Suppl 1:25-9. doi: 10.1111/j.1463-1318.2006.00989.x. PMID: 16594961.

819: Weersma RK, van Dullemen HM, Kleibeuker JH, Ploeg RJ, Dijkstra G. De behandeling van ernstige colitis ulcerosa [Treatment of servere ulcerative colitis]. Ned Tijdschr Geneeskd. 2006 Jan 7;150(1):12-7. Dutch. PMID: 16440618.

820: Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach--EPACT. Digestion. 2006;73(4):237-48. doi: 10.1159/000095505. Epub 2006 Aug 29. PMID: 16940727.

821: Triester SL, Hara AK, Young-Fadok TM, Heigh RI. Colonic perforation after computed tomographic colonography in a patient with fibrostenosing Crohn's disease. Am J Gastroenterol. 2006 Jan;101(1):189-92. doi: 10.1111/j.1572-0241.2005.00310.x. PMID: 16405553.

822: Canani RB, de Horatio LT, Terrin G, Romano MT, Miele E, Staiano A, Rapacciuolo L, Polito G, Bisesti V, Manguso F, Vallone G, Sodano A, Troncone R. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):9-15. doi: 10.1097/01.mpg.0000187818.76954.9a. PMID: 16385247.

823: Doganci A, Neurath MF, Finotto S. Mucosal immunoregulation: transcription factors as possible therapeutic targets. Curr Drug Targets Inflamm Allergy. 2005 Oct;4(5):565-75. doi: 10.2174/156801005774322153. PMID: 16248825.

824: Myung SJ, Yang SK, Chang HS, Byeon JS, Kim KJ, Hong SS, Jeong JY, Lee SM, Hong WS, Kim JH, Min YI. Clinical usefulness of telomerase for the detection of colon cancer in ulcerative colitis patients. J Gastroenterol Hepatol. 2005 Oct;20(10):1578-83. doi: 10.1111/j.1440-1746.2005.03877.x. PMID: 16174077.

825: Chambers WM, Warren BF, Jewell DP, Mortensen NJ. Cancer surveillance in ulcerative colitis. Br J Surg. 2005 Aug;92(8):928-36. doi: 10.1002/bjs.5106. PMID: 16034807.

826: Solignac M. Sensibilisation aux modalités de prise en charge des pathologies inflammatoires chroniques [Enhancing awareness of the modalities in the management of chronic inflammatory diseases]. Presse Med. 2005 Jun 18;34(11 Suppl):suppl 3-15. French. doi: 10.1016/s0755-4982(05)73430-8. PMID: 16095019.

827: Becker E, Horn S, Hussla B, Irle H, Knorr I, Korsukéwitz C, Pottins I, Rohwetter M, Schuhknecht P, Timner K; German Insurance Institutue for Salaried Employees (BfA). Leitlinien zur sozialmedizinischen Leistungsbeurteilung bei chronisch entzündlichen Darmkrankheiten [Guidelines for the sociomedical assessment of performance in patients suffering from inflammatory bowel disease]. Gesundheitswesen. 2005 Jun;67(6):396-415. German. doi: 10.1055/s-2005-858333. PMID: 16001355.

828: Persson E, Gustavsson B, Hellström AL, Lappas G, Hultén L. Ostomy patients' perceptions of quality of care. J Adv Nurs. 2005 Jan;49(1):51-8. doi: 10.1111/j.1365-2648.2004.03263.x. PMID: 15610381.

829: Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis. 2005 Jan;20(1):1-8. doi: 10.1007/s00384-004-0634-0. Epub 2004 Sep 30. PMID: 15459771.

830: Barisic G, Krivokapic Z, Markovic V, Saranovic D, Masulovic D. Ulcerative colitis indications and timing for surgery. Acta Chir Iugosl. 2004;51(2):123-6. doi: 10.2298/aci0402123b. PMID: 15771303.

831: Lebreton G, Fatome A. Prise en charge des colites aiguës graves [Management

of severe acute colitis]. J Chir (Paris). 2003 Sep;140(4):201-10. French. PMID: 13679769.

832: Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:11-7. doi: 10.1046/j.1365-2036.17.s2.17.x. PMID: 12786607.

833: Dubinsky MC, Fleshner PP. Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. Curr Treat Options Gastroenterol. 2003 Jun;6(3):183-200. doi: 10.1007/s11938-003-0001-1. PMID: 12744819.

834: Babic Z, Jagić V, Petrović Z, Bilić A, Dinko K, Kubat G, Troskot R, Vukelić M. Elevated serum values of procollagen III peptide (PIIIP) in patients with ulcerative colitis who will develop pseudopolyps. World J Gastroenterol. 2003 Mar;9(3):619-21. doi: 10.3748/wjg.v9.i3.619. PMID: 12632532; PMCID: PMC4621596.

835: Inadomi JM. Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand J Gastroenterol Suppl. 2003;(237):17-21. doi: 10.1080/00855910310001430. PMID: 12797675.

836: Kennedy AP, Rogers AE. Improving patient involvement in chronic disease management: the views of patients, GPs and specialists on a guidebook for ulcerative colitis. Patient Educ Couns. 2002 Jul;47(3):257-63. doi: 10.1016/s0738-3991(01)00228-2. PMID: 12088604.

837: Goldring AB, Taylor SE, Kemeny ME, Anton PA. Impact of health beliefs, quality of life, and the physician-patient relationship on the treatment intentions of inflammatory bowel disease patients. Health Psychol. 2002 May;21(3):219-28. doi: 10.1037//0278-6133.21.3.219. PMID: 12027027.

838: Levenstein S, Li Z, Almer S, Barbosa A, Marquis P, Moser G, Sperber A,

Toner B, Drossman DA. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am J Gastroenterol. 2001 Jun;96(6):1822-30. doi: 10.1111/j.1572-0241.2001.03878.x. PMID: 11419836.

839: Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001 Mar;96(3):758-65. doi: 10.1111/j.1572-0241.2001.03618.x. PMID: 11280547.

840: Buhr HJ, Ritz JP. Themen und Schwerpunkte klinischer Studien in der gastroenterologischen Chirurgie [Topics and focuses of clinical studies in gastroenterological surgery]. Chirurg. 2000 Jun;71(6):626-34. German. doi: 10.1007/s001040051114. PMID: 10948729.

841: Angelini DJ. Obstetric triage: management of acute nonobstetric abdominal pain in pregnancy. J Nurse Midwifery. 1999 Nov-Dec;44(6):572-84. doi: 10.1016/s0091-2182(99)00106-8. PMID: 10634014.

842: Tillinger W, Mittermaier C, Lochs H, Moser G. Health-related quality of life in patients with Crohn's disease: influence of surgical operation--a prospective trial. Dig Dis Sci. 1999 May;44(5):932-8. doi: 10.1023/a:1026600428484. PMID: 10235600.

843: Klar E, Herfarth C. State-of-the-Art: Gastroenterologische Chirurgie [State of the art: gastroenterologic surgery]. Praxis (Bern 1994). 1999 Jan 7;88(1-2):18-24. German. PMID: 10067103.

844: Schippers EF, de Meijer PH, Meinders AE. Klinisch denken en beslissen in de praktijk. Een patiënt met buikpijn en een koude rilling [Clinical decision making in family practice. A patient with abdominal pain and chills]. Ned Tijdschr Geneeskd. 1998 Jun 27;142(26):1493-500. Dutch. PMID: 9752068.

845: Kjeldsen J, Lauritsen K, De Muckadell OB. Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Scand J Gastroenterol. 1997 Sep;32(9):933-41. doi: 10.3109/00365529709011205. PMID: 9299674.

846: Freeman HJ, Roeck B, Devine DV, Carter CJ. Atypical perinuclear antineutrophil cytoplasmic antibodies after colectomy in inflammatory bowel disease. Can J Gastroenterol. 1997 May-Jun;11(4):305-10. doi: 10.1155/1997/765202. PMID: 9218855.

847: Nordgren S, McPheeters G, Svaninger G, Oresland T, Hultén L. Small bowel length in inflammatory bowel disease. Int J Colorectal Dis. 1997;12(4):230-4. doi: 10.1007/s003840050095. PMID: 9272453.

848: Shand WS. Surgical therapy of chronic inflammatory bowel disease in childhood. Baillieres Clin Gastroenterol. 1994 Mar;8(1):149-80. doi: 10.1016/s0950-3528(06)80024-2. PMID: 8003741.

849: Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994 Jan 8;343(8889):71-4. doi: 10.1016/s0140-6736(94)90813-3. PMID: 7903776.

850: McLeod RS. Chronic ulcerative colitis. Traditional surgical techniques. Surg Clin North Am. 1993 Oct;73(5):891-908. doi: 10.1016/s0039-6109(16)46132-3. PMID: 8378831.

851: Ohmann C, Horstmann O. Formale Entscheidungshilfen in der Gastroenterologie --Ergebnisse einer Umfrage [Formal decision aids in gastroenterology--results of a survey]. Z Gastroenterol. 1992 Aug;30(8):558-64. German. PMID: 1413939.

852: Alemayehu G, Järnerot G. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol. 1991 Feb;86(2):187-90. PMID: 1992632.

853: Künsebeck HW, Körber J, Freyberger H. Quality of life in patients with inflammatory bowel disease. Psychother Psychosom. 1990;54(2-3):110-6. doi: 10.1159/000288385. PMID: 2098773.

854: Gore RM. CT of inflammatory bowel disease. Radiol Clin North Am. 1989 Jul;27(4):717-29. PMID: 2657850.

855: Gore RM. Cross-sectional imaging of inflammatory bowel disease. Radiol Clin North Am. 1987 Jan;25(1):115-31. PMID: 3547465.

856: Herfarth C. Chronisch-entzündliche Darmerkrankungen [Chronic inflammatory bowel diseases]. Langenbecks Arch Chir. 1984;364:143-7. German. doi: 10.1007/BF01823186. PMID: 6503512.

857: de Dombal FT, Staniland JR, Clamp SE. Geographical variation in disease presentation. Does it constitute a problem and can information science help? Med Decis Making. 1981;1(1):59-69. doi: 10.1177/0272989X8100100108. PMID: 6984875.

858: Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, Kern F Jr. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology. 1979 Oct;77(4 Pt 2):829-42. PMID: 38175.

859: Staniland JR, Ditchburn J, de Dombal FT. Clinical presentation of diseases of the large bowel. A detailed study of 642 patients. Gastroenterology. 1976 Jan;70(1):22-8. PMID: 1245282.